Clinical trial NCT03490942
Conditions: Hypoglycemia Unawareness Diabetes Mellitus, Type 1
Keywords: glucagon hypoglycemia counter-regulation
Sponsor: Xeris Pharmaceuticals
Start date: 2018-03-15; Completion date: 2020-02-10
Enrollment: 49 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
This is a prospective, randomized, controlled, double-blind, parallel 4-group trial with the primary analysis after 4 weeks of treatment with continuous subcutaneous glucagon infusion (CSGI) or placebo. After a 1-week qualification on continuous glucose monitoring (CGM), subjects will have their baseline hypoglycemia counter-regulatory response hormones quantified using a step-wise hypoglycemia induction procedure. Subjects meeting eligibility requirements will be randomized to 1 of 4 treatment groups, 2 glucagon, 2 placebo. Subjects will receive blinded study drug for 4 weeks, and they will be followed for an additional 26 weeks post-treatment. Subjects' counter-regulatory hormone response will be measured at baseline, the end of treatment (4 weeks), and 13 and 26 weeks after treatment ends.

Detailed description:

Arms: arm 1: Glucagon given as a continuous subcutaneous infusion for 28 days arm 2: Glucagon given as a continuous subcutaneous infusion for 28 days arm 3: Placebo given as a continuous subcutaneous infusion for 28 days arm 4: Placebo given as a continuous subcutaneous infusion for 28 days
Interventions: intervention 1: Glucagon intervention 2: Placebo
Intervention descriptions: intervention 1: CSI-Glucagon is a room temperature stable, non-aqueous, liquid formulation of glucagon. intervention 2: The placebo solution is a non-active formulation containing excipients only.

Protocol documents:
Prot_000.pdf: 
XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
1 
Confidential 
 
 
 
 
 
 
 
CSI-GLUCAGON™ (CONTINUOUS SUBCUTANEOUS 
GLUCAGON INJECTION) 
PROTOCOL XSGO-AF01 
 
FIXED RATE CONTINUOUS SUBCUTANEOUS GLUCAGON 
INFUSION (CSGI) VS PLACEBO IN TYPE 1 DIABETES 
MELLITUS PATIENTS WITH RECURRENT SEVERE 
HYPOGLYCEMIA: EFFECTS ON COUNTER REGULATORY 
RESPONSES TO INSULIN INDUCED HYPOGLYCEMIA 
 
 
 
Version 4.0 
21-Dec-2018 
Approved


Xeris_XSGO-AF01_Protocol_ Amendment 4.0_21Dec_2018Signed | VV-TMF-01992 | 1.0
Approved
Downloaded by Ashley Gregory on 10/8/2019
***APPROVED COPY*** PRO-19-00084 Version 4.0


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
3 
Confidential 
 
 
INVESTIGATOR’S AGREEMENT 
 
I have read the XSGO-AF01 protocol version 4.0 dated 21-Dec-2018 and agree to conduct the 
study as outlined. I agree to maintain the confidentiality of all information received or developed 
in connection with this protocol. 
 
 
 
 
 
 
 
Printed Name of Investigator 
 
 
 
Signature of Investigator 
 
 
 
Date 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
4 
Confidential 
 
 
PROCEDURES IN CASE OF EMERGENCY 
Table 1: 
Emergency Contact Information 
 
Role in Study 
Name & Title 
Email Address & Telephone Number 
Sponsor’s Study Leader & 
primary contact 
Joy Geallis 
Clinical Project Manager 
JGeallis@xerispharma.com 
815-546-9130 
Medical Monitor & 
24-hour emergency contact 
Khaled Junaidi, MD 
Medical Director 
kjunaidi@xerispharma.com 
312-517-1461 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
5 
Confidential 
 
 
2. 
SYNOPSIS 
 
Protocol Number: XSGO-AF01 
Fixed Rate Continuous Subcutaneous Glucagon Infusion (CSGI) vs Placebo in Type 1 
Diabetes Mellitus Patients with Recurrent Severe Hypoglycemia: Effects on Counter- 
Regulatory Responses to Insulin-Induced Hypoglycemia 
Principal 
Investigator: 
Each participating clinical site will nominate a physician who, based on 
training and experience, will serve as principal investigator for that site. The 
Sponsor will qualify the Investigator. 
IND: 
120653 
Project phase: 
Phase 2a 
Compound(s): 
G-Pump™ (glucagon infusion) 
Objectives: 
Primary Objective: 
The change from baseline in plasma epinephrine will be compared between 
subjects who have received either 4 weeks of continuous subcutaneous 
glucagon infusion (CSGI) or placebo. After 30 minutes of a maintained 
insulin-induced hypoglycemia clamp (plasma glucose (PG) < 50 mg/dL), 
these hormone levels will be measured in adult type 1 diabetes (T1D) 
subjects with hypoglycemia associated autonomic failure (HAAF). 
The secondary objectives are to: 
1. Compare change from baseline in cumulative glucose infusion 
required to maintain glucose at 50 mg/dL for the first 30 minutes 
after the 50 mg/dL is achieved. 
2. Compare changes from baseline in the other counter-regulatory 
hormones: norepinephrine, glucagon, cortisol and growth hormone. 
3. Compare changes from baseline to week 4 in subject responses to a 
validated symptom questionnaire administered during induced 
hypoglycemia. 
4. Compare changes from baseline to week 4 in continuous glucose 
meter (CGM)-derived hypoglycemia parameters of: 
a. Proportional time spent with interstitial glucose < 70, 60, and 
50 mg/dL. 
b. Rate of hypoglycemic event episodes at thresholds of < 70, 
60, and 50 mg/dL. 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
6 
Confidential 
 
 
 
5. Compare change from baseline to week 4 in CGM-derived 
parameters of: 
a. Average glucose and proportional time: 
i. Time within range with PG 70 - 180 mg/dL, 
ii. Time above range with PG ≥ 180 mg/dL. 
iii. Time below range < 70 mg/dL 
b. Plasma glucose standard deviation. 
6. Describe subject reported hypoglycemic events: 
a. Symptomatic events confirmed with self-monitored glucose < 
70 mg/dL. 
b. Symptomatic events with no accompanying glucose meter 
reading or a reading ≥ 70 mg/dL. 
c. Asymptomatic events of self-monitored glucose < 70 mg/dL. 
d. Severe hypoglycemia as defined by affected consciousness of 
hypoglycemic origin confirmed by a glucose meter reading 
<36 mg/dL, requiring external assistance, or prompt recovery 
upon hypoglycemia treatment. 
7. Describe change from baseline to week 4 of unawareness measured 
by the Gold scale. 
8. Describe basal, bolus and total daily insulin dose changes by 
treatment group. 
9. Describe the time course of the endpoints (primary and secondary 1- 
7) from week 4 through the rest of the study. 
10. Describe non-serious and serious adverse events by treatment group 
11. Describe change from baseline through week 4 of serum 
concentrations of glucagon while still on the CSGI, and glucagon 
antibodies. 
Study design: 
This is a prospective, randomized, double-blind, parallel trial with the 
primary endpoint analysis after 4 weeks treatment with CSGI or placebo. As 
both the low and high dose group use the same formulation the dose will be 
determined by infusion. To preserve the blind, the placebo is administered by 
matching infusion methods to CSGI . 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
7 
Confidential 
 
 
 
Study Schematic 
 
After a run-in on CGM, subjects will have key hormones of their 
hypoglycemia counter regulatory response quantified using a stepwise 
hypoglycemia induction. They will then receive investigational product for 4 
weeks before discontinuation and reassessment of the same hypoglycemia 
counter regulatory response. 
Treatment stops at 4 weeks, but subjects will continue blinded for 6 
additional months to investigate duration of response with assessments at 3 
and 6 months. 
Study location: Approximately 6-8 clinical research centers in the United States. 
Study 
duration: 
The estimated duration of study participation for individual subjects is 
approximately 7.5 months. The estimated duration of the entire study is 1 
year from first patient in to last patient out. 
Sample size: 
The primary hypothesis is to evaluate change from baseline to 4 weeks of 
plasma epinephrine concentration after 30 minutes of induced hypoglycemia 
with plasma glucose <50mg/dL between treatment groups. Sample size is 
based on a hierarchical hypothesis test in which the comparison of treatment 
groups will be implemented in the following order: 
CSGI (combined groups -high and low dose) versus placebo 
CSGI high dose versus placebo 
CSGI low dose versus placebo 
CSGI high dose versus CSGI low dose 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
8 
Confidential 
 
 
 
Using this method, an alpha of 5% will be preserved for each hypothesis test 
where the next ordered test will only be conducted if statistical significance 
is achieved for that hypothesis. Final calculations are based on 80% power 
and an alpha of 5%, to demonstrate a plasma epinephrine increase compared 
to placebo of 1.5 nmol/l given and SD of 1.34 nmol/l at an induced PG of 50 
mg/dl. Sixteen subjects per group (CSGI high dose, CSGI low dose, and 
placebo) are required based on the minimum sample size estimate for a 
comparison against placebo (N=42). To account for attrition, a total of 48 
subjects will be randomized for the study. 
Subjects: 
Male or female type 1 diabetes mellitus patients with recurrent severe 
hypoglycemic episodes indicative of hypoglycemia associated autonomic 
failure (HAAF) ages 21-64 years, inclusive. 
Inclusion 
Criteria: 
1. Males or females diagnosed with type 1 diabetes mellitus for at least 24 
months. 
2. Random serum C-peptide concentration < 0.6 ng/ml at Screening. 
3. Age 21-64 years, inclusive, at screening. 
4. Documented Hypoglycemia unawareness as evidenced by a Gold Scale 
score ≥4, at screening 
5. Medical history of an episode of severe hypoglycemia as reported by 
patient < 50 mg/dL, in the 1 year prior to screening. 
6. Current use of multiple daily dosing insulin treatment (< 1 U/(kg*day) 
total daily dose) either administered with subcutaneous injections or 
continuous subcutaneous insulin infusion (CSII). 
7. Performs monitoring of glucose minimally 3 times a day. Patients using 
continuous glucose monitoring for monitoring should continue to do so 
during the course of the study. 
8. Willingness to provide informed consent and follow all study 
procedures, including using the Medtronic smartphone application 
“iPRO2mylog” for diabetes data logging and attending all scheduled 
visits. 
Exclusion 
Criteria: 
1. HbA1c ≥ 10% at Screening. 
2. Chronic kidney disease stage 4 or 5. 
3. Hepatic disease, including serum ALT or AST greater than or equal to 3 
times the upper limit of normal; hepatic synthetic insufficiency as 
defined as serum albumin < 3 g/dL. 
4. Hematocrit of less than or equal to 30% at Screening. 
5. Clinically significant ECG abnormalities at Screening. 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
9 
Confidential 
 
 
6. Congestive heart failure, NYHA class III or IV. 
7. History of myocardial infarction, unstable angina or revascularization 
within the past 6 months. 
8. History of a cerebrovascular accident with residual neurologic deficit. 
9. Current seizure disorder, unrelated to hypoglycemia. 
10. History of pheochromocytoma or disorder with increased risk of 
pheochromocytoma (MEN 2, neurofibromatosis, or Von Hippel-Lindau 
disease). 
11. History of insulinoma. 
12. Active malignancy within 5 years from Screening, except basal cell or 
squamous cell skin cancers. Any history of breast cancer or malignant 
melanoma will be exclusionary. 
13. Major surgical operation within 90 days prior to Screening. 
14. Current bleeding disorder, treatment with anticoagulants, or platelet 
count below 50,000/mL at Screening. 
15. History of allergies to glucagon or glucagon-like products, or any 
history of significant hypersensitivity to glucagon or any related 
products or to any of the excipients (DMSO, trehalose) in the 
investigational formulation. 
16. History of glycogen storage disease. 
17. Any concurrent illness, other than diabetes, that is not controlled by a 
stable therapeutic regimen. 
18. Active substance or alcohol abuse (more than 21 drinks/wk. for males or 
14 drinks/wk. for females). Subjects reporting active marijuana use 
and/or testing positive for THC via rapid urine test will be allowed to 
participate in the study at the discretion of the investigator. Subjects 
positive for other drugs of abuse via rapid urine test who report use of a 
prescription or OTC medication that would explain such a finding will 
be allowed to participate at the discretion of the investigator. 
19. Administration of glucagon within 7 days of Screening. 
20. Pregnant and/or Lactating. For subjects of childbearing potential, there 
is a requirement for a negative urine pregnancy test and for agreement to 
use contraception and to refrain from breast feeding during the study and 
for at least 1 month after participating in the study. Acceptable 
contraception includes birth control pill / patch / vaginal ring, Depo- 
Provera, Norplant, an IUD, the double barrier method (the female uses a 
diaphragm and spermicide and the male uses a condom), or abstinence. 
21. Inadequate venous access. 
22. Participation in other studies involving administration of an 
investigational drug or interventional device within 30 days or 5 half- 
lives, whichever is longer, before Screening for the current study and 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
10 
Confidential 
 
 
 
during the four weeks of study product administration in the current 
study. 
23. Any reason the principal investigator deems exclusionary. 
Brief outline 
of treatments: 
Baseline Qualification: 
Subjects will continue their insulin regimen as usual throughout the study, 
adjusted by the investigator to achieve ADA recommended targets. 
After enrollment, the subjects will require approximately one week of CGM 
data prior to their baseline hypoglycemia induction procedure. Subjects will 
enter a run-in phase of 1 week wearing a blinded CGM device. 
Subjects will arrive in the Clinical Research Unit (CRU) the morning of the 
planned hypoglycemia induction procedure. The CGM data will be retrieved. 
The following CGM criteria must be met: a minimum of 6 days must be 
recorded using the CGM before the subject will be inserted with a new CGM 
device. If the CGM criteria are not met, the subject is inserted with another 
CGM for renewed baseline period. Should the second baseline period not 
yield eligible CGM data, the subject will stop further participation in the 
screening procedures. 
The subject will fast after midnight. They will remain fasting until the end of 
the hypoglycemia procedure the following day. CGM data will be checked 
for a minimum of six days of data and a confirmation that the subject did not 
have a hypoglycemic event, < 70 mg/dL during the previous 8 hours. 
Hypoglycemia induction procedure: 
Insulin induced hypoglycemia (PG < 50 mg/dL as measured by YSI) is 
achieved through a hyperinsulinemic clamp procedure. 
The plasma glucose should be verified to be between the 80-120 mg/dL. The 
IV insulin infusion rate is then increased to 20 mU/(body surface 
area(BSA)*min) as a set rate and the subject’s plasma glucose is stabilized at 
100±10 mg/dL for minimally 60 minutes, through adjustments in continuous 
IV glucose. After this 60 minute stable period, the plasma glucose will be 
reduced to 70 mg/dL by decreasing the continuous IV glucose infusion rate. 
When the plasma glucose has been stable at 70+/-5 mg/dL for 20 minutes, a 
hypoglycemia symptom questionnaire administered, which will be repeated 
after 10 minutes. 
The hypoglycemia induction will then begin, decreasing the continuous IV 
glucose infusion rate to bring the plasma glucose down to < 50 mg/dL. 
Plasma glucose is measured every 5 minutes and the continuous IV glucose 
infusion rate is adjusted to achieve the target glucose concentration of < 50 
mg/dL. When the target plasma glucose of < 50 mg/dL has been achieved, 
blood samples for the assessment of counter regulatory hormones are drawn, 
and the hypoglycemia questionnaire is administered. Plasma glucose 
concentration will be measured and maintained at 50+/-5 mg/dL for 30 
minutes after which another set of blood samples for assessment of counter 
regulatory hormones are drawn and the hypoglycemia questionnaire re- 
administered. The insulin infusion is then stopped, and plasma glucose is 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
11 
Confidential 
 
 
 
raised to >70 mg/dL through the continuous IV glucose. The continuous IV 
glucose infusion is stopped once the subject’s PG > 70 mg/dL and the 
subject will be given a standardized meal. The subject is monitored until 
deemed medically stable for discharge, per investigator discretion. 
Visit Overview: 
After the completion of the first study visit (the baseline hypoglycemia 
induction procedure), the investigator will train the subjects to load, prime, 
and use of the modified OmniPod. In this training, the subject will learn to 
prepare and use an OmniPod at a suitable infusion site. This includes direct 
observation of the subject when they attach and initiate the device, by the 
investigational staff. 
The subject is then randomized to a study treatment and begins therapy in the 
CRU. The assigned study treatment will be 4 weeks in duration. They are 
initially provided with a 1-week supply of blinded study drug and OmniPods. 
The subjects will return weekly for a safety check, CGM device data 
retrieval, new sensor insertion, and receipt of study supplies. The subject is 
expected to complete at least 90% of the study therapy during the 4-week 
treatment period. 
After 4 weeks of study therapy, the subject will return to the clinic. The 
study product will be stopped and the CGM data retrieved before a repeat of 
the hypoglycemia induction procedure as described above. 
12 weeks after study treatment, the subjects will return to the CRU for 
insertion of a CGM device. One week later (13 weeks after completing study 
treatment), the CGM will be retrieved and the subject will undergo the 
hypoglycemia induction procedure as described above. 
At 25 weeks after study treatment, the subjects will return to the CRU for 
insertion of a CGM device. One week later (26 weeks after completing study 
treatment), the CGM will be retrieved and the subject will undergo the 
hypoglycemia induction procedure as described above. 
After completion of the hypoglycemia induction procedure at 26 weeks, the 
subject’s participation in the study is completed. 
Data 
management 
and statistical 
analysis: 
Data will be entered into an electronic Case Report Form by site personnel. 
Data will be monitored at on-site visits by Xeris personnel or by a CRO 
acting as Xeris’ agent. Data will be reviewed on an ongoing basis for missing 
values, out of range values and missingness. 
The primary analysis for the study is the comparison of the change from 
baseline of plasma epinephrine concentration during induced hypoglycemia 
with PG <50 mg/dL between CSGI and placebo, and to evaluate if there is a 
difference between CSGI high dose and low dose versus placebo after 4 
weeks of blinded treatment. 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
12 
Confidential 
 
 
 
 
The analysis of the primary endpoint will be performed using a two-group t- 
test for each hypothesis test in the hierarchy, while preserving alpha at 0.05. 
CSGI (high and low dose combined) will first be tested against placebo, and 
if the difference is statistically significant <0.05, CSGI high dose versus 
placebo will be tested. If statistically significant <0.5, then CSGI low dose 
versus placebo will be tested, and if statistically significant, CSGI high dose 
versus CSGI low dose will be tested. 
Analyses of the secondary endpoints including CGM and hormone variables 
will be conducted with descriptive and inferential statistics. Responses to the 
Gold scale and hypoglycemia symptom questionnaire will be analyzed using 
Chi-square tests. The mean endpoints (3-6) from week 4 through the end of 
study will be presented graphically to assess the time course. 
Adverse events, laboratory safety variables (Screening to Day 28), physical 
examination, vital signs, ECG (Screening to Day 28), and local tolerability 
data will be reviewed and summarized on an ongoing basis during the study 
to evaluate the safety of subjects. Safety data will be presented in tabular 
and/or graphical format and summarized descriptively, where appropriate. 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
13 
Confidential 
 
 
3. 
TABLE OF CONTENTS, LIST OF TABLES, AND LIST OF 
FIGURES 
TABLE OF CONTENTS 
1. 
TITLE PAGE ................................................................................................................1 
2. 
SYNOPSIS ...................................................................................................................5 
3. 
TABLE OF CONTENTS, LIST OF TABLES, AND LIST OF FIGURES ...............13 
4. 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS .............................18 
5. 
STUDY OBJECTIVES AND ENDPOINTS ..............................................................21 
5.1. 
Primary Objective .......................................................................................................21 
5.2. 
Secondary Objectives .................................................................................................21 
5.3. 
Endpoints ....................................................................................................................22 
5.3.1. 
Primary Endpoint ........................................................................................................22 
5.3.2. 
Secondary Endpoints ..................................................................................................22 
6. 
BACKGROUND AND RATIONALE .......................................................................23 
6.1. 
Indication ....................................................................................................................23 
6.1.1. 
Background .................................................................................................................23 
6.1.2. 
Rationale .....................................................................................................................23 
6.1.2.1. 
Hypoglycemia Associated Autonomic Failure (or Impairment) Identification ..........23 
6.1.2.2. 
Duration ......................................................................................................................23 
6.1.2.3. 
Glucagon Infusion Rate Selection ..............................................................................24 
6.1.2.4. 
Insulin Dose Adjustments ...........................................................................................24 
6.1.2.5. 
Hypoglycemia induction .............................................................................................24 
6.2. 
Non-Clinical Pharmacology and Toxicology Experience with Glucagon ..................24 
6.2.1. 
Nonclinical Pharmacology and Toxicology of Xeris Investigational Non- 
Aqueous, Synthetic Glucagon ....................................................................................25 
6.3. 
Description and Composition of Drug Product ..........................................................25 
6.4. 
Clinical Experience with Glucagon ............................................................................25 
7. 
STUDY DESIGN .......................................................................................................26 
7.1. 
Study Overview ..........................................................................................................26 
7.2. 
Interruption and Termination of Dosing .....................................................................28 
8. 
ELIGIBILITY CRITERIA AND STUDY ENROLLMENT .....................................29 
8.1. 
Inclusion Criteria ........................................................................................................29 
8.2. 
Exclusion Criteria .......................................................................................................29 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
14 
Confidential 
 
 
8.3. 
Enrollment ..................................................................................................................31 
8.4. 
Allocation to Treatment ..............................................................................................31 
8.5. 
Blinding ......................................................................................................................31 
8.6. 
Supplies.......................................................................................................................31 
8.6.1. 
Investigational Product ...............................................................................................31 
8.6.1.1. 
Drug Product Formulation and Packaging ..................................................................31 
8.6.1.2. 
Matching Placebo .......................................................................................................31 
8.6.2. 
Drug Delivery Devices ...............................................................................................32 
8.6.3. 
Preparation, Dispensing and Administration ..............................................................32 
8.6.4. 
Drug Storage and Drug Accountability ......................................................................32 
8.7. 
CGM Devices .............................................................................................................32 
8.8. 
Glucose Meters for Self-Monitoring and Calibration of the CGM Devices ...............33 
8.9. 
Subject Data Log and Smartphone .............................................................................33 
8.10. 
Concomitant Medications ...........................................................................................33 
9. 
STUDY PROCEDURES ............................................................................................34 
9.1. 
Outpatient Insulin Dose Adjustment During Run-in and Treatment Phases 
Weeks -1-4 ..................................................................................................................34 
9.2. 
CGM, Glucose Meter, Electronic Diary and Pump Data............................................34 
9.3. 
Euglycemia Maintenance Procedure  .........................................................................34 
9.4. 
Hypoglycemia Induction Procedure ...........................................................................36 
9.4.1. 
Baseline Stabilization with Constant Insulin Infusion Rate .......................................37 
9.4.2. 
Hypoglycemia Induction, 1st Step ...............................................................................37 
9.4.3. 
70 mg/dL Stabilization................................................................................................37 
9.4.4. 
Hypoglycemia Induction, 2nd Step ..............................................................................38 
9.4.5. 
50 mg/dL Stabilization................................................................................................38 
9.4.6. 
Normalization to Euglycemia .....................................................................................38 
9.5. 
Visit Structure .............................................................................................................38 
9.5.1. 
Visit 1 - Screening (Day -25 ± 5) ...............................................................................38 
9.5.2. 
Visit 2 (Day -8 ±2) Initiation of Baseline CGM Assessment and Diary Data 
Collection ....................................................................................................................39 
9.5.3. 
Visit 3 (Day 1) Start of Treatment Phase ....................................................................40 
9.5.4. 
Visit 4 – Safety check (Day 7±2) ................................................................................42 
9.5.5. 
Visits 5 (Day 14±2) .....................................................................................................42 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
15 
Confidential 
 
 
9.5.6. 
Visit procedures are identical to visit 4.Visit 6 (Day 21±1) .......................................42 
9.5.7. 
Visit 7 (Day 27-28±1) .................................................................................................43 
9.5.8. 
Visit 8 (Week 12±1 week) CGM Resumption for 3-Month Follow Up .....................44 
9.5.9. 
Visit 9 (Approximately Week 13±1 Week) 3-Month Follow Up ...............................44 
9.5.10. 
Visit 10 (Week 25±1 Week) CGM Resumption for 6-Month Follow Up ..................44 
9.5.11. 
Visit 11 (Week 26±1 Week) 6-Month Follow Up and Completion of Study .............44 
9.6. 
Subject Withdrawal ....................................................................................................44 
10. 
ASSESSMENTS.........................................................................................................49 
10.1. 
Estimated Blood Volume Drawn through Time .........................................................49 
10.2. 
Clinical Laboratory Tests............................................................................................50 
10.3. 
Electrocardiogram (12-lead ECG) ..............................................................................52 
10.4. 
Blood Pressure and Heart Rate ...................................................................................52 
10.5. 
Definition of an Adverse Event ..................................................................................52 
10.6. 
Reporting Adverse Events ..........................................................................................53 
10.7. 
Reporting Period .........................................................................................................53 
10.8. 
Serious Adverse Events ..............................................................................................53 
10.9. 
Severity Assessment ...................................................................................................54 
10.10. 
Causality Assessment .................................................................................................54 
10.11. 
Withdrawal Due to Adverse Events............................................................................54 
10.12. 
Eliciting Adverse Event Information and Reporting ..................................................54 
10.13. 
Serious Adverse Event Reporting Requirements ........................................................55 
10.14. 
Non-Serious Adverse Event Reporting Requirements ...............................................55 
10.15. 
AE Reporting Requirements to Regulatory Authorities .............................................55 
10.16. 
Pregnancy ...................................................................................................................55 
10.17. 
Subject Monitoring .....................................................................................................56 
11. 
DATA ANALYSIS AND STATISTICAL METHODS ............................................57 
11.1. 
Efficacy .......................................................................................................................57 
11.1.1. 
Closed Hierarchical Hypothesis Tests ........................................................................57 
11.1.2. 
Analysis Populations ..................................................................................................58 
11.1.3. 
Sample Size Calculation .............................................................................................58 
11.2. 
Pharmacokinetic and Pharmacodynamic Analyses ....................................................58 
11.2.1. 
Pharmacokinetic Secondary Endpoints ......................................................................59 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
16 
Confidential 
 
 
11.2.2. 
Pharmacodynamic Secondary Endpoints ....................................................................59 
11.3. 
Safety Analysis ...........................................................................................................59 
11.3.1. 
Adverse events ............................................................................................................59 
11.3.2. 
Laboratory safety assessments ....................................................................................59 
11.3.3. 
Physical examination ..................................................................................................60 
11.3.4. 
Vital signs and body weight ........................................................................................60 
11.3.5. 
ECG: ...........................................................................................................................60 
11.3.6. 
Local Tolerability .......................................................................................................60 
11.4. 
Subgroup Analysis ......................................................................................................60 
11.5. 
Interim Analyses .........................................................................................................60 
12. 
QUALITY CONTROL AND QUALITY ASSURANCE..........................................61 
13. 
DATA HANDLING, RECORD KEEPING, MONITORING AND AUDITS ..........62 
13.1. 
Case Report Forms/Electronic Data Record ...............................................................62 
13.2. 
Record Retention ........................................................................................................62 
13.3. 
Monitoring ..................................................................................................................62 
13.4. 
Audits and Inspections ................................................................................................63 
14. 
ETHICAL CONSIDERATIONS ................................................................................64 
14.1. 
Conduct .......................................................................................................................64 
14.2. 
Institutional Review Board (IRB) ...............................................................................64 
14.3. 
Subject Information and Consent ...............................................................................64 
14.4. 
Subject Recruitment ....................................................................................................65 
14.5. 
Reporting of Safety Issues and Serious Breaches of the Protocol ..............................65 
15. 
DEFINITION OF END OF TRIAL ...........................................................................66 
16. 
PROCEDURES FOR MODIFYING THE PROTOCOL OR 
TERMINATING THE STUDY .................................................................................67 
16.1. 
Protocol Modifications and Deviations ......................................................................67 
16.2. 
Study Termination ......................................................................................................67 
17. 
PUBLICATION OF STUDY RESULTS ...................................................................68 
18. 
REFERENCES ...........................................................................................................69 
APPENDICES ...............................................................................................................................70 
APPENDIX 1. GOLD SCORE ...................................................................................................70 
APPENDIX 2. HYPOGLYCEMIA SYMPTOM QUESTIONNAIRE ......................................71 
APPENDIX 3. INJECTION SITE DISCOMFORT ASSESSMENT .........................................72 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
17 
Confidential 
 
 
APPENDIX 4. DRAIZE SCALE ................................................................................................74 
List of Tables 
Table 1: 
Emergency Contact Information ...................................................................................4 
Table 2: 
Abbreviations and Specialist Terms ...........................................................................18 
Table 3: 
Insulin Infusion Rate Management Following Measured PG ....................................35 
Table 4: 
Euglycemia Maintenance IV Insulin Infusion Rate Algorithms ................................36 
Table 5: 
Hypoglycemia Induction Overview ............................................................................37 
Table 6: 
Schedule of Assessments ............................................................................................46 
Table 7: 
Frequency and Volume of Blood Collections .............................................................49 
Table 8: 
Clinical and Safety related Laboratory Tests Performed at Site .................................50 
Table 9: 
AE Severity Assessment .............................................................................................54 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
18 
Confidential 
 
 
4. 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS 
The following abbreviations and specialist terms are used in this study protocol. 
Table 2: 
Abbreviations and Specialist Terms 
 
AE 
Adverse Event 
ALT 
Alanine Aminotransferase 
AST 
Aspartate Aminotransferase 
AUC 
Area Under the Curve 
BP 
Blood Pressure 
BSA 
Body Surface Area 
CGM 
Continuous Glucose Monitor 
CHO 
Carbohydrate 
CLIA 
Clinical Laboratory Improvement Act 
Cmax 
Maximum Plasma Concentration 
CRF 
Case Report Form 
CRC 
Clinical Research Center 
CRO 
Contract Research Organization 
CSGI 
Continuous Subcutaneous Glucagon Infusion 
SCII 
Continuous Subcutaneous Insulin Infusion 
DMSO 
Dimethyl sulfoxide 
ECG 
Electrocardiogram 
GCP 
GLP 
Good Clinical Practice 
Good Lab Practice 
GIR 
Glucose Infusion Rate 
HAAF 
Hypoglycemia Associated Autonomic Failure 
HbA1c 
Glycated hemoglobin 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
19 
Confidential 
 
 
 
HBV 
Hepatitis B Virus 
HCV 
Hepatitis C Virus 
HIV 
Human Immunodeficiency Virus 
HR 
Heart Rate 
ICF 
Informed Consent Form 
IB 
Investigator’s Brochure 
ICH 
International Conference on Harmonization 
IEC 
Independent Ethics Committee 
im 
Intramuscular 
IRB 
Institutional Review Board 
IIR 
Insulin Infusion Rate 
IUD 
Intra-uterine Device 
IV 
Intravenous 
kg 
Kilogram 
L 
Liters 
LSLV 
Last Subject Last Visit 
MedDRA 
Medical Dictionary for Regulatory Activities 
mg 
Milligram 
min 
Minute 
mmHg 
Millimeters Mercury 
NOAEL 
No Observed Adverse Effect Level 
PD 
Pharmacodynamics 
PG 
Plasma Glucose 
PK 
Pharmacokinetic 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
20 
Confidential 
 
 
 
RBC 
Red Blood Cells 
rDNA 
Recombinant 
RLD 
Reference Listed Drug 
SAE 
Serious Adverse Event 
sc 
Subcutaneous 
THC 
Tetrahydrocannabinol 
Tmax 
Time to Maximum Plasma Concentration 
T1D 
Type 1 Diabetes Mellitus 
ULN 
Upper Limit of Normal 
VAS 
Visual Analog Scale 
WHO 
World Health Organization 
YSI 
Yellow Springs Instrument 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
21 
Confidential 
 
 
5. 
STUDY OBJECTIVES AND ENDPOINTS 
5.1. 
Primary Objective 
The primary objective is to compare the plasma epinephrine concentration after 30 minutes of 
induced hypoglycemia (PG <50mg/dL) in adult T1D subjects with HAAF, who have received 4 
weeks of treatment with either CSGI or placebo. 
5.2. 
Secondary Objectives 
The secondary objectives are to: 
1. Compare change in cumulative glucose infusion to maintain glucose at 50 mg/dL for the 
first 30 minutes after the 50 mg/dL is achieved. 
2. Compare changes in the other counter-regulatory hormones: norepinephrine, glucagon, 
cortisol and growth hormone. 
3. Compare changes from baseline to week 4 in subject responses to a validated 
hypoglycemia symptom questionnaire administered during induced hypoglycemia. 
4. Compare changes from baseline to week 4 in CGM-derived hypoglycemia parameters of: 
a. Proportional time spent with interstitial glucose < 70, 60 and 50 mg/dL. 
b. Rate of hypoglycemic event episodes at < 70, 60, and 50 mg/dL. 
5. Compare change from baseline to week 4 in CGM-derived parameters of: 
a. Average glucose, proportional time with 70 ≤ PG < 180 mg/dL, and proportional 
time with PG ≥ 180 mg/dL. 
b. Plasma glucose standard deviation. 
6. Describe subject reported hypoglycemic events: 
a. Symptomatic events confirmed with self-monitored glucose < 70 mg/dL. 
b. Symptomatic events with no accompanying glucose meter reading or a reading ≥ 
70 mg/dL. 
c. Asymptomatic events of self-monitored glucose < 70 mg/dL. 
d. Severe hypoglycemia as defined by affected consciousness of hypoglycemic 
origin confirmed by a glucose meter reading <36 mg/dL, requiring external 
assistance, or prompt recovery upon hypoglycemia treatment. 
7. Describe change from baseline to week 4 of unawareness measured by the Gold scale. 
8. Describe basal, bolus and total daily insulin dose changes by treatment group. 
9. Describe the time course of the endpoints (primary and secondary 1-7) from week 4 
through the rest of the study. 
10. Describe non-serious and serious adverse events by treatment group 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
22 
Confidential 
 
 
11. Describe change from baseline through week 4 of serum concentrations of glucagon 
while still on the CSGI, and serum and plasma glucagon antibodies. 
5.3. 
Endpoints 
5.3.1. 
Primary Endpoint 
The primary endpoint is change from baseline of plasma epinephrine concentration, from time 
zero and after 30 minutes of induced hypoglycemia with PG <50mg/dL. This assessment is 
performed for each hypoglycemia induction procedure. 
5.3.2. 
Secondary Endpoints 
The secondary endpoints for this study include: 
• intravenous glucose infusion rate (GIR). 
• Other counter regulatory hormones norepinephrine, glucagon, cortisol and growth 
hormone plasma concentrations. 
• Symptoms of hypoglycemia (if present) as documented using the hypoglycemia 
symptom questionnaire (Appendix 1). 
• Various CGM derived variables (Secondary Objectives 4 & 5). 
• Hypoglycemia awareness assessment by the Gold scale. 
• Safety-related parameters including: 
o Reported hypoglycemic events.. 
o Insulin dose. 
o Vital signs. 
o Physical exam. 
o ECG. 
o Plasma glucagon and serum glucagon antibodies. 
o Standard safety laboratory parameters. 
o Incidence of adverse events (AEs) and serious adverse events (SAEs). 
o Subjective injection site discomfort as reported by subjects using a 100-mm VAS 
and other questionnaires (Appendix 3). 
o Erythema and/or edema formation at site of injection assessed by an investigator 
using the modified Draize scale (see Appendix 4). 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
23 
Confidential 
 
 
6. 
BACKGROUND AND RATIONALE 
6.1. 
Indication 
The proposed indication is for the prevention of severe hypoglycemia in diabetes mellitus 
patients with recurrent severe hypoglycemia. 
 
6.1.1. 
Background 
Approximately 20% of the type 1 diabetes mellitus (T1DM) population suffers from recurrent 
severe hypoglycemia, which is of considerable consequence to the affected persons in rare cases 
leading to death and to the health care systems as the treatment often involves acute care and 
even hospitalization. 
For many of these people a key component of the underlying pathology is hypoglycemia 
associated autonomic failure (HAAF). Hypoglycemic events decrease autonomic responsiveness 
further increasing the risk of subsequent hypoglycemic events thus constituting a vicious cycle. It 
has been shown scrupulous hypoglycemia avoidance at least partially restores autonomic 
function and diminishes the risk of hypoglycemia and that this effect lasts for years in some 
patients. 
T1DM patients, with time, lose not only Langerhans’ islet B-cell, but also A-cell function 
leading to glucagon deficiency. As the primary counter regulatory hormone to insulin this 
increases the risk of hypoglycemia substantially. The risk of HAAF increases as endogenous 
glucagon is diminished or lost. Administrating exogenous glucagon to partially replace the 
missing endogenous glucagon may therefore, similar to the scrupulous hypoglycemia avoidance, 
restore autonomic function and diminish the increased hypoglycemia risk. 
In support of that hypothesis, continuous subcutaneous administration of low dose glucagon has 
been shown to decrease the number of nocturnal hypoglycemic events in T1DM (Edelman, ADA 
annual scientific sessions, 2006). 
Glucagon is indicated for the treatment of severe hypoglycemia in a 1 mg dose. Xeris has used 
its biocompatible, non-aqueous peptide/protein reformulation technology to create a 
concentrated, low volume, stable glucagon formulation. This glucagon formulation has 
successfully been delivered using the Omnipod®. 
6.1.2. 
Rationale 
 
6.1.2.1. 
Hypoglycemia Associated Autonomic Failure (or Impairment) Identification 
The Gold score is based on the response to a single question and has the advantages of being 
simple to execute and being supported by numerous investigations since the 1990’s. 
 
6.1.2.2. 
Duration 
The present study tests the hypothesis that 4 weeks of continuous subcutaneous infusion of low 
dose glucagon will increase counter regulatory hormone response to insulin induced 
hypoglycemia. This is consistent with the finding that scrupulous avoidance of hypoglycemia has 
been demonstrated to partially restore autonomic responses to hypoglycemia in this population. 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
24 
Confidential 
 
 
To obtain preliminary data describing the duration of such response, subjects are retested 3 and 6 
months after the cessation of the investigational product. 
6.1.2.3. 
Glucagon Infusion Rate Selection 
A previous study (Edelman, ADA annual scientific sessions, 2006) evaluating continuous 
glucagon administration for the prevention of hypoglycemia tested doses at 2, 4 and 8 
ng/(kg*min) and found apparently no effect at 2 ng/(kg*min), weak indications of effect at 4 
ng/(kg*min) and, given a modest sample size, reasonably clear effect at 8 ng/(kg*min) with 
some but limited room for further effect. 
These findings would suggest doses in the vicinity of 4 and 16 ng/(kg*min) corresponding to 
19.2 and 76.8 µg/hr for an 80-kg person would be well chosen in this proof-of-concept study. As 
further development would most likely lead to a device with a fixed infusion rate, the glucagon 
doses chosen for the study are 20 and 80 µg/hr, or given the formulation concentration of 5 
mg/ml, infusion rates of 4 and 16 µl/hr. For the pump setting that measures in insulin U100 units 
that corresponds to 0.4 and 1.6 U/hr. 
This highest dose to be tested in the study will allow a greater than 10x safety margin based on 
findings from a 28-day toxicology study in rats conducted with Xeris glucagon (see current 
Investigator’s Brochure). 
6.1.2.4. 
Insulin Dose Adjustments 
Constant infusion of low rate of glucagon may be expected to elevate glucose not only during 
circumstances that may have led to hypoglycemia, but also when not needed. To avoid glycemic 
escape, subjects’ glucose data will be reviewed weekly and insulin doses adjusted accordingly by 
the clinical personnel. 
6.1.2.5. 
Hypoglycemia induction 
The hypoglycemia induction using a high continuous IV insulin infusion rate countered by a 
continuous IV glucose infusion is standard for HAAF protocols as published in a substantial 
body of literature. The planned insulin infusion rate of 20 mU/(BSA*min) is somewhat smaller 
than what is used in other studies but is still a sufficiently high rate to bring most subjects into 
hypoglycemia. 
6.2. 
Non-Clinical Pharmacology and Toxicology Experience with 
Glucagon 
Native glucagon for injection (bovine, porcine origin) was approved for use in humans in 1960 
[FDA CDER #1]. The 29 amino acid sequence of pancreatic glucagon is identical in humans, 
cows, pigs, dogs, and rats, and is also conserved in biosynthetic versions of glucagon [Eistrup]. 
Glucagon for injection (rDNA origin) was approved in 1998 and is currently the subject of two 
approved NDAs ([NDA 20-928] and [NDA 20-918]). Complete NDA-required pharmacology 
and toxicology data have been reviewed and accepted by the FDA, as described in Lilly 
Glucagon [rDNA origin] for injection and Novo GlucaGen® (glucagon [rDNA origin] for 
injection) labeling [Glucagon, Glucagen]. As Xeris’ drug product is produced by solid-phase 
peptide synthesis (SPPS), which also conserves the glucagon peptide sequence, the rDNA 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
25 
Confidential 
 
 
glucagon information is pertinent to the development of Xeris’ glucagon formulation. A 
summary of this information can be found in Xeris’ current Investigator’s Brochure, which will 
be provided to each investigator participating in this study. 
 
6.2.1. 
Nonclinical Pharmacology and Toxicology of Xeris Investigational Non- 
Aqueous, Synthetic Glucagon 
Information on the nonclinical pharmacology, pharmacokinetics and toxicology of Xeris’ 
glucagon formulation is referenced to Xeris’ current Investigator’s Brochure. 
6.3. 
Description and Composition of Drug Product 
Synthetic glucagon is the drug substance in Xeris’ glucagon formulation. Glucagon cGMP grade 
is manufactured, packaged and released by Bachem AG (Bubendorf, Switzerland), conforms 
with USP standards and has a Type II DMF filed with the FDA.  Xeris’ glucagon formulation is 
a sterile subcutaneous injectable non-aqueous formulation for treatment of severe hypoglycemia. 
Xeris’ glucagon formulation contains 5 mg/ml of glucagon, with trehalose and DMSO as 
excipients. Xeris’ glucagon formulation is supplied in 1.0 mL vials. The drug product is stored at 
controlled room temperature (20-25°C) prior to use. 
 
6.4. 
Clinical Experience with Glucagon 
Glucagon has a long history of medical use in the US, and is currently marketed by Eli Lilly & 
Co. as Glucagon (Glucagon Injection [rDNA origin]), and Novo Nordisk as GlucaGen® 
HypoKit®, both RLDs for treatment of severe hypoglycemia. Glucagon has a rapid onset of 
action and an extremely short half-life, and its safety, efficacy and clinical pharmacology have 
been well established [FDA CDER #2]. The Agency first approved glucagon for use in humans 
in 1960. 
Since 2013 when the first IND for Xeris formulation went into effect, multiple clinical studies 
have been successfully completed including two studies utilizing the Omnipod for delivery. 
Details are provided in Xeris’ current Investigator’s Brochure. 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
26 
Confidential 
 
 
7. 
STUDY DESIGN 
7.1. 
Study Overview 
This is a prospective, randomized, double-blind, parallel trial with the primary analysis after 4 
weeks treatment with CSGI or placebo. As both the low and high dose group use the same 
formulation, the dose will be determined by infusion. To preserve the blind, the placebo 
therefore is administered by matching infusion methods to CSGI (high and low infusion rates, 
split to create the appearance of a 4-group trial on the schematic). 
 
Study Schematic: 
 
 
After a 1-week run-in on CGM, subjects will have key hormones of their hypoglycemia counter 
regulatory response quantified using a stepwise hypoglycemia induction. They will then receive 
investigational product for 4 weeks before discontinuation and reassessment of the same 
hypoglycemia counter regulatory response. 
Treatment stops at 4 weeks, but subjects will continue blinded for 6 additional months to 
investigate duration of response with assessments at 3 and 6 months. The primary endpoint will 
be tested at 4 weeks post randomization, but the double blind will remain intact until the end of 
the study. 
 
Baseline Qualification: 
Subjects will continue their insulin regimen as usual throughout the study, adjusted by the 
investigator to achieve ADA recommended targets. 
After enrollment, the subjects will require approximately one week of CGM data prior to their 
baseline hypoglycemia induction procedure. Subjects will enter a run-in phase of 1 week wearing 
a blinded CGM device. 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
27 
Confidential 
 
 
Subjects will arrive in the Clinical Research Unit (CRU) the morning of the planned 
hypoglycemia induction procedure. The CGM data will be retrieved. The following CGM 
criteria must be met: a minimum of 6 days must be recorded using the CGM before the subject 
will be fitted with a new CGM device. If the CGM criteria are not met, the subject is inserted 
with another CGM for renewed baseline period. Should the second baseline period not yield 
eligible CGM data, the subject will stop further participation in the screening procedures. 
The subject will fast after midnight. The subject’s arms are cannulated venously, one side for 
both insulin and glucose infusion and the other side for venous sampling. The subject will stop 
their own insulin treatment and receive IV insulin and IV glucose to maintain their plasma 
glucose between 80 to 120 mg/dL, as measured by either BGM or YSI. They will remain fasting 
until the end of the hypoglycemia procedure the following day. 
Hypoglycemia induction procedure: 
In the morning, insulin induced hypoglycemia (PG < 50 mg/dL as measured by YSI) is achieved 
through a hyperinsulinemic clamp procedure. 
The plasma glucose should be verified to be between the 80-120 mg/dL. The IV insulin infusion 
rate is then increased to 20 mU/(body surface area(BSA)*min) as a set rate and the subject’s 
plasma glucose is stabilized at 100±10 mg/dL for minimally 60 minutes, through adjustments in 
continuous IV glucose. After this 60-minute stable period, the plasma glucose will be reduced to 
70 mg/dL by decreasing the continuous IV glucose infusion rate. When the plasma glucose has 
been stable at 70+/-5 mg/dL for 20 minutes, a hypoglycemia symptom questionnaire 
administered, which will be repeated after 10 minutes. 
The hypoglycemia induction will then begin, decreasing the continuous IV glucose infusion rate 
to bring the plasma glucose down to < 50 mg/dL. Plasma glucose is measured every 5 minutes 
and the continuous IV glucose infusion rate is adjusted to achieve the target glucose 
concentration of < 50 mg/dL. Hypoglycemia assessment will be administered every five minutes 
from this point until the end of the induction and PG recovery phase. When the target plasma 
glucose of < 50 mg/dL has been achieved, blood samples for the assessment of counter 
regulatory hormones are drawn. Plasma glucose concentration will be measured and maintained 
at 50+/-5 mg/dL for 30 minutes after which another set of blood samples for the assessment of 
counter regulatory hormones are drawn and the hypoglycemia questionnaire re-administered. 
The insulin infusion is then stopped, and plasma glucose is raised to >70 mg/dL through the 
continuous IV glucose. The continuous IV glucose infusion is stopped once the subject’s PG > 
70 mg/dL and the subject will be given a standardized meal. The subject is monitored until 
deemed medically stable for discharge, per investigator discretion. 
 
 
 
Visit Overview: 
After the completion of the first study visit (the baseline hypoglycemia induction procedure), the 
investigator will train the subjects to load, prime, and use the modified OmniPod. In this training, 
the subject will learn to prepare and use an OmniPod at a suitable infusion site. This includes 
direct observation of the subject when they attach and initiate the device, by the investigational 
staff. 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
28 
Confidential 
 
 
The subject is then randomized to a study treatment and begins therapy in the CRU. The 
assigned study treatment will be 4 weeks in duration. They are initially provided with a 1-week 
supply of blinded study drug and OmniPods. The subjects will return weekly for a safety check, 
CGM device data retrieval, new sensor insertion, and receipt of study supplies. The subject is 
expected to complete at least 90% of the study therapy during the 4-week treatment period. 
After 4 weeks of study therapy, the subject will return to the clinic. The study product will be 
stopped and the CGM data retrieved before a repeat of the hypoglycemia induction procedure as 
described above. 
After 12 weeks after study treatment, the subjects will return to the CRU for insertion of a CGM 
device. One week later (13 weeks after completing study treatment), the CGM will be retrieved 
and the subject will undergo the hypoglycemia induction procedure as described above. 
After 25 weeks after study treatment, the subjects will return to the CRU for insertion of a CGM 
device. One week later (26 weeks after completing study treatment), the CGM will be retrieved 
and the subject will undergo the hypoglycemia induction procedure as described above. 
After completion of the hypoglycemia induction procedure at 26 weeks, the subject’s 
participation in the study is completed. 
 
7.2. 
Interruption and Termination of Dosing 
Dosing will be paused for any SAE that occurs in a subject receiving treatment until causality is 
fully assessed by the Investigator. Dosing will cease if the SAE is determined to be either drug- 
related or unknown, and may resume if the SAE is determined to be not drug-related by the 
investigator and the Sponsor agrees. 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
29 
Confidential 
 
 
8. 
ELIGIBILITY CRITERIA AND STUDY ENROLLMENT 
Subject eligibility should be reviewed and documented by an appropriately qualified member of 
the investigator’s study team before a subject is included in the study. Subjects must meet the 
following inclusion and exclusion criteria to be eligible for enrollment into the study. 
 
8.1. 
Inclusion Criteria 
1. Males or females diagnosed with type 1 diabetes mellitus for at least 24 months. 
2. Random serum C-peptide concentration < 0.6 ng/ml at Screening. 
3. Age 21-64 years, inclusive, at screening. 
4. Documented Hypoglycemia unawareness as evidenced by a Gold Scale score ≥4, at 
screening 
5. Medical history of an episode of severe hypoglycemia as reported by patient < 50 mg/dL, 
in the 1 year prior to screening. 
6. Current use of multiple daily dosing insulin treatment (< 1 U/(kg*day) total daily dose) 
either administered with subcutaneous injections or continuous subcutaneous insulin 
infusion (CSII). 
7. Performs monitoring of glucose minimally 3 times a day. Patients using continuous 
glucose monitoring for monitoring should continue to do so during the course of the 
study. 
8. Willingness to provide informed consent and follow all study procedures, including using 
the Medtronic smartphone application “iPRO2mylog” for diabetes data logging and 
attending all scheduled visits. 
 
8.2. 
Exclusion Criteria 
1. HbA1c ≥ 10% at Screening. 
2. Chronic kidney disease stage 4 or 5. 
3. Hepatic disease, including serum ALT or AST greater than or equal to 3 times the 
upper limit of normal; hepatic synthetic insufficiency as defined as serum albumin < 
3 g/dL. 
4. Hematocrit of less than or equal to 30% at Screening. 
5. BP reading at Screening where SBP <90 or >150 mm Hg, or DBP <50 or >100 mm 
Hg. 
6. Clinically significant ECG abnormalities at Screening. 
7. Congestive heart failure, NYHA class III or IV 
8. History of myocardial infarction, unstable angina or revascularization within the past 
6 months. 
9. History of a cerebrovascular accident with residual neurologic deficit. 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
30 
Confidential 
 
 
10. Current seizure disorder, unrelated to hypoglycemia. 
11. History of pheochromocytoma or disorder with increased risk of pheochromocytoma 
(MEN 2, neurofibromatosis, or Von Hippel-Lindau disease). 
12. History of insulinoma. 
13. Active malignancy within 5 years from Screening, except basal cell or squamous cell 
skin cancers. Any history of breast cancer or malignant melanoma will be 
exclusionary. 
14. Major surgical operation within 90 days prior to Screening. 
15. Current bleeding disorder, treatment with anticoagulants, or platelet count below 
50,000/mL at Screening. 
16. History of allergies to glucagon or glucagon-like products, or any history of 
significant hypersensitivity to glucagon or any related products or to any of the 
excipients (DMSO, trehalose) in the investigational formulation. 
17. History of glycogen storage disease. 
18. Any concurrent illness, other than diabetes, that is not controlled by a stable 
therapeutic regimen. 
19. Active substance or alcohol abuse (more than 21 drinks/wk. for males or 14 
drinks/wk. for females). Subjects reporting active marijuana use and/or testing 
positive for THC via rapid urine test will be allowed to participate in the study at the 
discretion of the investigator. Subjects positive for other drugs of abuse via rapid 
urine test who report use of a prescription or OTC medication that would explain such 
a finding will be allowed to participate at the discretion of the investigator. 
20. Administration of glucagon within 7 days of Screening. 
21. Pregnant and/or Lactating. For subjects of childbearing potential, there is a 
requirement for a negative urine pregnancy test and for agreement to use 
contraception and to refrain from breast feeding during the study and for at least 1 
month after participating in the study. Acceptable contraception includes birth control 
pill / patch / vaginal ring, Depo-Provera, Norplant, an IUD, the double barrier method 
(the female uses a diaphragm and spermicide and the male uses a condom), or 
abstinence. 
22. Inadequate venous access. 
23. Participation in other studies involving administration of an investigational drug or 
interventional device within 30 days or 5 half-lives, whichever is longer, before 
Screening for the current study and during the four weeks of study product 
administration in the current study. 
24. Any reason the principal investigator deems exclusionary. 
Waivers to the inclusion/exclusion criteria will not be granted 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
31 
Confidential 
 
 
8.3. 
Enrollment 
Screening will continue until 48 subjects are qualified and randomized for the study. Subjects 
will not be considered enrolled in the study until the time of randomization 
8.4. 
Allocation to Treatment 
Subjects will be assigned a unique Screening number upon entry in the eCRF, which will consist 
of a unique 2-digit site code (starting with 01) and a 2-digit subject number (starting with 01 at 
each site) indicating the sequence at which the subject was screened for eligibility. Subjects will 
keep this number throughout the study. 
The randomization scheme is 1:1:1 for high dose, low dose and placebo. Each group will have 
16 subjects, but the placebo group will be matched to high and low infusion rates (8 in each 
group). The randomization is stratified by site. 
When the subject is qualified and the hypoglycemia induction procedure begins day 1, the 
subject will be randomized by the study coordinator by either a central randomization or by 
logging into the IWRS and requesting a treatment allocation. The site personnel will receive the 
blinded treatment allocation number for the study drug product. 
 
8.5. 
Blinding 
For this study, subjects, investigators and study staff will be blinded. 
The investigator has access to break the blind if necessary in emergency situations for reasons of 
subject safety. Whenever possible, the investigator or sub-investigator should consult the 
Sponsor prior to breaking the blind. When the blinding is broken, the reason must be fully 
documented and entered in the CRF. 
8.6. 
Supplies 
8.6.1. 
Investigational Product 
 
8.6.1.1. 
Drug Product Formulation and Packaging 
CSI-Glucagon™ is a room temperature stable, non-aqueous, injectable liquid formulation of 
glucagon. The formulation consists of 5 mg/mL synthetic glucagon peptide dissolved in a 
primary DMSO solvent, with trehalose added as a stabilizing excipient. A volume of 1 mL of 
formulation is filled into West Pharmaceutical’s 2 mL Crystal Zenith® pre-filled cyclic olefin 
polymer (plastic) vial with Flurotec® coated stopper. The drug product is stored at controlled 
room temperature (20-25°C) prior to use. 
 
8.6.1.2. 
Matching Placebo 
The placebo consists of the vehicle for CSI-Glucagon, so it contains DMSO and trehalose, but no 
glucagon. The placebo is indistinguishable from the investigational drug and will be stored under 
the same conditions. 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
32 
Confidential 
 
 
8.6.2. 
Drug Delivery Devices 
All OmniPod® devices to be used in the study are FDA approved and will not be modified in 
any way from their original state as provided by the manufacturer. 
All devices will be stored at the hospital pharmacies where the clinical investigation takes place 
or in the investigators’ offices prior to use in the clinical trial. 
 
8.6.3. 
Preparation, Dispensing and Administration 
CSI-Glucagon™ and placebo will be supplied as 1 mL of non-aqueous solution in plastic Crystal 
Zenith (CZ) 2 mL vials. CSI-Glucagon™ will be transferred to the OmniPod® using the syringe 
and the fill needle supplied by the pump manufacturer. DMSO-compatible B Braun Injekt F® 
Low Waste Syringe 1 mL will be supplied by Xeris as backup. Each vial of CSI-Glucagon™ will 
be used to fill a single OmniPod® pump. If CSI Glucagon™ is not transferred into the 
OmniPod® within one hour of being drawn up into the syringe, the syringe, needle and drug 
should be discarded, and a fresh vial, needle and syringe should be used to fill the pod. 
8.6.4. 
Drug Storage and Drug Accountability 
Unless notified otherwise by the Sponsor, all supplied Xeris’ investigational product is to be 
stored at controlled room temperature between 20°C to 25°C (68° to 77°F), and drug solution 
should be clear and of a water-like consistency at time of use. 
The investigator or an approved study staff will ensure that the study medications are stored in a 
secure area under recommended storage conditions and in accordance with applicable regulatory 
requirements. 
The site will maintain appropriate documentation of continuous storage conditions and these 
records will be monitored in an on-going basis by the monitor. Any deviations in the storage 
conditions must be documented (including minimum and maximum temperature excursion as 
well as estimate of total duration of storage outside the recommended storage conditions). Such 
deviations must be communicated to the Sponsor as soon as identified by the site with 
appropriate course of action taken regarding the future use of the study medications upon 
consultation with Xeris Pharmaceuticals. 
The investigator must maintain adequate records documenting the receipt, use, loss or other 
disposition of the investigational drug products and supplies. Used and unused investigational 
product will be returned to Xeris. Other used supplies will be destroyed according to local 
regulation and site level SOPs following accountability by Xeris Pharmaceuticals or its designee. 
 
8.7. 
CGM Devices 
Sites will be supplied with sufficient iPRO2 recorder devices to have a dedicated device for each 
subject. The sites will store this device between the CGM data gathering periods and will clean 
the devices before return to Xeris at the end of the study. 
The sites will be supplied sufficient sensors for the study. 
Subjects using their own CGM may continue to use their own device during the study, but these 
will not be re-supplied through the study. 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
33 
Confidential 
 
 
8.8. 
Glucose Meters for Self-Monitoring and Calibration of the CGM 
Devices 
Subjects will be supplied Contour Next meters and strips for use during the CGM data collection 
periods of the study. Subjects must use the supplied meter during these periods of the study, and 
may use it at other times during the study, but are not required to do so. 
8.9. 
Subject Data Log and Smartphone 
The study will capture diabetes management data using the iPRO2mylog application on their 
own device. The application is available in Apples’ and Google’s respective online stores. Xeris 
will make smartphones available for subjects, during the course of the study, if they do not own a 
compatible smartphone. 
 
8.10. 
Concomitant Medications 
Subjects should be on a stable dose of all concomitant medications for at least 30 days prior to 
Screening. All subjects must have their concomitant medications reviewed at each visit. 
Medications taken within 4 weeks before Day 1 will be documented in the CRF. Any changes to 
a subject’s concomitant medication regimen will be documented. Investigators are encouraged to 
avoid adding to or changing a participant’s medications until week 4 of study participation unless 
deemed medically necessary. 
There are not medications that are specifically prohibited during participation in this study, 
except the medications (e.g., anticoagulants) listed under the exclusion criteria (see Section 8). 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
34 
Confidential 
 
 
9. 
STUDY PROCEDURES 
9.1. 
Outpatient Insulin Dose Adjustment During Run-in and Treatment 
Phases Weeks -1-4 
Subjects’ insulin doses should be reviewed and adjusted to maintain current ADA recommended 
glycemic targets of pre-prandial PG of 80-130 mg/dL and post-prandial PG<180 mg/dL, per 
investigator’s discretion. 
9.2. 
CGM, Glucose Meter, Electronic Diary and Pump Data 
CGM, glucose meter, electronic diary data, and insulin pump data for CSII users should be 
collected weekly. The subject is expected to return to the clinic for data upload. The 
Medtronic iPRO2 platform will be familiarized with both the investigator and the subject. 
 
9.3. 
Euglycemia Maintenance Procedure   
The subject will begin fasting at midnight. The subject must have been fasting for a minimum of 
eight hours before the induction procedure may begin. 
Upon the subject’s early morning arrival to clinic*, their plasma glucose should be maintained 
within a target range between 80-120 mg/dL, via IV insulin infusion and/or IV glucose infusion. 
This target range should be obtained as soon as possible. The plasma glucose should be 
remeasured every 30 minutes and appropriately treated until it reaches the desired target range 
has been reached. Afterwards, the plasma glucose may be rechecked every hour. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Per institutional/departmental policy and the approval of the sponsor a subject may be brought in the evening 
prior to the induction procedure. 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
35 
Confidential 
 
 
Table 3: 
Recommended Guidelines for Insulin Infusion Rate Management Following 
Measured PG 
 
Below Goal Range 
Less than 90 mg/dL 
Within Goal Range 
90-120 mg/dL 
Above Goal Range 
Over 120 mg/dL 
Less than 70 mg/dL 
• Turn off infusion 
• Follow Hypoglycemia 
orders*** 
• Recheck BG and re-retreat 
every 15. Then proceed 
according to the appropriate 
column of this table for next 
measured BG. 
70 – 80 mg/dL 
• Turn off infusion. 
• Check BG in 30 minutes. 
• Once BG is > 80mg/dl resume 
insulin infusion after moving 
one column to the left 
80-90 mg/dL 
If BG decreased by 30 mg/dL 
or more, or previous BG 80-90 
mg/dL 
• Move left one algorithm and 
adjust rate per BG. 
• If already at ½ Standard move 
left to ¼ Standard Algorithm 
and adjust rate per BG. 
• If already at ¼ algorithm, may 
remain there. 
If BG decreased less than 30 
mg/dL and/or previous BG was 
in goal range 
• Adjust rate in current 
algorithm per BG. 
If BG decreased by >30 
mg/dL between checks 
• Move left one algorithm and 
adjust rate per BG. 
• If already at ½ Standard, 
move left to ¼ Standard 
(Low) Algorithm and adjust 
rate per BG 
If BG DECREASED by 1- 
30mg/dl or INCREASED by 
any amount 
• Adjust rate in current 
algorithm per BG 
IF BG decreased by more than 50 
mg/dL 
• Move left one algorithm and 
adjust rate per BG. 
• If already at ½ Standard, move 
left to ¼ Standard (Low) 
Algorithm and adjust rate per BG. 
• Check BG in 15 minutes if 
decrease was over 100 mg/dL. 
If BG decreased by 25 – 50 mg/dL 
• Adjust rate in current algorithm 
per BG 
If BG increased by any amount, 
remained the same or decreased 
by less than 25 mg/dL 
Step 1. Remain in current 
algorithm and adjust rate per 
BG. 
Step 2. If after remaining in 
current algorithm and next 
BG check continues to 
increase by any amount or 
decrease by less than 25 
mg/dL, move right one 
algorithm 
Step 3. Check BG at next time 
point per protocol, and restart 
at step 1 if appropriate. 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
36 
Confidential 
 
 
Table 4: 
Recommended Euglycemia Maintenance IV Insulin Infusion Rate 
Algorithms 
 
BG 
mg/dL 
# 1/8 
units/hr 
(ml/hr)* 
# 1/4 
units/hr 
(ml/hr)* 
# 1/2 
units/hr 
(ml/hr)* 
# 1 
Standard 
units/hr 
(ml/hr)* 
# 2 
units/hr 
(ml/hr)* 
# 3 
units/hr 
(ml/hr)* 
# 4 
units/hr 
(ml/hr)* 
# 5 
units/hr 
(ml/hr)* 
# 6 
units/hr 
(ml/hr)* 
80-90 
0.1 
(0.5)* 
0.2 
(1) 
0.3 
(1.5) 
0.5 
(2.5) 
0.6 
(3) 
0.8 
(4) 
1.0 
(5) 
1.2 
(6) 
1.4 
(7) 
90 - 120 
0.2 
(1) 
0.3 
(1.5) 
0.5 
(2.5) 
0.7 
(3.5) 
0.8 
(4) 
1.0 
(5) 
1.2 
(6) 
1.4 
(7) 
1.6 
(8) 
121-160 
0.3 
(1.5) 
0.4 
(2) 
0.7 
(3.5) 
0.9 
(4.5) 
1.1 
(5.5) 
1.2 
(6) 
1.4 
(7) 
1.6 
(8) 
1.8 
(9) 
161-180 
0.4 
(2) 
0.5 
(2.5) 
1 
(5) 
1.1 
(5.5) 
1.3 
(6.5) 
1.5 
(7.5) 
1.7 
(8.5) 
1.9 
(9.5) 
2.1 
10.5 
181-220 
0.5 
(2.5) 
0.6 
(3) 
1.2 
(6) 
1.3 
(6.5) 
1.5 
(7.5) 
1.7 
(8.5) 
1.9 
(9.5) 
2.1 
(10.5 
2.3 
11.5) 
221-260 
0.6 
(3) 
0.8 
(4) 
1.5 
(7.5) 
1.7 
(8.5) 
1.9 
(9.5) 
2.1 
(10.5 
2.3 
(11.5 
2.5 
(12.5 
2.7 
(13.5 
261-300 
0.8 
(4) 
1 
(5) 
2 
(10) 
2.2 
(11) 
2.4 
(12) 
2.6 
(13) 
2.8 
(14) 
3.0 
(15) 
3.2 
(16) 
Over 
300 
1 
(5) 
1.3 
(6.5) 
2.5 
(12.5 
2.8 
(14) 
3.0 
(15) 
3.2 
(16) 
3.4 
(17) 
3.6 
(18) 
4.0 
(20) 
*When using 100 units of regular insulin per 500ml of saline, the pump infusion rates in parentheses apply. 
 
9.4. 
Hypoglycemia Induction Procedure 
After the data are checked and PG confirmed to have been within range the visit proceeds. If the 
PG is < 70 mg/dL or > 200 mg/dL, the subject must be rescheduled. 
The hypoglycemia induction procedures have to be initiated in the morning defined as 6 A.M. to 
12 P.M. Subjects should have both arms cannulated one for infusion and one for sampling. 
Separate infusion pumps for insulin and glucose should be ready to begin the procedure. Subjects 
should remain blinded to their PG levels throughout this procedure. 
The venous sampling arm should be kept warm in a heated hand box throughout the treatment 
procedure, in order to achieve “arterialized” samples. The subject’s hand should be monitored at 
least twice an hour to assure it remains warm during the hypoglycemia induction procedure, and 
if it turns cool appropriate measures take to keep it warm. 
The periods of the procedure and what is adjusted are outlined in Table 5. 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
37 
Confidential 
 
 
Table 5: 
Hypoglycemia Induction Overview 
 
Period Reference 
Measured PG (mg/dl) 
Minimum 
Time 
Insulin infusion 
Glucose infusion 
Target 
+/- 
Range 
Insulin infusion rate 
Adjustments 
Glucose infusion rate 
Overnight stabilization 
100 
20 
80-120 
Euglycemia algorithm 
Yes 
0, but ready 
Baseline stabilization 
100 
10 
90-110 
60 min. 
20 mU/(BSA*min) 
Change only if insufficient 
As needed for stabilization 
Start induction 1st step 
70 
20 mU/(BSA*min) 
Change only if insufficient 
Decrease to drop PG at a rate of ≈1 mg/(dl*min) 
Induction 1st step 
70 
20 mU/(BSA*min) 
Change only if insufficient 
Increase when PG nears target 
70 mg/dl stabilization 
70 
5 
65-75 
30 min. 
20 mU/(BSA*min) 
Change only if insufficient 
As needed for stabilization 
Start induction 2nd step 
70 
20 mU/(BSA*min) 
Change only if insufficient 
Decrease to drop PG at a rate of ≈1 mg/(dl*min) 
Induction 2st step 
50 
20 mU/(BSA*min) 
Change only if insufficient 
Increase when PG nears target 
50 mg/dl stabilization 
50 
5 
45-55 
30 min. 
20 mU/(BSA*min) 
Change only if insufficient 
As needed for stabilization 
Normalization 
100 
80-140 
0 No 
As needed until PG> 70 mg/dl 
 
9.4.1. 
Baseline Stabilization with Constant Insulin Infusion Rate 
1. After the baseline procedures are complete the insulin infusion rate is set at 20 
mU/(BSA*min). The rate should be kept constant until the hypoglycemia procedure is 
over unless it proves insufficient. The BSA is calculated using the formula 
BSA=0.007184*W0.425*H0.725 where ‘W’ is weight measured in kg and ‘H’ is height 
measured in cm [Du Bois].  
2. Based on PG measurement every 5 minutes the glucose infusion rate (GIR) is adjusted to 
maintain plasma glucose within in the 90-110 mg/dL range with a target of 100 mg/dL.  
3.  Time 0 begins at the first PG reading within the range of 90-110 mg/dL. 
4.  The PG will be measured every 5 minutes for sixty minutes: 
a. If > 2 of 12 PG measurements are not within the specified range, the sixty 
minute stabilization period will restart. 
• 
This baseline stabilization must be completed within 120 minutes. 
b. If no more than 2 of 12 PG readings are outside the range, subject will continue 
to step Hypoglycemia induction, 1st step.   
c. Plasma Glucose and assessment of hypoglycemia symptoms will be measured as 
a baseline 
d. Hypoglycemia symptoms will be assessed every ten minutes while subject is 
above 70 mg/dL 
e. Two sets of baseline counter regulatory hormone blood samples are drawn 10 
minutes apart once the sixty minutes are met (e.g. 60 and 70 minutes) 
 
9.4.2. 
Hypoglycemia Induction, 1st Step 
1. The GIR will be decreased with the goal of achieving a PG change rate of – 1 
mg/(dL*min) to achieve the target of 70 mg/dL. 
2. At every PG measurement the estimated time to the 70 mg/dL target will be assessed and 
the GIR adjusted accordingly. 
• Hypoglycemia symptoms will be assessed every five minutes when subject is 
below 70 mg/dL 
 
 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
38 
Confidential 
 
 
 
9.4.3. 
70 mg/dL Stabilization 
1. The GIR will be adjusted to maintain the target 70 mg/dL ± 5 mg/dl guided by PG 
measurements every 5 minutes. 
2. Should PG briefly be lower than target range, the steps may be prolonged. 
3. When the plasma glucose has been maintained at 70 mg/dL ± 5 mg/dl, for a minimum of 
30 minutes and the described data collection procedures completed. Then the next phase 
may begin. 
9.4.4. 
Hypoglycemia Induction and Stabilization, 2nd Step 
1. The GIR will be decreased with the goal of achieving a PG change rate of – 1 
mg/(dl*min) to achieve the target of 50 mg/dL but no greater than 54 mg/dL. 
2. The PG will be measured every 5 minutes for thirty minutes: 
a. If 1 PG measurement is greater than 54 mg/dL during the thirty minutes; the 2nd 
step will re-start, per investigator discretion. 
3. At every PG measurement the estimated time to the 50 mg/dL target will be assessed and 
the GIR adjusted accordingly. 
a. Plasma Glucose and assessment of hypoglycemia symptoms will be measured and 
assessed every 5 minutes. 
 
4. 
When the plasma glucose at 50 mg/dL has been maintained for a minimum of 30 
continuous minutes, two sets of blood samples for assessment of counter regulatory 
hormones will be drawn 10 minutes apart (e.g. 30 and 40 minutes). 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
39 
Confidential 
 
 
 
 
9.4.5. 
Normalization to Euglycemia 
1. When the plasma glucose at 50 mg/dL has been maintained for a minimum of 30 minutes 
and the described data collection procedures completed, the IV insulin infusion will be 
stopped and the IV glucose infusion will continue. 
a. Plasma Glucose and assessment of hypoglycemia symptoms will be measured and 
assessed every 5 minutes until subject’s PG is ≥ 70mg/dL 
b. Plasma Glucose and assessment of hypoglycemia symptoms will be measured and 
assessed every 10 minutes until subject’s PG is between 90-110 mg/dL or the 
subject reaches Euglycemia. 
 
2. When PG is >70 mg/dL, the IV glucose infusion is stopped. 
3. The subject will be offered a standardized meal. Euglycemia is confirmed in this recovery 
period. 
4. The subject may be discharged when deemed medically stable by the investigator, per 
CRU criteria. 
5. The subject’s outpatient insulin dosing will be resumed to their baseline setting, after 
discharge from the CRU. 
 
9.5. 
Visit Structure 
A schedule of assessments for this study is provided below in Table 6. All visits should occur 
relative to the randomization which is day zero. 
9.5.1. 
Visit 1 - Screening (Day  up to 25 days + 5) 
Subjects will be screened to confirm they meet the inclusion/exclusion criteria for the study. Prior 
to completing any screening activities, the investigator or study team member will obtain 
informed consent from each subject in accordance with the procedures described in Section 14.3. 
Subject Information and Consent. Assessment of inclusion/exclusion criteria by a study 
investigator, including a review of the subject’s medical history. 
1. Demographic data collection 
2. Concomitant medication review 
3. Recording of the subject’s insulin correction factor (i.e., the reduction in blood glucose in 
mg/dL per 1 unit of insulin taken). 
4. Assessment of vital signs, including measurement of BP, after a 5-minute seated rest. 
5. Physical examination, excluding breast, pelvic and genitourinary exams. 
• 
Measurement of height and weight 
6. Performance of a 12-lead ECG (after subject has completed a 10-minute supine rest.) 
7. Urine pregnancy test for women of childbearing potential. 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
40 
Confidential 
 
 
8. Rapid Urine drug screen. 
9. Collection of venous blood for the following tests as outlined in the Schedule of 
Activities: hemoglobin A1C, complete blood count (without differential), complete 
metabolic panel (CMP), screening for HIV, HBV and HCV (Table 8), and 
immunogenicity testing. 
10. The subject will complete the Gold Scale 
 
11. The subject will be asked if he/she has a smartphone for the logging, and if not order a 
smartphone for subject use during the study. 
12. The subject will be instructed to continue their usual diabetes management. 
13. Once laboratory results are obtained and a final determination of eligibility is made, 
subject will be contacted to schedule visit 2 for initiation CGM baseline assessment. 
** If a subject is outside of the screening window, the laboratory assessments will need to 
be repeated before enrollment. 
 
9.5.2. 
Visit 2 (Day -7 ) Initiation of Baseline CGM Assessment and Diary Data 
Collection 
The subject will arrive at the clinic and the following procedures will be completed: 
1. Eligibility review 
2. Recording of the subject’s insulin correction factor (i.e., the reduction in blood glucose in 
mg/dL per 1 unit of insulin taken). 
3. Review Adverse Events 
4. The subject will receive and be trained in the use of the glucose meter and strips for use 
in the study during the CGM data collections periods. 
5. The study personnel will assist the subject with downloading the iPRO mylog App and 
creating the appropriate account to allow synchronization with the CGM data. 
a. Each site is provided with their specific clinic i.d. from the sponsor 
6. The subject will have the blinded iPRO2 CGM device assigned, inserted and initiated 
according to the manufacturer’s instructions. The iPRO2 device ID will be logged for 
later entry into the eCRF. 
7. The importance of using the study glucose meter no less than 12 hours apart will be 
emphasized for the subject. 
a. Subjects must perform blood glucose readings at a minimum of twice per 
twenty-four hour period. 
8. The subject’s clinical practice glucose, insulin, diary and pump data, if applicable, 
leading up to the visit will be reviewed and any dose adjustments as required will be 
made. 
a. An Insulin Diary will be provided to the subject to collect the following, 
daily: 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
41 
Confidential 
 
 
• 
Total daily dose 
• 
Total Daily Bolus 
• 
Basal Rate 
9. Schedule the subject’s next visit and provide the following reminder: 
a. Subject should not administer any long acting insulin dose after dinner the day 
before the induction procedure.  
b. Sensors will only hold 7 days of data. Should a subject receive an alert from 
the iPro app, S/He should contact the site for guidance. 
 
9.5.3. 
Visit 3 (Day 1) Start of Treatment Phase 
The subject will arrive to the clinic at about 6-9 am for the planned randomization. The subject 
will fast after midnight until the end of the hypoglycemia procedure the subsequent day. 
The following procedures will be completed: 
1. Eligibility Review 
2. The subject’s CGM, electronic diary, and insulin utilization data will be 
collected/uploaded to the electronic data capture (EDC). 
3. Assessment will be made whether the CGM baseline data meet the criteria of minimum 6 
days are recorded using the CGM device. The clinic will be notified within 30 minutes 
from time of subject data upload as follows: 
a. If the data do not meet the above criteria, the subject is inserted with another 
CGM for renewed baseline of CGM period. The visit is rescheduled for a week 
later and the subject is sent home with instructions for another baseline attempt. 
Should the second baseline period not yield eligible CGM data, the subject will 
stop further participation in the procedures. 
b. If the data meets criteria, the visit proceeds. 
 
The following procedures will be carried out once CGM data is confirmed. This includes a        
confirmation that the subject did not have a hypoglycemic event, < 70 mg/dL during the 8 
hours prior to the induction. 
 
4. A new CGM sensor will be inserted. 
5. The subject will be asked of any changes in concomitant medications since their last visit 
and this will be documented in the CRF. 
6. The subject will fill out the Gold Score about hypoglycemia awareness. 
7. Urine pregnancy test for women of childbearing potential. 
8. The subject will be reminded to refrain from using his or her own insulin until the 
hypoglycemia induction procedure the following day is complete. However, the subject 
will withhold their long acting insulin. 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
42 
Confidential 
 
 
9. The Insulin Diary will be collected from the previous visit and a new diary given to the 
subject to collect the following, daily: 
• 
Total daily dose 
• 
Total Daily Bolus 
• 
Basal Rate 
10. IV lines are inserted in both upper extremities. One side will be used for both IV insulin 
infusion and IV glucose infusion. The other side will be used for venous sampling 
during the clamp procedure. 
11. Collection of venous blood for the following tests as outlined in the Schedule of 
Activities:  
• 
CBC/CMP  
• 
Plasma glucagon (PK) prior to Omnipod placement 
12. Plasma glucose is measured using a laboratory quality instrument, e.g. the YSI 2300 or 
2900 that will be used for the clamping procedure. 
13. Insulin infusion should begin after the baseline venous blood samples are obtained. An 
IV glucose infusion should be started concomitantly. 
14.  Assessment of vital signs, including measurement of BP, after a 5-minute seated rest 
15. The 100 mg/dL baseline prior to hypoglycemia induction will be assessed for adequacy 
or initiated as described in section 9.4.1. 
a. When the baseline has been deemed adequate for at least 60 minutes two sets of 
blood samples for assessment of counter regulatory hormones will be drawn 10 
minutes apart and processed. 
16. The hypoglycemia induction including PG determination and hypoglycemia symptoms 
assessments (Appendix 2) will be executed as described in sections 9.4.2 to 9.4.5. 
17. When hypoglycemia at 50 mg/dL has been held for 30 minutes, two sets of blood 
samples for assessment of counter regulatory hormones will be drawn 10 minutes apart 
and processed. 
18. Treatment allocation and dispensing: The subject will be randomized as described in 
section 8.4, investigational product and Omnipods for the subject will be retrieved from 
storage. 
19. When PG is >70 mg/dL in the normalization phase (section 9.4.6) the subject will be 
instructed in the filling and deployment of the OmniPod. 
20. The study personnel will ensure the Omnipod flow rate is correctly set per protocol. 
21. The subject will fill and deploy the first Omnipod under the observation of study 
personnel, insert and initiate the device as part of the training so that the subject can do 
this at home 2-3 days later. 
22. The subject will be supplied with sufficient investigational product, Omnipods, and other 
study materials until the next weekly visit. The subject’s training will include 
instructions to prepare a new Omnipod with the study drug for insertion, every 2-3 days. 
23. Each time a new OmniPod is started local tolerability will be assessed as follows: 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
43 
Confidential 
 
 
a. Subjects will complete a Visual Analog (VAS) questionnaire regarding infusion 
site discomfort (Appendix 3) at 10±5 minutes, at 30±5 minutes and again at 
180±5 minutes following the injection of study drug. 
b. Subjects will complete an Injection Site Discomfort Description and Duration 
Questionnaire at 10±5 minutes post-dosing. If discomfort is ongoing at 10 
minutes post-dosing, the questionnaire will be completed again before the subject 
leaves the clinic to document the final duration. 
24. When the normalization procedure is complete and the subject is medically stable for 
discharge, the next CRU visit, to replenish supplies, will be scheduled. The subject will 
be reminded to keep his or her iPROmylog diary, bring used and unused Omnipods and 
investigational product vials back at the next visit. 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
44 
Confidential 
 
 
9.5.4. 
Visit 4 – Safety check (Day 7±2) 
This visit can occur at any time of day as is least cumbersome for subject and clinic scheduling. 
The following will occur. 
1. AEs since the last visit will be recorded. 
2. Concomitant medication review. 
3. Subject data including CGM, insulin utilization, electronic diary data will be uploaded to 
the MedTronic iPRO2 platform. 
4. The subject’s Omnipod will be removed. 
5. The investigator or sub-investigator will use the modified Draize scales (Appendix 4) to 
assess erythema and edema formation at the injection site at 10±5 minutes following 
removal of the Omnipod. Any injection site with a score > 0 for either erythema or 
edema at 10 minutes post-dosing will be re-evaluated for both at 60±5 minutes post- 
dosing. If any scores remain > 1 at the 60-minute evaluation, the subject may leave the 
clinic but will be instructed to contact study staff if the condition fails to resolve. 
6. Investigational Product and Omnipod accountability will be performed  
7. The subject will load and initiate a new Omnipod with investigational product. 
8. The subject will be given investigational product and Omnipods to cover time to next 
visit and will be instructed to exchange the Omnipod every 2-3 days. 
9. Each time a new OmniPod is started local tolerability will be assessed as follows: 
• Subjects will complete a Visual Analog (VAS) questionnaire regarding infusion 
site discomfort (Appendix 3) at 10±5 minutes, at 30±5 minutes and again at 
180±5 minutes following the injection of study drug. 
• Subjects will complete an Injection Site Discomfort Description and Duration 
Questionnaire (Appendix 4) at 10±5 minutes post-dosing. If discomfort is 
ongoing at 10 minutes post-dosing, the questionnaire will be completed again 
before the subject leaves the clinic to document the final duration. 
10. The next visit will be scheduled 
11. The subject will be reminded to keep his or her iPROmylog diary, bring used and unused 
Omnipods and investigational product vials back at the next visit 
9.5.5. 
Visits 5 (Day 14±2) 
Visit procedures are identical to Visit 4 listed in section 9.5.4. 
 
9.5.6. 
Visit 6 (Day 21±1) 
Visit procedures are identical to Visit 5 listed in section 9.5.4. 
    Additionally, the Insulin Diary will be given to the subject to collect the following, daily: 
• 
Total Daily Dose 
• 
Total Daily Bolus 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
45 
Confidential 
 
 
• 
Basal Rate 
 
9.5.7. 
Visit 7 (Day  28±1) 
The subject will fast after midnight the night before and arrive to the clinic at about 6-9 am the 
day of the planned hypoglycemia induction procedure. They will fast until the end of the 
hypoglycemia induction procedure the subsequent day. The subject will undergo the 
Hypoglycemia Induction Procedure as described in Section 9.4 
1. AEs since the last visit will be recorded. 
2. Concomitant medication review. 
3. Assessment of vital signs, including measurement of BP, after a 5-minute seated rest 
4. Physical examination, excluding breast, pelvic and genitourinary exams. 
• 
Measurement of height and weight 
5. Performance of a 12-lead ECG (after subject has completed a 10-minute supine rest.) 
6. Urine pregnancy test for women of childbearing potential. 
7. Rapid urine drug screen. 
8. The subject will have the following samples drawn: 
• 
 CBC/CMP  
• 
Plasma glucagon (PK) before the Omnipod is removed 
• 
Immunogenicity sample 
9. The subject’s glucose, insulin, diary and pump data, if applicable, since the last visit will 
be reviewed. Subject data will be uploaded to the Medtronic Carelink Portal. 
10. The Insulin Diary will be collected from the previous visit 
11. The subject will complete the Gold Scale 
12. The subject’s Omnipod will be removed. Drug and Omnipod accountability will be 
completed. 
13. The investigator will use the modified Draize scales (Appendix 5) to assess erythema and 
edema formation at the injection site at 10±5 minutes following removal of the Omnipod. 
Any injection site with a score > 0 for either erythema or edema at 10 minutes post- 
dosing will be re-evaluated for both at 60±5 minutes post-dosing. If any scores remain > 
1 at the 60-minute evaluation, the subject may leave the clinic but will be instructed to 
contact study staff if the condition fails to resolve. 
14. The subject will be reminded to refrain from using his or her own insulin until the 
hypoglycemia induction procedure is complete. 
15. IV lines are inserted in both upper extremities for IV insulin and glucose infusion, and for 
venous sampling. 
16. Plasma glucose is measured using a laboratory quality instrument, e.g. the YSI 2300 or 
2900 that will be used for the clamping procedure. 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
46 
Confidential 
 
 
17. Plasma Glucose will be maintained in the 80-120 mg/dL range until  as described in 
section 9.4. 
18. The subject will undergo the hypoglycemia induction procedure and normalization to 
euglycemia, per Section 9.4. 
19. At the end of the treatment visit, the subject will discontinue use of the iPRO2mylog. 
20. For the rest of the study, the subject will continue their standard of care for diabetes 
management. Study drug and devices are no longer used. 
9.5.9. 
Visit 8 (Week 12±1 week)  
CGM Resumption for 3-Month Follow Up 
This visit can occur at any time of day as is least cumbersome for subject and clinic scheduling. 
The following will occur. 
1.  Concomitant Medication Review 
2. AEs since the last visit will be recorded. 
3. The subject’s dedicated blood glucose meter and iPRO2 recorder will be retrieved from 
storage and the subject will resume use as well as the iPRO2mylog diary with the 
insertion of a new CGM sensor. 
4. The subject will be given a supply of BGM strips until the next visit a week later, to 
verify calibration of the CGM. 
5. The Insulin Diary will be given to the subject to collect the following, daily: 
• 
Total Daily Dose 
• 
Total Daily Bolus 
• 
Basal Rate 
 
6. The next visit will be scheduled. 
9.5.10. 
Visit 9 (Week 13±1 Week) 3-Month Follow Up 
The subject will arrive to the clinic at about 6-9 am the day of the planned hypoglycemia 
induction procedure. The subjects will undergo this inpatient CRU visit. 
 
1. AEs since the last visit will be recorded. 
2. Concomitant medication review. 
3. Assessment of vital signs, including measurement of BP, after a 5-minute seated rest 
4. Urine pregnancy test for women of childbearing potential. 
5. The subject will be reminded to refrain from using his or her own insulin until the 
hypoglycemia induction procedure is complete. 
6. The subject will complete the Gold Scale 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
47 
Confidential 
 
 
7. Subject data including CGM, insulin utilization, electronic diary data will be uploaded to 
the MedTronic iPRO2 platform. 
8. The Insulin Diary will be collected from the previous visit. 
9. IV lines are inserted in both upper extremities for IV insulin and glucose infusion, and for 
venous sampling. 
10. Plasma glucose is measured using a laboratory quality instrument, e.g. the YSI 2300 or 
2900 that will be used for the clamping procedure. 
11. Plasma Glucose will be maintained in the 80-120 mg/dL range as described in section 
9.4. 
12. The subject will undergo the hypoglycemia induction procedure and normalization to 
euglycemia, per Section 9.4 
13. The subject will have the following sample drawn: 
• Immunogenicity Sample 
 
 
9.5.11. 
Visit 10 (Week 25±1 Week)  
 
CGM Resumption for 6-Month Follow Up 
The visit procedures are identical to those on Visit 8 week 12 as described in section 9.5.8. 
 
9.5.12. 
Visit 11 (Week 26±1 Week)  
  
 
6-Month Follow Up and Completion of Study 
The visit procedures are identical to those on Visit 9 as described in section 9.5.9 with the 
additions that the following is performed: 
1. A physical examination, excluding breast, pelvic and genitourinary exams. 
2. The subject will have the following samples drawn: 
• 
 CBC/CMP  
3. Final discharge of the subject from the study. 
 
 
9.6. 
Subject Withdrawal 
Subjects may withdraw from the study at any time at their own request, or they may be 
withdrawn at any time at the discretion of the investigator or Sponsor for safety, behavioral or 
administrative reasons. If a subject does not return for a scheduled visit, every effort should be 
made to contact the subject to determine the reason(s) why the subject failed to return for the 
scheduled visit, and to reschedule the missed visit. In all circumstances, every effort should be 
made to document subject outcome. Information regarding the reason for not completing the 
study will be recorded in the CRF. The investigator should inquire about the reason for 
withdrawal, request that the subject return for a final visit, and follow-up with the subject 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
48 
Confidential 
 
 
regarding any unresolved AEs. It will be documented whether each subject completed the study. 
Any subject who receives at least one treatment dose of study medication will be included in the 
safety analysis. 
If a decision by the investigator or sponsor is made to withdraw a subject, a final visit should be 
scheduled soon after the decision to withdraw is made. The subject will be asked to return to site 
for the assessments listed in Section 9.5.11. 
If the subject withdraws from the study and also withdraws consent, no further evaluations 
should be performed, and no additional data should be collected. The Sponsor may retain and 
continue to use any data collected before such withdrawal of consent
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
46 
Confidential 
 
 
 
Table 6: 
Schedule of Assessments 
 
Assessment 
V1 
V2 
V3 
V4 
V5 
V6 
V7 
V8 
V9 
V10 
V11 
Screening 
CGM 
Baseline 
Safety 
CGM 
CGM 
Treatment 
CGM 
3- 
CGM 
6- 
Day  
Placement 
Day 1 
Check 
Placement 
Placement 
End 
Placement 
Month 
Placement 
Month 
25+ 5 
Day -7 
Day 
7±1 
Day 14±1 
Day 21±1 
Day 27- 
28±1 
12±1 
weeks 
F-up  
+13±1 
25±1 
weeks 
F-up 
26±1 
weeks 
 weeks 
Informed consent 
X 
Demographic 
data 
X 
Concomitant 
medications 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Eligibility review 
X 
X 
X 
Vital signs 
X 
X 
X 
X 
X 
Physical exam a 
X 
X 
X 
ECG 
X 
X 
Urine pregnancy 
test 
X 
X 
X 
X 
X 
Rapid urine drug 
screen 
X 
X 
CBC/CMP 
X 
X 
X 
X 
HbA1c 
X 
Subject glucose 
testing data 
review and 
insulin dose 
adjustment 
X 
X 
X 
X 
X 
X 
Randomization 
X 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
47 
Confidential 
 
 
 
Assessment 
V1 
V2 
V3 
V4 
V5 
V6 
V7 
V8 
V9 
V10 
V11 
Screening 
CGM 
Baseline 
Safety 
CGM 
CGM 
Treatment 
CGM 
3- 
CGM 
6- 
Day -- 
Placement 
Day 1 
Check 
Placement 
Placement 
End 
Placement 
Month 
Placement 
Month 
25±5 
Day -7 
Day 
7±1 
Day 14±1 
Day 21±1 
Day 27- 
28±1 
12±1 
weeks 
F-up 
13±
1 
25±1 
weeks 
F-up 
26±1 
weeks 
weeks 
Hypoglycemia 
induction 
X 
X 
X 
X 
Plasma glucose 
(YSI)b 
X 
X 
X 
X 
Hormone levelsc 
Xd 
Xd 
X 
X 
Gold scale & 
Hypoglycemia 
symptom 
questionnaire 
Xe 
X 
X 
X 
X 
Blood samples 
for 
immunogenicity 
testing 
X 
X 
X 
X 
X 
Insert new CGM 
X 
X 
X 
X 
X 
X 
X 
Retrieve prior 
CGM 
X 
X 
X 
X 
X 
X 
X 
Account for and 
Dispense vials & 
OmniPods 
X 
X 
X 
X 
Xf 
Subject 
questionnaire for 
InjectionSite 
Discomfort 
X 
X 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
48 
Confidential 
 
 
 
Assessment 
V1 
V2 
V3 
V4 
V5 
V6 
V7 
V8 
V9 
V10 
V11 
Screening 
CGM 
Baseline 
Safety 
CGM 
CGM 
Treatment 
CGM 
3- 
CGM 
6- 
Day -- 
Placement 
Day 1 
Check 
Placement 
Placement 
End 
Placement 
Month 
Placement 
Month 
25±5 
Day -7 
Day 
7±1 
Day 14±1 
Day 21±1 
Day 27- 
28±1 
12±1 
weeks 
F-up  
13±1 
V6 +25±1 
weeks 
F-up 
26±1 
weeks 
weeks 
Draize scales 
X 
X 
Subject Insulin 
Diaryg 
X 
Xh 
 
 
X 
Xh 
X 
Xh 
X 
Xh 
Review AE 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
a Excluding breast and pelvic/genitourinary exam. 
b Every 5 minutes during hypoglycemia induction 
c Norepinephrine, glucagon, cortisol and growth hormone 10 minutes apart when PG is at 100 mg/dl and 50 mg/dl, 4 times total per hypoglycemia procedure. 
d For glucagon prior to hypoglycemia induction at baseline day -1 and before the removing of the Omnipod at day 27. 
e Only the Gold Scale is administered at screening 
f Accounting only, no dispensing. 
g Subject Insulin Diary will be provided to the subject to collect the following: Total Daily Dose, Total Daily Bolus, Total Basal.  
h Subject Insulin Diary is only collected from the subject 
 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
49 
Confidential 
 
 
 
10. 
ASSESSMENTS 
Every effort should be made to ensure that the required tests and procedures are completed as 
described. However, it is anticipated that there may be circumstances outside the control of the 
investigator, who will take all steps necessary to ensure the safety and well-being of the subject. 
When a protocol-required test cannot be performed, the investigator will document the reason(s) 
and any corrective and preventive actions taken to ensure that study processes are adhered to as 
soon as possible. The study team and the sponsor will be informed of these incidents in a timely 
fashion. 
For all blood and urine collections, an effort should be made to obtain these samples at roughly 
the same time of day (i.e., morning or afternoon) across all visits as well as at the time periods 
specified in the Schedule of Activities. In addition, visits to the site must occur within the pre- 
defined windows outlined in this protocol, otherwise they will be considered as protocol 
deviations. 
10.1. 
Estimated Blood Volume Drawn through Time 
At each hypoglycemia induction there will be approximately 50 blood samples for PG 
determination of about 2cc each Additional sample requirements are shown in (Table 7). The 
largest blood volume drawn over any 3-month period is < 350 ml (less than 24 tablespoons). 
Table 7: 
Frequency and Volume of Blood Collections 
 
Assay 
Sample 
Volume 
(mL) 
Screening 
V3 
V7 
V9 
V11 
Total 
(mL) 
Plasma Glucose 
(YSI)* 
2 
50 
50 
50 
50 
400 
Serum Ethanol 
5 
1 
5 
Chemistry (14 gen 
chem. incl. ALT, 
AST, bilirubin, 
albumin) 
7.5 
1 
1 
1 
1 
30 
C-peptide, serum 
2.5 
1 
2.5 
Hematology 
(Hemoglobin, 
Hematocrit, 
Platelet Count, 
MPV, RDW, 
RBC Count, WBC 
Count, MCV, 
MCH, MCHC, - 
no differential) 
3.5 
1 
1 
1 
1 
14 
HbA1c (included 
in hematology) 
1 
0 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
50 
Confidential 
 
 
 
Assay 
Sample 
Volume 
(mL) 
Screening 
V3 
V7 
V9 
V11 
Total 
(mL) 
Hormone levels: 
Cortisol, 
Norepinephrine, 
Growth hormone 
2 
4 
4 
4 
4 
32 
Hormone levels: 
Plasma 
epinephrine 
4 
4 
4 
4 
4 
64 
Glucagon 
8.5 
4 
5 
4 
4 
144.5 
Immunogenicity 
(Anti-glucagon 
antibody) 
3.5 
1 
1 
1 
1 
14 
Total/Visit (mL) 
22 
169 
181 
161.5 
172.5 
706 
a Single PG measurements at bedside via rapid glucose analyzer. 
 
10.2. 
Clinical Laboratory Tests 
The tests outlined in Table 8 will be performed at the specified time points described in the 
Schedule of Activities. 
Table 8: 
Clinical and Safety Related Laboratory Tests Performed at Site 
 
Hematology 
WBC count 
RBC count 
Hemoglobin 
Hematocrit 
Platelet count 
MPV 
RDW 
MCV 
MCH 
MCHC 
(no differential) 
CMP/Metabolic 
Ca++ 
Random Glucose 
Albumin 
Na+ 
K+ 
Total Protein 
Bicarbonate 
Chloride 
BUN 
Creatinine 
Alkaline Phosphatase 
AST/SGOT 
ALT/SGPT 
Bilirubin 
Urine 
β-hCGa 
Drug screenb 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
51 
Confidential 
 
 
 
Hormones 
Growth 
Cortisol 
Epinephrine 
Norepinephrine 
Glucagon 
Immunogenicity 
Anti-glucagon-antibody 
Laboratory 
HbA1c 
C-peptide 
HIVab 
HCVab 
HBsAg 
a Female participants of childbearing potential require a negative pregnancy test at Screening. Pregnancy testing will 
be repeated at the last treatment visit. 
b Drug screening performed at Screening and the 2 Treatment Visits will include: cocaine, THC, opiates, 
benzodiazepines, and amphetamines. Except as noted below, inclusion in the study requires all tests to be negative at 
screening with the exception of THC, which will be noted, but will not be considered exclusionary. 
A central laboratory will be utilized for analysis of all variables with the exception of urine tests, 
and rapid PG measurements made during treatment visits. A procedures manual will be provided 
to each site by the central laboratory. This manual will cover procedures for the collection, 
processing and shipping of blood samples, along with the Clinical Laboratory Improvement Act 
(CLIA) certification and normal ranges for the central laboratory. 
The central laboratory will provide sites with all supplies needed for collection, processing and 
shipping of all blood samples, including PK samples, as well as point-of-care urine pregnancy 
tests. 
Rapid urine drug screen kits will be provided to the sites. If a subject tests positive for other than 
THC at screening, the subject will normally be excluded from further study participation. 
However, if subject reports use of a concomitant medication (prescription or OTC) that provides 
a reasonable explanation for a positive result other than THC, the subject may be allowed to 
participate in the study at the investigator’s discretion. If the subject is not able to provide a 
reasonable explanation but still refutes a positive finding, a urine sample will be sent to the 
central laboratory for confirmation. The result of this confirmatory test will be considered 
definitive. 
A central analytical lab will analyze the PK samples collected in this study. The procedures for 
preparing, storing and shipping PK samples to the analytical lab are discussed. To the extent 
possible based on storage limitations at the sites, PK samples will be batched so as to reduce 
the overall number of shipments. The main and back-up PK samples (i.e., Aliquots 1 and 2) 
for a particular subject should never be included in the same shipment. 
During treatment visits, PG levels will be measured using a bedside rapid glucose analyzer (e.g. 
YSI 2300 or 2900). At each time point specified in Section9.5, the results of both the black and 
white leads to one decimal place will be recorded in the source documents, with the average of 
the two values rounded up to the nearest one decimal place accepted as the PG level for the time 
point as per the following examples. 
Example #1: black lead = 50.1 and white lead = 49.8 
Calculation: 50.1 + 49.8 = 99.9/2 = 49.95 = 50.0 mg/dL recorded result 
Example #2: black lead = 74.4 and white lead = 74.5 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
52 
Confidential 
 
 
Calculation: 74.4 + 74.5 = 148.9/2 = 74.45 = 74.5 mg/dL recorded result 
The glucose analyzer will be set to auto-calibrate following the standard practice at each site. 
Before each subject visit, performance checks will be made as per the standard practice at each 
site, and sites will maintain a log of these results. 
 
10.3. 
Electrocardiogram (12-lead ECG) 
Single, supine 12-lead ECGs will be obtained at the pre-defined time-points outlined in Schedule 
of Activities as follows: 
• 12-lead ECGs should be performed after the subject has rested quietly for at least 10 
minutes in a supine position. 
• 12-lead ECGs should be obtained before assessment of BP and heart rate, and prior to 
blood collections. 
 
10.4. 
Blood Pressure and Heart Rate 
The BP and heart rate will be measured at the times specified in the Schedule of Activities. 
Additional or changes to collection times, or collection of BP and heart rate using automated 
devices is permitted, as necessary, to ensure appropriate subject’s safety. 
BP and heart rate will be measured in the sitting position with the subject’s arm supported at the 
level of the heart, and recorded to the nearest mmHg. The dominant arm will be used throughout 
the study. The subject should be rested for at least 5 min. before the BP is obtained. SAFETY 
AND ADVERSE EVENT (AE) REPORTING 
 
10.5. 
Definition of an Adverse Event 
An AE is any untoward medical occurrence in a clinical investigation subject administered a 
pharmaceutical product and which is not necessarily required to have a causal relationship with 
this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or 
disease temporally associated with the use of a medicinal product, whether or not considered 
related to the medicinal product. Examples of AEs include: 
• Abnormal test findings. 
• Clinically significant symptoms and signs. 
• Changes in physical examination findings which are untoward and deemed clinically 
significant by the investigator. 
• Allergy/hypersensitivity. 
The criteria for determining whether an abnormal objective test finding may be reported as an 
AE are as follows: 
• Test result is associated with accompanying symptoms, 
• Test result requires additional diagnostic testing or medical/surgical intervention, 
• Test result leads to a change in study dosing or discontinuation from the study, 
significant additional concomitant drug treatment or other treatment. 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
53 
Confidential 
 
 
• Test result is considered to be an AE by the investigator or Sponsor. 
Repeat of a test based on an abnormal result in the absence of the above conditions does not 
constitute an AE. Any abnormal test result determined to be an error does not require reporting 
as an AE. 
A treatment-emergent AE (TEAE) is an AE that either commenced following initiation of study 
treatment or was present prior to study treatment but increased in frequency or severity following 
initiation of study treatment. 
Standard medical terminology should be used in describing AEs. Informal descriptions should 
be avoided. 
 
10.6. 
Reporting Adverse Events 
All observed or volunteered AEs regardless of treatment group or suspected causal relationship 
to the study treatment will be reported with two exceptions. Since it is being experimentally 
induced in this study, hypoglycemia will not be considered an AE in this study unless the event 
meets one of the definitions of an SAE (see Section 10.8). Injection site reactions will not be 
considered an AE unless a skin reaction or pain requires medical intervention. 
For all AEs, the investigator must pursue and attempt to obtain information adequate to 
determine the outcome of the AE and to assess whether it meets the FDA criteria for 
classification as an SAE, requiring immediate notification to Xeris Pharmaceuticals. For AEs 
with a causal relationship to the investigational product, follow-up by the investigator is required 
until the event resolves or stabilizes at a level acceptable to the investigator to consider it closed, 
and Xeris Pharmaceuticals should concur with that assessment. 
As part of ongoing safety reviews conducted by the Sponsor, the Sponsor may escalate any non- 
serious adverse event that is determined to be serious (according to the FDA definitions of an 
SAE). To assist in the determination of case seriousness, further information may be requested 
from the investigator to provide clarity and understanding of the event in the context of the 
clinical study. 
10.7. 
Reporting Period 
For all AEs, the reporting period to Xeris Pharmaceuticals begins from the subject providing 
informed consent, through the last subject Visit. All adverse events will be followed until 
resolution or the subject is medically stable. 
10.8. 
Serious Adverse Events 
An SAE is any untoward medical occurrence which: 
• Results in death. 
• Is life-threatening. 
• Requires inpatient hospitalization or extends hospitalization. 
• Results in persistent or significant disability. 
• Is another important medical event. 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
54 
Confidential 
 
 
Medical and scientific judgment is exercised in determining whether an event is an important 
medical event. An important medical event may not be immediately life-threatening and/or 
result in hospitalization or death. However, if it is determined that the event may jeopardize the 
subject or may require intervention to prevent a SAE outcome, the important medical event 
should be reported as serious. Examples of such events are intensive treatment in an emergency 
room or at home for allergic bronchospasm or blood dyscrasias or convulsions which do not 
result in hospitalization. 
 
10.9. 
Severity Assessment 
On the AE case report forms (CRF), the investigator will use the adjectives “mild,” “moderate,” 
or “severe” to describe the maximum intensity of the AE. 
These intensity grades are defined as 
follows in Table 9 below. 
Table 9: 
AE Severity Assessment 
 
Mild 
Does not interfere with subject’s usual function 
Moderate 
Interferes to some extent (<50%) with subject’s usual function 
Severe 
Interferes significantly (≥50%) with subject’s usual function 
The terms “serious” and “severe” are not synonymous. The term “severe” is often used to 
describe the intensity (severity) of a specific event. The event itself, however, may be of 
relatively minor medical significance. This is not the same as “serious,” which is based on 
subject/event outcome or action criteria. Accordingly, a severe event is not necessarily a serious 
event. 
10.10. 
Causality Assessment 
The investigator will use the following question when assessing causality of an adverse event to 
study drug, where an affirmative answer designates the event as a suspected adverse reaction: “Is 
there a reasonable possibility that the drug caused the event?” A ‘‘reasonable possibility’’ means 
that there is evidence to suggest a causal relationship between the drug and the adverse event. 
The investigator’s assessment of causality must be provided for all AEs. The investigator must 
record the causal relationship in the CRF, as appropriate, and report such an assessment in 
accordance with the serious adverse event reporting requirements, if applicable. 
 
10.11. 
Withdrawal Due to Adverse Events 
Withdrawal due to AE should be distinguished from withdrawal due to insufficient response, and 
recorded on the appropriate CRF. When a subject withdraws due to an SAE, the SAE must be 
reported in accordance with the reporting requirements (see Section 10.13). 
 
10.12. 
Eliciting Adverse Event Information and Reporting 
The investigator is to report all directly observed AEs and all AEs spontaneously reported by the 
study subject. Each study subject will be questioned about AEs. Each AE is to be assessed to 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
55 
Confidential 
 
 
determine if it meets the criteria for SAEs. If an SAE occurs, expedited reporting will follow the 
provisions of Section 10.13. 
10.13. 
Serious Adverse Event Reporting Requirements 
If an SAE occurs, Xeris Pharmaceuticals is to be notified within 24 hours of awareness of the 
event by the investigator. In particular, if the SAE is fatal or life-threatening, notification to 
Xeris Pharmaceuticals must be made immediately, irrespective of the extent of available AE 
information. This time frame also applies to follow-up on previously forwarded SAE reports. 
In the rare event that the investigator does not become aware of the occurrence of an SAE 
immediately (e.g., a study subject initially seeks treatment elsewhere), the investigator is to 
report the event within 24 hours after learning of the event and document the time of first 
awareness of the AE. 
A death occurring during the study, during the protocol follow-up period, or within 30 days after 
stopping treatment with test drug must be reported to Xeris Pharmaceuticals or its designee(s) 
immediately, whether or not it is considered treatment-related. Initial SAE reports must be 
followed by detailed descriptions. These should include copies of hospital case records and 
other documents when requested. Telephone and e-mail reports must be confirmed promptly 
either by facsimile or by overnight courier or mail. 
10.14. 
Non-Serious Adverse Event Reporting Requirements 
All AEs will be reported on the AE page(s) of the CRF. AEs should be reported using concise 
medical terminology on the CRFs as well as on the form for collection of the SAE information. 
10.15. 
AE Reporting Requirements to Regulatory Authorities 
AE reporting by the Sponsor, including suspected serious unexpected adverse reactions, will be 
carried out in accordance with applicable regulations. 
The investigator must notify the IRB of the occurrence of any SAE, in writing, as soon as is 
practicable and in accordance with local regulations. A copy of this notification must be 
provided to Xeris Pharmaceuticals or its designee. 
In the event of an SAE that meets the criteria for expedited reporting, an SAE report will be 
prepared for submission to the FDA and any other applicable authorities by the Sponsor or its 
designee. 
 
10.16. 
Pregnancy 
The active pharmaceutical product in Xeris Pharmaceuticals’ glucagon formulation is glucagon, 
which is in Pregnancy Category B. Female subjects able to become pregnant will be tested 
(rapid, urine) for pregnancy at the Screening visit. Any subject found to be pregnant at the 
Screening visit (Visit 1) will not be randomized into the study. Pregnancy testing will be 
repeated prior to each induced hypoglycemia procedure (i.e., Visits 3, 7, 9 and 11). Any subject 
who is found to be pregnant at one of the treatment visits will be withdrawn from the study 
immediately and no further study treatments will be given, nor will induced hypoglycemia 
procedures be performed. Pregnancy at the follow-up visit will be noted, but the visit will be 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
56 
Confidential 
 
 
completed. Any pregnancy in a subject who received at least one dose of study drug will be 
followed until resolution (i.e., birth or voluntary or spontaneous termination of the pregnancy). 
Any pregnancy outcome that meets the criteria for an SAE will be reported as an SAE. 
 
10.17. 
Subject Monitoring 
Subjects will be monitored for AEs throughout the study by the study staff. The principal 
investigator or designated sub-investigator will be on site for drug administration initiation and 
during hypoglycemia induction procedures. If necessary, a physician, either at the study site or in 
a nearby hospital, will administer treatment for any AEs. 
Safety parameters, including laboratory results and ECGs, will be assessed by the principal 
investigator or his/her delegate using the site’s criteria for clinical laboratory and ECG 
acceptance ranges as suggested guidelines in making the medical assessment. 
Scheduled safety measurements will be repeated according to appropriate SOPs or upon request 
from a physician. Any abnormal repeated measurement will be evaluated by a physician and 
repeated if judged necessary. Further action may be taken on the physician’s request. 
Subjects will be advised to notify their health care professionals (e.g., physician, dentist, and/or 
pharmacist) that they are participating in a clinical research study of a drug called synthetic 
Glucagon Injection before taking any medicines or undergoing any medical procedure. 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
57 
Confidential 
 
 
11. 
DATA ANALYSIS AND STATISTICAL METHODS 
Descriptive and inferential statistical methods will be used to summarize the data from this 
study. Unless stated otherwise, the term “descriptive statistics” refers to number of subjects (n), 
mean, median, standard deviation (SD), minimum, and maximum for continuous data and 
frequencies and percentages for categorical data. For some data that may be presented as 
continuous variables, there may be scientific reasons to present that data in constructed 
categories as well (e.g., BMI). Reasons for the categories will be described in the Clinical Study 
Report (CSR). Graphical displays may be presented for selected results. 
A stand-alone Statistical Analysis Plan (SAP) will be written to describe in detail all statistical 
analyses planned for the study. It will be accompanied by mock Tables, Figures, and Listings. 
The SAP will be finalized and approved by signature and dates prior to database lock. The SAP 
will take precedence over the protocol for details about the statistical analyses for the study. In 
addition to the SAP, other graphical representations of the results may be produced after review 
of the data (post hoc). 
Verbatim terms recorded for medical history conditions and adverse events will be mapped to a 
System Organ Class (SOC) and preferred term using the Medical Dictionary for Regulatory 
Activities (MedDRA) and all prior and concomitant medications will be coded using the World 
Health Organization (WHO) Drug Dictionary. 
11.1. 
Efficacy 
The primary aim of the study is to evaluate change from baseline of plasma epinephrine 
concentration during induced hypoglycemia with PG <50 mg/dl between placebo and CSGI after 
4 weeks of blinded treatment. The null hypothesis to be tested is there is no difference in the 
change from baseline to 4 weeks between the two groups for plasma epinephrine concentration 
during induced hypoglycemia with PG<50 mg/dl. Two-group t-test will be implemented for each 
hypothesis test. 
11.1.1. 
Closed Hierarchical Hypothesis Tests 
The analysis of the primary endpoint will be performed using a hierarchical hypothesis test in 
which an alpha of 5% will be preserved for each test. Testing will be employed in the following 
order: 
• CSGI (combined groups) versus Placebo (if statistically significant <0.05, then the next 
hypothesis test will be conducted) 
• CSGI high dose versus Placebo (if statistically significant <0.05, then the next 
hypothesis test will be conducted) 
• CSGI low dose versus Placebo (if statistically significant <0.05, then the next 
hypothesis test will be conducted) 
• CSGI high dose versus CSGI low dose 
 
Sensitivity analysis of the primary efficacy outcome in the PP population will be conducted 
where: 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
58 
Confidential 
 
 
• All subjects who are lost to follow-up or have missing outcome data will be considered to 
have a favorable outcome in each of the treatment groups. 
• Subjects who are lost to follow-up or have a missing primary endpoint at Day 27 in the 
high or low dose group will be considered to have an unfavorable outcome whereas in the 
placebo group will be considered to have a favorable outcome 
• Subjects who have a missing outcome data will be excluded from the analysis 
11.1.2. 
Analysis Populations 
Three analysis populations are planned for the study: 
Intent-to-treat Population (ITT or All Randomized): All subjects randomized into the study. The 
ITT population will be analyzed according to the treatment group to which subjects were 
randomized. 
Per-Protocol Population (PP Population): Subjects in the ITT population who receive at least 
90% of study treatment through Day 27, including use of a concomitant medication or other 
therapy that could confound the assessment of efficacy. 
Safety Population 
All enrolled subjects who received at least one study treatment application. Unless otherwise 
stated, the safety population will be the default analysis population for all safety analyses. 
Analyses of safety will be performed based on treatment received, even if different from 
treatment group to which subjects were randomized. 
11.1.3. 
Sample Size Calculation: 
 
The primary hypothesis is to evaluate change from baseline to 4 weeks of plasma epinephrine 
concentration after 30 minutes of induced hypoglycemia with plasma glucose <50mg/dL 
between treatment groups. Sample size is based on a closed hierarchical hypothesis test as 
described above in section 13.1.1. 
Using this method, an alpha of 5% will be preserved for each hypothesis test where the next 
ordered test will only be conducted if statistical significance is achieved for that hypothesis. 
Final calculations are based on 80% power and an alpha of 5%, to demonstrate a plasma 
epinephrine increase compared to placebo of 1.5 nmol/l given and SD of 1.34 nmol/l at an 
induced PG of 50 mg/dl. Sixteen subjects per treatment group (CSGI high dose, CSGI low dose, 
and placebo) are required based on the minimum sample size estimate for a comparison. 
11.2. 
Pharmacokinetic and Pharmacodynamic Analyses 
The pharmacokinetic endpoint of steady state glucagon concentration will be derived from the 
individual plasma glucagon assessments. The pharmacodynamic endpoints will be derived from 
the glucose infusion rates, the plasma sample hormone analyses, and the CGM data. 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
59 
Confidential 
 
 
11.2.1. 
Pharmacokinetic Secondary Endpoints: 
Change from baseline in serum glucagon steady state across the treatment groups will be 
analyzed descriptively. 
11.2.2. 
Pharmacodynamic Secondary Endpoints: 
The secondary endpoints cumulative glucose infusion to maintain glucose at 50 mg/dl for the 
first 30 minutes, other counter regulatory hormones, and CGM derived variables will be 
analyzed by mixed model analysis. 
Other endpoints will be analyzed descriptive with inferential testing being performed should the 
descriptive data indicate differences of clinical importance between the groups. 
 
11.3. 
Safety Analysis 
All safety analyses will be performed using the safety analysis population. 
The following variables will be compared between the treatments for safety purposes: 
• Adverse events and serious adverse events (Screening to Final Visit) 
• Laboratory safety variables (Screening to Final Visit) 
• Physical examination (Screening to Final Visit) 
• Vital signs (Screening to Final Visit) 
• Body weight (Screening to Final Visit) 
• ECG (Screening to Final Visit) 
• Local tolerability, including: 
o Subjective injection site discomfort as reported by subjects using a 100-mm VAS 
and ordinal pain scales (Appendix 3). 
o Erythema and or edema formation at site of injection assessed using the Draize 
scale (Appendix 4). 
 
11.3.1. 
Adverse events: 
All AEs will be reviewed by the Medical Monitor once they are coded using the Medical 
Dictionary for Regulatory Activities (MedDRA). A summary table indicating the number and the 
percentage of subjects having at least one AE will be made by SOC and preferred term. 
 
11.3.2. 
Laboratory safety assessments: 
Laboratory values (biochemistry and hematology) will be flagged if outside the normal range. A 
listing of abnormal values will be presented in listings. The individual values will be listed 
indicating values outside normal range. Laboratory assessments will be summarized for 
Screening and end of study. 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
60 
Confidential 
 
 
11.3.3. 
Physical examination: 
Subjects with any findings in the physical examination evaluation at Screening will be listed. 
Changes to physical examination from Screening to end of study will be recorded as AEs if the 
Investigator judges these as being clinically significant. 
 
11.3.4. 
Vital signs and body weight: 
Vital signs will be summarized by descriptive statistics. Change from baseline will be presented. 
 
11.3.5. 
ECG: 
12-lead electrocardiogram (ECG) will be performed at baseline and at end of treatment (Visit 7). 
ECG results will be reviewed by the principal investigator for clinically notable abnormalities. 
The safety analysis for ECG measurements and outliers will be described based on the 
investigator assessments. 
11.3.6. 
Local Tolerability: 
The incidence of any injection site discomfort (score >0 on the ordinal rating scale) will be 
analyzed descriptively. The incidences of erythema and edema will be analyzed in a similar 
manner. Descriptive statistics (only) will be provided for time of onset and duration (of 
discomfort) and discomfort description (i.e., pain, irritation, itching, etc.). Mean VAS scores will 
be compared between the treatments. 
11.4. 
Subgroup Analysis 
No subgroup analyses are planned. 
 
11.5. 
Interim Analyses 
There are no planned statistical interim analyses. 
However, the primary endpoint analysis at Day 27 will be executed when the last subject data for 
this the visit has been completed and monitored. Primary endpoint analysis results will only be 
unblinded at the treatment group level (CSGI high dose. CSGI low dose, and placebo) and 
individual treatment assignments will remain blinded until the end of the study and the database 
locked. Study investigators, study staff, subjects and the sponsor will remain blinded to 
individual treatment group assignments. 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
61 
Confidential 
 
 
12. 
QUALITY CONTROL AND QUALITY ASSURANCE 
During study conduct, Xeris Pharmaceuticals or its agent will conduct periodic visits to ensure 
that the protocol and Good Clinical Practices are being followed. The monitor may review 
source documents to confirm that the data recorded on CRFs is accurate. The investigator and 
institution will allow Xeris Pharmaceuticals’ monitor or its designee, and appropriate regulatory 
authorities, direct access to source documents to perform this verification. 
The study site may be subjected to review by the Institutional Review Board and/or to quality 
assurance audits performed by Xeris Pharmaceuticals or its designee, and/or to inspection by 
appropriate regulatory authorities. It is important that the investigator and study staff are 
available during the monitoring visits and possible audits or inspections and that sufficient time 
is devoted to the process. 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
62 
Confidential 
 
 
13. 
DATA HANDLING, RECORD KEEPING, MONITORING AND 
AUDITS 
13.1. 
Case Report Forms/Electronic Data Record 
As used in this protocol, the term CRF should be understood to refer to either a paper form or an 
electronic data record, or both. A CRF is required and should be completed for each individual 
subject. The completed original CRFs are the property of Xeris Pharmaceuticals and should not 
be made available in any form to third parties, except for authorized representatives of Xeris 
Pharmaceuticals or appropriate regulatory authorities, without written permission from Xeris 
Pharmaceuticals. 
The investigator has the responsibility for the collection and reporting of all clinical, safety and 
laboratory data entered on the CRFs and any other data collection forms (source documents) and 
ensuring that these are accurate, authentic, attributable, complete, consistent, legible, 
contemporaneous, enduring and available when required. The CRFs must be signed by the 
investigator or by an authorized staff member to attest that the data contained in the CRFs is true. 
Any corrections to entries made in the CRFs or source documents must be dated, initialed and 
explained (if necessary), and should not obscure the original entry. 
In most cases, the source documents are the hospital’s or physician’s subject chart. In these 
cases, data collected on the CRFs must match the data in those charts. In some cases, the CRF, 
or part of the CRF, may also serve as source documents. In these cases, a document should be 
available at the investigator’s site as well as at Xeris Pharmaceuticals and clearly identify those 
data that will be recorded in the CRF, and for which the CRF will stand as the source document 
13.2. 
Record Retention 
To enable evaluations and/or audits from regulatory authorities or Xeris Pharmaceuticals, the 
investigator agrees to keep records, including the identity of all participating subjects (sufficient 
information to link records, e.g., CRFs and hospital records), all original signed informed 
consent documents, copies of all CRFs, safety reporting forms, source documents, and detailed 
records of treatment disposition, and adequate documentation of relevant correspondence (e.g., 
letters, meeting minutes, telephone calls reports). The records should be retained by the 
investigator according to the International Conference on Harmonisation (ICH), regulations, or 
as specified in the Clinical Study Agreement, whichever is longer. The investigator must obtain 
Xeris Pharmaceuticals’ written permission before disposing of any records, even if retention 
requirements have been met. 
13.3. 
Monitoring 
Monitoring and auditing procedures developed by Xeris Pharmaceuticals and/or its designee will 
be implemented to ensure compliance with FDA and ICH GCP and GLP guidelines. 
The Xeris Pharmaceuticals’ designated representative (the monitor or auditor) will contact the 
investigator and conduct regular visits to the clinical site. The monitor will be expected and 
allowed to verify the investigator’s qualifications, to inspect clinical site facilities, and to inspect 
study records, including proof of IRB review, with the stipulation that subject confidentiality will 
be maintained in accordance with local and federal regulations, including HIPAA requirements. 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
63 
Confidential 
 
 
The monitor will also be responsible for confirming adherence to the study protocol, inspecting 
CRFs and source documents, and ensuring the integrity of the data. CRFs will be checked for 
accuracy, completeness, and clarity and will be cross-checked for consistency with source 
documents, including laboratory test reports and other subject records. Instances of missing or 
uninterpretable data will be resolved in coordination with the investigator. 
The monitor/auditor will also investigate any questions concerning adherence to regulatory 
requirements. Any administrative concerns will be clarified and followed. The monitor will 
maintain contact with the site through frequent direct communications with the study site by e- 
mail, telephone, facsimile, and mail. The investigator and all other site personnel agree to 
cooperate fully with the monitor and will work in good faith with the monitor to resolve any and 
all questions raised and difficulties detected by the monitor. 
13.4. 
Audits and Inspections 
The investigator understands that regulatory authorities, the IRB, and/or Xeris Pharmaceuticals 
or their designees have the right to access all CRFs, source documents, and other study 
documentation for on-site audit or inspection and will retain this right from the start of the study 
to at least 2 years after the last approval of a marketing application or for at least 2 years after 
clinical development of the study drug for the indication being studied has been discontinued. 
The investigator is required to guarantee access to these documents and to cooperate with and 
support such audits and inspections. 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
64 
Confidential 
 
 
14. 
ETHICAL CONSIDERATIONS 
14.1. 
Conduct 
This protocol is written in accordance with the principles established by the 18th World Medical 
Assembly General Assembly (Helsinki, 1964) and amendments and clarifications adopted by the 
29th (Tokyo, 1975), 35th (Venice, 1983), 41st (Hong Kong, 1989), 48th (Somerset West, South 
Africa, 1996), 52nd (Edinburgh, 2000), 53rd (Washington, 2002), 55th (Tokyo, 2004), and 59th 
(Seoul, 2008) General Assemblies. The investigator will ensure that the study described in this 
protocol is conducted in full conformance with those principles, the protocol, current FDA 
regulations, ICH Good Clinical Practices (GCP) guidelines, Good Laboratory Practices (GLP) 
guidelines, local ethical and regulatory requirements, including the Federal Food, Drug and 
Cosmetic Act, U.S. applicable Code of Federal Regulations (title 21), any IRB/IEC requirements 
relative to clinical studies. 
Should a conflict arise, the investigator will follow whichever law or guideline affords the 
greater protection to the individual subject. The investigator will also ensure thorough familiarity 
with the appropriate administration and potential risks of administration of the study drug, as 
described in this protocol and the Investigator’s Brochure, prior to the initiation of the study. 
 
14.2. 
Institutional Review Board (IRB) 
The Ethics Committee/IRB must be a properly constituted board or committee operating in 
accordance with 21 CFR Part 56, “Institutional Review Boards.” This protocol, any protocol 
amendments, the associated informed consent forms, and the informed consent procedures must 
be submitted to the IRB for review and approved before the enrollment of any subject into the 
trial. Study drug may not be shipped to the investigator until Xeris Pharmaceuticals has received 
a copy of the letter or certificate of approval from the IRB for the protocol and any protocol 
amendments. 
All types of subject recruitment or advertising information must be submitted to Xeris 
Pharmaceuticals or its designee and to the IRB for review and approval prior to implementation. 
IRB approval of any protocol amendments must be received before any of the changes outlined 
in the amendments are put into effect, except when the amendment has been enacted to eliminate 
a potential hazard to study subjects. In such cases, the chair of the IRB should be notified 
immediately, and the amendment forwarded to the IRB for review and approval. 
It is the responsibility of the investigator to have prospective approval of the study protocol, 
protocol amendments, informed consent documents, and other relevant documents, e.g., 
recruitment advertisements from the IRB. All correspondence with the IRB should be retained 
in the Investigator File. Copies of IRB approvals should be forwarded to Xeris Pharmaceuticals. 
 
14.3. 
Subject Information and Consent 
All parties will ensure protection of subject personal data and will not include subject names on 
any sponsor forms, reports, publications, or in any other disclosures. Subject names, address, 
date of birth and other identifiable data will be replaced by a numerical code consisting of a 
numbering system provided by Xeris Pharmaceuticals to de-identify the study subject. In the 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
65 
Confidential 
 
 
case of data transfer, Xeris Pharmaceuticals will maintain confidentiality and protection of 
subject personal data. 
The informed consent document used in this study, and any changes made during the course of 
the study, must be prospectively approved by both the IRB and Xeris Pharmaceuticals before 
use. The investigator must ensure that each study subject is fully informed about the nature and 
objectives of the study and possible risks associated with participation. The investigator, or a 
study staff designated by the investigator, will obtain written informed consent from each subject 
before any study-specific activity is performed. The investigator will retain the original of each 
subject’s signed consent document. Receipt of written informed consent will be documented in 
each subject’s or potential subject’s CRF. The signed informed consent document must remain 
on file at the study site and be available for verification by the study monitors at all times. 
14.4. 
Subject Recruitment 
Any type of subject recruitment or advertising information must be submitted to Xeris 
Pharmaceuticals or its designee and to the IRB for review and approval prior to implementation. 
Advertisements approved by the IRB may be used as recruitment procedures. 
14.5. 
Reporting of Safety Issues and Serious Breaches of the Protocol 
In the event of any prohibition or restriction imposed (i.e., clinical hold), or if the investigator is 
aware of any new information which might influence the evaluation of the benefits and risks of 
the investigational product, Xeris Pharmaceuticals should be notified immediately. In addition, 
the investigator will inform Xeris Pharmaceuticals immediately of any urgent safety measures 
taken by the investigator to protect study subjects against any immediate hazard, and of any 
serious breaches of this protocol 
15. 
DEFINITION OF END OF TRIAL 
Last Subject Last Visit (LSLV) for each site is defined as the date the last subject at that site 
completes the 6-month follow-up visit (Visit 11). 
.
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
66 
Confidential 
 
 
16. 
PROCEDURES FOR MODIFYING THE PROTOCOL OR 
TERMINATING THE STUDY 
16.1. 
Protocol Modifications and Deviations 
The principal investigator must sign this protocol and its amendments (if any) before initiating 
the study at a particular site. The investigator will make all reasonable efforts to comply with the 
written protocol. Protocol modifications to ongoing studies that affect the safety of subjects or 
that alter the scope of the investigation, the scientific quality of the study, the experimental 
design, dosing, study assessments, the number of subjects exposed to test drug, or subject 
selection criteria must be made only after consultation between Xeris Pharmaceuticals and the 
investigator. All protocol modifications must be reviewed and approved by the IRB before the 
revised protocol can be implemented. Emergency revisions that eliminate an apparent hazard to 
subjects do not require preapproval by the IRB. However, the IRB must be notified in writing as 
soon as possible after the modification has been made. A copy of this communication must be 
forwarded to Xeris Pharmaceuticals. All departures from the protocol must be fully documented 
in the source documents and the CRFs of the subjects involved. 
16.2. 
Study Termination 
The study may be prematurely terminated at any time because of a regulatory authority decision, 
change in opinion of the IRB, safety problems, or at the discretion of Xeris Pharmaceuticals or 
the principal investigator. Circumstances that may warrant premature study termination include, 
but are not limited, to the following: 
• Determination of unexpected, significant, or unacceptable risk to subjects, 
• Failure to enter subjects at an acceptable rate, 
• Insufficient adherence to the requirements of the protocol, 
• Insufficient provision of complete and evaluable data, or 
• Plans to modify, suspend, or discontinue development of the study drug. 
If the study is prematurely terminated or discontinued, Xeris Pharmaceuticals will promptly 
notify the investigator documenting the reason for study termination, and specific procedures for 
termination will be arranged by the sponsor in coordination with the investigator. After 
notification, the investigator must contact all participating subjects within 7 days. All study 
materials must be collected and all CRFs completed to the greatest extent possible, and all study 
materials must be returned to Xeris Pharmaceuticals or its designee within an additional 28 days. 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
67 
Confidential 
 
 
17. 
PUBLICATION OF STUDY RESULTS 
Publication of study results is discussed in the Clinical Study Agreement. 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
68 
Confidential 
 
 
18. 
REFERENCES 
American Diabetes Association (ADA) Workgroup on Hypoglycemia: Defining and reporting 
hypoglycemia in diabetes. Diabetes Care 28:1245–1249, 2005 
The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and 
Complications (DCCT/EDIC) Study Research Group: Long-term effect of diabetes and its 
treatment on cognitive function. N Engl J Med 356:1842–1852, 2007. 
Skrivarhaug T, Bangstad H-J, Stene LC, Sandvik L, Hanssen KF, Joner G: Long-term mortality 
in a nationwide cohort of childhood-onset type 1 diabetic patients in Norway. Diabetologia 
49:298 –305, 2006. 
U.K. Hypoglycaemia Study Group: Risk of hypoglycaemia in types 1 and 2 diabetes: effects of 
treatment modalities and their duration. Diabetologia 50:1140 –1147, 2007. 
McLeod KM, Hepburn DA, Frier BM. Frequency and morbidity of severe hypoglycaemia in 
insulin-treated diabetic patients. Diabet. Med. 1993. 10: 238-245. 
Centers for Disease Control (CDC) and Prevention. National diabetes fact sheet: national 
estimates and general information on diabetes and prediabetes in the United States, 2011. 
Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and 
Prevention, 2011 
Close Concerns, Inc. Market Survey (2,808 respondents). 2010. 
Glucagon™ (glucagon for injection [rDNA origin]) Prescribing Information. Eli Lilly and 
Company, revised February 2005 
Glucagen® (glucagon [rDNA origin] for injection) Prescribing Information. Novo Nordisk, Inc. 
revised December 2011. 
Jelinek LJ, Lok S, Rosenberg GB, Smith RA, Grant FJ, Biggs S, Bensch PA, Kuijper JL, 
Sheppard PO, Sprecher CA, et al. Expression cloning and signaling properties of the rat 
glucagon receptor. Science. 1993 Mar 12; 259(5101): 1614-6. 
Wakelam MJ, Murphy GJ, Hruby VJ, Houslay MD. Activation of two signal-transduction 
systems in hepatocytes by glucagon. Nature. 1986 Sep 4-10; 323(6083): 68-71. 
FDA CDER #1. Glucagon (glucagon hydrochloride). NDA No. 01-2122. Eli Lilly and 
Company, Indianapolis, IN, November 14, 1960. 
Eistrup, C., Hjortkjæ, R. K., Pickersgill, N., Virgo, D. M. and Woolley, A. P. A. H. (1993), 
Glucagon Produced by Recombinant DNA Technology: Repeated Dose Toxicity Studies, 
Intravenous Administration to CD Rats and Beagle Dogs for Four Weeks. Pharmacology & 
Toxicology, 73: 103–108. 
FDA CDER #2. rDNA Glucagon for Injection, Pharmacology and Toxicology Review. NDA 
No. 20-928. Eli Lilly and Company, Indianapolis, IN, April 16, 1998. 
Du Bois D, Du Bois EF (Jun 1916). "A formula to estimate the approximate surface area if 
height and weight be known". Archives of Internal Medicine. 17 (6): 863–71. 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
69 
Confidential 
 
 
APPENDICES 
 
APPENDIX 1. GOLD SCORE 
Investigative Site Instructions: The subject should complete the gold scale questionnaire at the 
start of screening and each treatment phase in visits 3, 7, 9 and 11. 
Note: If a subject is unable to physically complete the questionnaire, the subject will provide 
verbal responses, which will be recorded on the questionnaire by study staff. Documentation will 
be provided on each completed questionnaire as to who completed the form. 
 
Subject Instructions: Please respond to the following question using the scale of 1-7 below. A 
minimum score of “1” indicates that you are always aware of an onset of hypoglycemia and a 
maximum score of “7” indicates that you are never aware of an onset of hypoglycemia. 
 
To what extent are you aware of the onset of hypoglycemia? 
 
 
1 
2 
Almost 
Always 
3 
Often 
4 
Sometimes 
5 
Seldom 
6 
Almost 
Never 
7 
Never 
Always 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
70 
Confidential 
 
 
 
 
 
APPENDIX 2. HYPOGLYCEMIA SYMPTOM QUESTIONNAIRE 
Investigative Site Instructions: The subject should complete the Hypoglycemia Symptom 
Questionnaire at the following time points: 
• When the plasma glucose has been stable at 70+/-5 mg/dL for 20 minutes, a 
hypoglycemia symptom questionnaire administered, which will be repeated after 10 
minutes 
• Every 5 minutes the hypoglycemic questionnaire will be administered while the 
subject PG is <70 mg/dL 
• Subjects should remain blinded to their PG levels throughout the treatment visit. 
Note: If a subject is unable to physically complete the questionnaire, the subject will provide 
verbal responses, which will be recorded on the questionnaire by study staff. Documentation will 
be provided on each completed questionnaire as to who completed the form. 
Subject Instructions: Please rate the current intensity (severity) of each of the following 
symptoms on a scale of 1-6, with a minimum score of “1” meaning the symptom was absent and 
a maximum score of “6” meaning the symptom was severe. For the final question, please answer 
“yes” or “no.” 
 
Neuroglycopenic Symptoms 
Severity Score (1-6) 
Dizziness 
Blurred vision 
Difficulty in thinking 
Faintness 
Autonomic Symptoms 
Severity Score (1-6) 
Sweating 
Tremor 
Palpitations 
Feeling of nervousness 
Overall Assessment of Hypoglycemia 
Yes/No 
Do you currently feel hypoglycemic? 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
71 
Confidential 
 
 
APPENDIX 3. INJECTION SITE DISCOMFORT ASSESSMENT 
Visual Analog Scale (VAS) for Injection Site Discomfort 
Investigative Site Instructions: The subject should complete the 100-mm Visual Analog Scale 
(VAS) for Injection Site Discomfort at 10±5 minutes, at 30±5 minutes and again at 180±5 
minutes following the injection of study drug. The subject completes the VAS by drawing a 
single vertical line through the scale corresponding to the perceived intensity (severity) of 
discomfort according to the instructions below. The goal is for the subject to report the amount 
of discomfort, if any, remaining at each time point, as opposed to reporting the transient pain 
associated with needle insertion. 
Note: If a subject is unable to physically complete the questionnaire, the subject will indicate the 
point on the VAS corresponding to their level of discomfort, and study staff will enter a vertical 
line at that point. Documentation will be provided on each completed questionnaire as to who 
completed the form. 
Please verify the length of the VAS line to be 100-mm before providing it to the subject. 
Subject Instructions: Ignoring any pain from insertion of the needle, please draw a single vertical 
line through the scale below that corresponds to the intensity (severity) of any discomfort you are 
feeling right now at the study drug injection site. 
Discomfort could include stinging, burning, tingling, throbbing or pain. The further to the right 
you make your vertical mark, indicates the more intense discomfort you are feeling. 
You should normally draw a straight line across the scale to indicate your current level of 
discomfort. However if you are currently feeling no discomfort, you should circle the vertical 
line on the left end of scale (above the word “no”). If you are currently feeling the worst 
discomfort possible, you should circle the vertical line on the right end of the scale. 
 
├ 
┤ 
No Discomfort 
Worst Possible Discomfort 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
72 
Confidential 
 
 
APPENDIX 4. 
Delivery Site Discomfort Description and Duration Questionnaire 
Study Personnel Instructions: All questions should be completed by the subject at 10±5 minutes 
following the delivery of study drug. The goal is for the subject to report if they had any discomfort 
and if there was discomfort, the qualitative nature and duration of discomfort associated with the 
delivery of study drug, ignoring any transient pain associated with the pump placement. 
 
Note: If a subject is unable to physically complete the questionnaire, the subject will provide verbal 
responses, which will be recorded on the questionnaire by study staff. Documentation will be 
provided on each completed questionnaire as to who completed the form. 
 
Subject Instructions: Please answer all questions below. 
 
1. Did you have any discomfort when the pump administered the study 
drug? 
Yes 
 
No 
 
If yes, 
 
apply): 
 
1a. 
How would you describe any discomfort you felt from the study drug? (Check all that 
 
  
Pain (e.g., throbbing, soreness, muscle ache) 
  
Itching 
  
Tingling, twitching or numbness 
  
Irritation (e.g., burning, stinging) 
  
Other (specify) : 
 
 
 
1b. About how long after the study drug administration did the discomfort start? (please 
enter a number) 
 
minutes 
 
1c. In total, how long did the discomfort last? (please enter a 
number): 
 
minutes 
Approved


XSGO-AF01 Clinical Protocol, Version 4.0, 21-Dec-2018 
73 
Confidential 
 
 
APPENDIX 5. DRAIZE SCALE 
• Study Personnel Instructions: The modified Draize Scale as shown in the table below 
will be used for physical examination/rating of abnormalities at the Omnipod site. 
• The injection site should be examined for formation of both erythema and edema and 
results recorded in the Case Report Form. Evaluations of the injection site should be 
performed at 10 ± 5 and 60 ± 5 minutes post-treatment. 
 
Erythema Formation 
Edema Formation 
Description 
Score 
Description 
Score 
No erythema 
0 
No edema 
0 
Very slight erythema 
Barely perceptible 
1 
Very slight edema 
Barely perceptible 
1 
Well defined erythema 
2 
Slight edema 
(edges of area well defined 
by definite raising) 
2 
Moderate erythema 
3 
Moderate edema 
Raised approx. 1 mm 
3 
Severe erythema 
Beet redness to slight 
eschar formation 
4 
Severe edema 
Raised more than 1 mm and 
beyond exposure area 
4 
 
Approved


Document Approvals
Approved Date: 10/8/2019, PRO-19-00084 Version 4
Approval Task
Verdict:  Approve
Kimberly Alegado,
(kalegado@xerispharma.com)
Quality Approval
08-Oct-2019 14:50:28 GMT+0000
QA Approval Task
Verdict:  Approve
Ashley Gregory,
(agregory@xerispharma.com)
Quality Assurance Approval
08-Oct-2019 14:51:26 GMT+0000

SAP_001.pdf: 
Protocol Number: XSGO-AF0l 
FIXED RA TE CONTINUOUS SUBCUTANEOUS GLUCAGON INFUSION (CSGI) VS 
PLACEBO IN TYPE 1 DIABETES MELLITUS PATIENTS WITH RECURRENT 
SEVERE HYPOGLYCEMIA: EFFECTS ON COUNTER REGULATORY RESPONSES 
TO INSULIN INDUCED HYPOGLYCEMIA 
Study Biostatistician 
EmpiriStat, Inc. 
Medical 
Xeris Pharmaceuticals 
Clinical 
Xeris Pharmaceuticals 
Regulatory 
Xeris Pharmaceuticals 
Biostatistics 
Xeris Pharmaceuticals 
STATISTICAL ANALYSIS PLAN 
Prepared for: 
Xeris Pharmaceuticals 
Version 1.0 
Date: 21 October 2019 
______________ 
Date: ___ _ 


Statistical Analysis Plan 
Version 1.0, dated 21-0ct-2019 
Table of Contents 
Prepared for: Xeris Pharmaceuticals, Inc. 
Study: XSGO-AF0 I 
1 LIST OF ABBREVIATIONS ........................................................................ 3 
2 
INTRODUCTION .......................................................................................... 5 
2.1 
General Information ................................................................................................... 5 
3 
STUDY OBJECTIVES .................................................................................. 5 
3 .1 
Primary Objective ...................................................................................................... 5 
3.2 
Secondary Objectives ................................................................................................. 6 
3.2.1 
Efficacy Objectives .............................................................................................. 6 
4 
ENDPOINTS .................................................................................................. 7 
4.1 
Primary Endpoint ....................................................................................................... 7 
4.2 
Secondary Endpoints ................... .............................................................................. 7 
4.2.1 
Efficacy Endpoints ............................................................................................... 7 
4.2.2 
Safety and Tolerability Endpoints ....................................................................... 8 
4.2.3 
lmmunogenicity Endpoints .................................................................................. 8 
5 
SAMPLE SIZE ............................................................................................... 8 
6 
RANDOMIZATION ...................................................................................... 8 
7 
PLANNED ANALYSES ................................................................................ 8 
7 .1 
Analysis Populations .................................................................................................. 9 
7.1.1 
Intent-to-treat Population (ITT or All Randomized) ........................................... 9 
7 .1.2 
Per-Protocol Population (PP Population) ............................................................. 9 
7.1.3 
Safety Population ................................................................................................. 9 
7.2 
Derived Data .............................................................................................................. 9 
7 .2.1 
Baseline ................................................................................................................ 9 
7.2.2 
Duration/Study Day/Time .................................................................................. 10 
7.2.3 
Conventions for Missing and Partial Dates ....................................................... 10 
7.2.4 
Missing/Partial Start/Stop Date of Adverse Events and Concomitant 
Medications ...................................................................................................................... 10 
7.2.5 
Missing Diagnosis Dates .................................................................................... 12 
7.2.6 
Duration of Study Drug Exposure ..................................................................... 12 
7.2.7 
Inexact Values .................................................................................................... 12 
7.2.8 
Unscheduled Visits and Repeated assessments ................................................. 12 
7.2.9 
Counter Regulatory Hormones .......................................................................... 12 
7.2.10 
CGM Derived Parameters .................................................................................. 13 
7 .2.11 
Hypoglycemia Symptom Questionnaire ............................................................ 14 
7.2.12 
Local Tolerability ............................................................................................... 15 
7.3 
Conventions ............................................................................................................. 15 
7.3.1 
Technical Requirements ..................................................................................... 15 
7.3 .2 
Summary statistics ............................................................................................. 15 
7.3.3 
Decimal Places ................................................................................................... 16 
7 .4 
Subject Disposition .................................................................................................. 17 
Confidential 
Page 1 of 31 


Statistical Analysis Plan 
Version 1.0, dated 21-0ct-2019 
Prepared for: Xeris Pharmaceuticals, Inc. 
Study: XSGO-AF0l 
7.5 
Protocol Deviations .................................................................................................. 17 
7.6 
Demographic and Baseline Characteristics ............................................................. 17 
7. 7 
Medical History ....................................................................................................... 1 7 
7.8 
Prior and Concomitant Medications ........................................................................ 18 
7.9 
Exposure to Study Drug ........................................................................................... 18 
7 .10 
Efficacy Analyses .................................................................................................... 18 
7.10.1 
Primary Endpoint ............................................................................................... 18 
7 .10.2 
Primary Efficacy Analysis ................................................................................. 19 
7 .10.3 
Sensitivity Analysis ........................................................................................... 19 
7 .10.4 
Secondary Endpoints ......................................................................................... 19 
7 .10.5 
Multiplicity ........................................................................................................ 20 
7 .11 
Safety Analyses ........................................................................................................ 20 
7 .11.1 
Adverse Events .................................................................................................. 20 
7 .11.2 
Laboratory Data ................................................................................................. 21 
7.11.3 
Vital Signs .......................................................................................................... 21 
7 .11.4 
Electrocardiogram Data ..................................................................................... 22 
7 .11.5 
Physical Examination ......................................................................................... 22 
7 .11.6 
Local Tolerability ............................................................................................... 22 
8 
INTERIM ANALYSIS ................................................................................. 22 
9 
DATA SAFETY MONITORING BOARD ANALYSIS ............................ 22 
10 CHANGES TO PLANNED PROTOCOL ANALYSIS .............................. 23 
11 REFERENCES ............................................................................................. 24 
12 LIST OF TABLES, FIGURES AND LISTINGS ........................................ 25 
Confidential 
Page 2 of 31 


Statistical Analysis Plan 
Version 1.0, dated 21-0ct-2019 
Prepared for: Xeris Pharmaceuticals, Inc. 
Study: XSGO-AF0 I 
1 LIST OF ABBREVIATIONS 
Abbreviation or special 
term 
AE 
ALT 
AST 
AUC 
BP 
BSA 
CGM 
CLIA 
Cmax 
CSGI 
CSII 
ECG 
GIR 
HAAF 
HbAlc 
HBV 
HCV 
HIV 
HR 
ICF 
IIR 
IV 
LSLV 
MedDRA 
QTN 
PD 
PG 
PGR 
PK 
RBC 
SAE 
Confidential 
Explanation 
Adverse Event 
Alanine Aminotransferase 
Aspartate Aminotransferase 
Area Under the Curve 
Blood Pressure 
Body Surface Area 
Continuous Glucose Monitor 
Clinical Laboratory Improvement Act 
Maximum Plasma Concentration 
Continuous Subcutaneous Glucagon Infusion 
Continuous Subcutaneous Insulin Infusion 
Electrocardiogram 
Glucose Infusion Rate 
Hypoglycemia Associated Autonomic Failure 
Glycated hemoglobin 
Hepatitis B virus 
Hepatitis C virus 
Human immunodeficiency virus 
Heart Rate 
Informed Consent Form 
Insulin Infusion Rate 
Intravenous 
Last Subject Last Visit 
Medical Dictionary for Regulatory Activities 
Quartesian LLC 
Pharmacodynamics 
PG 
Positive Glucose Response 
Pharmacokinetic 
Red Blood Cells 
Serious Adverse Event 
Page 3 of31 


Statistical Analysis Plan 
Version 1.0, dated 21-0ct-2019 
Abbreviation or special 
term 
THC 
Tmax 
TID 
VAS 
WHO 
Confidential 
Prepared for: Xeris Pharmaceuticals, Inc. 
Explanation 
Tetrahydrocannabinol 
Time to Maximum Plasma Concentration 
Type 1 Diabetes Mellitus 
Visual Analog Scale 
World Health Organization 
Study: XSGO-AF0I 
Page 4 of 31 


Statistical Analysis Plan 
Version 1.0, dated 21-0ct-2019 
2 
INTRODUCTION 
Prepared for: Xeris Pharmaceuticals, Inc. 
Study: XSGO-AF0l 
This document describes the planned data analyses for clinical trial XSGO-AF0l sponsored by 
Xeris Pharmaceuticals, Inc. 
This SAP should be read in conjunction with the amended version of study protocol (XSGO-
AF01, Version 4.0, dated 21-Dec 2018). Any further changes to the protocol or eCRF may 
necessitate updates to the SAP. 
This SAP supersedes the statistical considerations identified in the protocol; where 
considerations are substantially different these differences will be identified. If additional 
analyses are required to supplement objectives described in the SAP, they may be performed 
and will be identified in the Clinical Study Report (CSR). 
2.1 General Information 
The proposed indication is for the management of blood glucose in type 1 diabetes patients. 
Approximately 20% of the type I diabetes mellitus (TlDM) population suffers from recurrent 
severe hypoglycemia, which is of considerable consequence to the affected persons in rare 
cases leading to death and to the health care systems as the treatment often involves acute care 
and even hospitalization. 
TlDM patients, with time, lose not only Langerhans' islet Beta-cell, but also Alpha-cell 
function leading to glucagon deficiency. Glucagon is the primary counterregulatory hormone 
to insulin. With fewer or no Alpha-cells, persons with diabetes who experience hypoglycemia 
have a delayed or insufficient glucagon response in order to both raise and normalize their 
blood glucose levels. Insufficient or deficient glucagon and other counter regulatory hormones 
response significantly increases the risk of persistent hypoglycemia in the setting of an excess 
exogenous insulin, that may progress to severe hypoglycemia. Hypoglycemia associated 
autonomic failure (HAAF) often occurs with recurrent episodes of hypoglycemia, a condition 
where the biologic stress response to hypoglycemia that includes loss of awareness to 
hypoglycemia and the corresponding loss of endogenous glucagon secretion. The pre-emptive 
administration of chronic exogenous glucagon, to partially replace the missing endogenous 
glucagon, may therefore normalize blood sugars to restore normal blood glucose over time, 
restore awareness, and ultimately restore autonomic function in the setting of hypoglycemia. 
Xeris has used its biocompatible, non-aqueous peptide/protein reformulation technology to 
create a concentrated, low volume, stable glucagon formulation. Glucagon is indicated for the 
treatment of severe hypoglycemia in a 1 mg dose for adults and 0.5 mg for children >2 to 12 
years, who are <45 kg. Additionally, Xeris glucagon has successfully been delivered for 
subchronic and chronic use, via the Omnipod® and vial & syringe, across multiple clinical 
programs. 
3 
STUDY OBJECTIVES 
3.1 Primary Objective 
The primary objective is to compare the plasma epinephrine concentration after 30 minutes of 
induced hypoglycemia (PG <50mg/dL) in adult TlD subjects with HAAF, who have received 
4 weeks of treatment with either CSGI or placebo. 
Confidential 
Page 5 of 31 


Statistical Analysis Plan 
Version 1.0, dated 21-0ct-2019 
Prepared for: Xeris Pharmaceuticals, Inc. 
Study: XSGO-AF0I 
3.2 Secondary Objectives 
3.2.1 
Efficacy Objectives 
1. Compare change in cumulative glucose infusion to maintain glucose at 50 mg/dL for 
the first 30 minutes after the 50 mg/dL is achieved. 
2. Compare change in cumulative insulin infusion to maintain glucose at 50 mg/dL for 
the first 30 minutes after the 50 mg/dL is achieved. 
3. Compare changes in the other counter-regulatory hormones: norepinephrine, 
glucagon, cortisol and growth hormone. 
4. Compare changes from Induction 1 (baseline visit) to Induction 2 (visit 7, week 4) in 
subject responses to a validated hypoglycemia symptom questionnaire administered 
during induced hypoglycemia. 
5. Compare changes from baseline to week 4 in CGM-derived hypoglycemia parameters 
of: 
a. Proportional time spent with interstitial glucose < 70, <60 and <50 mg/dL. 
b. Rate of hypoglycemic event episodes at plasma glucose< 70, <60, and <50 
mg/dL. 
c. Area over the curve (AOC) of the reduction from baseline in the interstitial 
glucose from TO (defined as the date/time of the CSGI injection) to Tx, where x 
corresponds to time when interstitial glucose < 70, <60 and <50 mg/dL is 
achieved. 
6. Compare change from baseline to week 4 in CGM-derived parameters of: 
a. Average (mean) interstitial glucose and standard deviation 
b. proportional time with 70 :'.S interstitial glucose < 180 mg/dL, 
c. proportional time with interstitial glucose~ 180 mg/dL. 
7. Describe subject reported hypoglycemic events 
a. Symptomatic events confirmed with self-monitored glucose < 70 mg/dL. 
b. Symptomatic events with no accompanying glucose meter reading or a reading 
~70 mg/dL. 
c. Asymptomatic events of self-monitored glucose < 70 mg/dL. 
d. Severe hypoglycemia as defined by affected consciousness of hypoglycemic 
origin confirmed by a glucose meter reading <50 mg/dL, requiring external 
assistance, or prompt recovery upon hypoglycemia treatment. 
8. Describe change from Induction 1 (baseline visit) to Induction 2 (visit 7, week 4) of 
unawareness measured by the Gold scale. 
9. Describe basal, bolus and total daily insulin dose changes by treatment group. 
10. Describe the time course of the endpoints (primary and secondary 1-7) from week 4 
through the rest of the study. 
11. Describe non-serious and serious adverse events by treatment group. 
12. Describe change from Induction 1 (baseline visit) through Induction 2 (visit 7, week 
4) of serum concentrations of glucagon while still on the CSGI, and serum and plasma 
glucagon antibodies. 
Confidential 
Page 6 of 31 


Statistical Analysis Plan 
Version 1.0, dated 21-0ct-2019 
Prepared for: Xeris Pharmaceuticals, Inc. 
Study: XSGO-AF0 I 
4 
ENDPOINTS 
4.1 Primary Endpoint 
Percent change from Induction 1 (baseline visit) to Induction 2 (visit 7, Week 4) in plasma 
epinephrine concentration after 30 minutes of induced hypoglycemia with PG <SO mg/dL. 
The average of the non-missing results at each step will be used in analysis. 
4.2 Secondary Endpoints 
The secondary endpoints for this study include: 
4.2.1 
Efficacy Endpoints 
• 
Absolute change from Induction 1 (baseline visit) to Induction 2 (visit 7, Week 4) in 
plasma epinephrine concentration after 30 minutes of induced hypoglycemia with PG 
<SO mg/dL. The average of the non-missing results at each step will be used in analysis. 
• 
Percent change from Induction 1 (baseline visit) to Induction 2 (visit 7, Week 4) in 
plasma epinephrine concentration after 30 minutes of induced hypoglycemia with PG 
<SO mg/dL by Diabetes Duration Category (<15 years, 2':15 years). The average of the 
non-missing results at each step will be used in analysis. 
• 
Intravenous glucose infusion rate (GIR) [time frame: 0-30 mins induced hypoglycemia] 
(cumulative glucose infusion rate required to maintain insulin-induced hypoglycemia). 
• 
Intravenous insulin infusion rate [time frame: 0-30 mins induced hypoglycemia] 
(cumulative insulin infusion rate required to maintain insulin-induced hypoglycemia). 
• 
Change from Induction 1 (baseline visit) to Induction 2 (visit 7, Week 4) in other 
counter regulatory hormones (norepinephrine, glucagon, cortisol and growth hormone 
plasma concentrations) after 30 mins of induced hypoglycemia. 
• 
Change from Induction 1 (baseline visit) to Induction 2 (visit 7, Week 4) in 
Neuroglycopenic Symptom Scores (if hypoglycemia present) as documented using the 
hypoglycemia symptom questionnaire. 
• 
Change from Induction 1 (baseline visit) to Induction 2 (visit 7, Week 4) in Autonomic 
Symptom Scores (if hypoglycemia present) as documented using the hypoglycemia 
symptom questionnaire. 
• 
Change from baseline to Week 4 in COM-derived hypoglycemia parameters of: 
o Proportional time spent with interstitial glucose (IG) <70, 60, and 50 mg/dL; 
o Rate of hypoglycemic event episodes at thresholds of plasma glucose <70, 60, 
and 50 mg/dL. 
o Area over the curve (AOC) of the reduction from baseline in the interstitial 
glucos~ from TO (defined as the date/time of the CSGI injection) to Tx, where 
x corresponds to time when interstitial glucose < 70, <60 and <SO mg/dL is 
achieved. 
• 
Change from baseline to Week 4 in COM-derived parameters of: 
o Average interstitial glucose and standard deviation; 
o Proportional time within 70:Sinterstitial glucose<l 80 mg/dL; 
Confidential 
Page 7 of31 


Statistical Analysis Plan 
Version l.0, dated 21-0ct-2019 
Prepared for: Xeris Pharmaceuticals, Inc. 
Study: XSGO-AF0I 
o Proportional time with interstitial glucose~ 180 mg/dL. 
• 
Change from Induction 1 (baseline visit) to Induction 2 (visit 7, Week 4) in the Gold 
scale as a measure of hypoglycemia awareness. 
4.2.2 
Safety and Tolerability Endpoints 
• 
Safety-related parameters including: 
4.2.3 
o Reported hypoglycemic events; 
o Insulin dose (adjustments during the study); 
o Vital signs; 
o Physical exam; 
o ECG; 
o Standard safety laboratory parameters; 
o Incidence of adverse events (AEs) and serious adverse events (SAEs); 
o Subjective injection site discomfort as reported by subjects using a 100-mm 
VAS and other questionnaires; 
o Erythema and/or edema formation at site of injection assessed by an 
investigator using the modified Draize scale. 
Immunogenicity Endpoints 
o Plasma glucagon and serum glucagon antibodies; 
5 
SAMPLE SIZE 
The primary hypothesis is to evaluate change from Induction 1 (baseline visit) to Induction 2 
(visit 7, Week 4) in plasma epinephrine concentration after 30 minutes of induced 
hypoglycemia with plasma glucose <50mg/dL between treatment groups. Sample size is based 
on a closed hierarchical hypothesis test. Using this method, an alpha of 5% will be preserved 
for each hypothesis test where the next ordered test will only be conducted if statistical 
significance is achieved for that hypothesis. 
Final calculations are based on 80% power and an alpha of 5%, to demonstrate a plasma 
epinephrine increase compared to placebo of 1.5 nmol/1 given a SD of 1.34 nmol/1 at an induced 
PG of 50 mg/di. Sixteen subjects per treatment group (CSGI high dose, CSGI low dose, and 
placebo) are required based on the minimum sample size estimate for a comparison. 
6 
RANDOMIZATION 
The randomization scheme is 1: 1: 1 for high dose, low dose and placebo. Each group will have 
16 subjects, but the placebo group will be matched to high and low infusion rates (8 in each 
group). The randomization is stratified by site. 
7 
PLANNED ANALYSES 
No statistical analysis plan (SAP) prepared in advance of the data can be absolutely definitive 
and the final clinical study report (CSR) may contain additional tables or statistical tests if 
warranted by the data obtained. The justification for any such additional analyses will be fully 
documented in the final CSR. 
Confidential 
Page 8 of31 


Statistical Analysis Plan 
Version 1.0, dated 21-0ct-2019 
Prepared for: Xeris Pharmaceuticals, Inc. 
Study: XSGO-AP0I 
7.1 Analysis Populations 
Subjects excluded from the analysis sets and the reason for their exclusion will be listed in 
Appendix 16.2. Enrolled subjects are subjects that have signed ICF, been assigned a subject 
number and randomized. 
7.1.1 
Intent-to-treat Population (ITT or All Randomized) 
The ITT population includes all randomized subjects. The ITT population will be analyzed 
according to the treatment group to which subjects were randomized. 
ITT population will be used for primary and secondary efficacy endpoints. 
7.1.2 
Per-Protocol Population (PP Population) 
The PP population will b~ a subset of the ITT population consisting of those subjects who: 
• 
Satisfy all of the inclusion/exclusion criteria; 
• 
Participate in the study through day 27 with no major protocol deviations 
All protocol deviations will be assessed and documented on a case-by-case basis before the 
database lock, and deviations considered to have a serious impact on the efficacy results will 
lead to the relevant subject being excluded from the PP population. Before database lock, 
potential subject exclusions from PP population will be reviewed by the Sponsor and 
documented in a subject evaluability document. 
PP population will be used for sensitivity analysis of the primary efficacy endpoint. 
7.1.3 
Safety Population 
All randomized subjects who received at least one study treatment application. Unless 
otherwise stated, the safety population will be the default analysis population for all safety and 
tolerability analyses. Analyses will be performed based on actual treatment received, even if 
different from treatment group to which subjects were randomized. 
7.2 Derived Data 
This section describes the derivations required for statistical analysis. Unless otherwise stated, 
variables derived in the source data will not be re-calculated. 
7.2.1 
Baseline 
For endpoints that are based on assessments that are collected once per visit, baseline is defined 
as the last non-missing value (either scheduled, unscheduled or repeat) before the subject 
receives the first dose of study drug. 
For baseline of Counter regulatory hormone parameters see Section 7.2.9. 
For baseline of CGM derived endpoints see Section 7.2.10. 
For baseline of hypoglycemia symptom questionnaire parameters see Section 7.2.11. 
Confidential 
Page 9 of31 


Statistical Analysis Plan 
Version 1.0, dated 21-0ct-2019 
Prepared for: Xeris Pharmaceuticals, Inc. 
Study: XSGO-AF0I 
7.2.2 
Duration/Study Day/Time 
Study day will be calculated as the number of days from first dose of study drug. 
• 
date of event - date of first dose of study drug + 1, for events on or after day of first 
dose; 
• 
date of event - date of first dose of study drug, for events before day of first dose. 
7.2.3 
Conventions for Missing and Partial Dates 
All rules explained below for partial/missing dates will be followed unless contradicted by any 
other data recorded on the electronic Case Report Form ( eCRF). 
All dates presented in the individual subject listings will be presented as recorded on the 
eCRF (i.e., not completed as per the below rules). 
7.2.4 
Missing/Partial Start/Stop Date of Adverse Events and 
Concomitant Medications 
When the AE start date is incomplete, then it will be imputed for analysis purposes ( e.g. when 
defining whether AE is treatment-emergent or not). 
For concomitant medications, incomplete or missing start date and stop date will be imputed 
for analysis purposes (e.g. prior and concomitant medications). When the start date and the 
stop date are both incomplete for a subject, consider imputing the start date first. 
Start and stop dates will be imputed as follows: 
Incomplete Start Date 
Missing day and month 
• 
If the year of the incomplete start date is the same as the year of the date of the first 
dose of investigational product, then the day and month of the date of the first dose will be 
assigned to the missing fields. 
• 
If the year of the incomplete start date is before the year of the date of the first dose of 
investigational product, then December 31 will be assigned to the missing fields. 
• 
If the year of the incomplete start date is after the year of the date of the first dose of 
investigational product, then January 1 will be assigned to the missing fields. 
Missing month only 
• 
The day will be treated as missing and both month and day will be replaced according 
to the above procedure. 
Missing day only 
Confidential 
Page 10 of31 


Statistical Analysis Plan 
Version 1.0, dated 21-0ct-2019 
Prepared for: Xeris Pharmaceuticals, Inc. 
Study: XSGO-AF0I 
• 
If the month and year of the incomplete start date are the same as the month and year 
of the date of the first dose of investigational product, then the day of the first dose will be 
assigned to the missing day. 
• 
If either the year is before the year of the date of the first dose of investigational product 
or if both years are the same but the month is before the month of the date of the first dose of 
investigational product, then the last day of the month will be assigned to the missing day. 
If either the year is after the year of the date of the first dose of investigational product 
or if both years are the same but the month is after the month of the date of the first dose of 
investigational product, then the first day of the month will be assigned to the missing day. 
Missing start date 
If the stop date is after the date of the first dose of investigational product, the date of the first 
dose of investigational product will be assigned to the missing start date 
If the stop date is before the date of the first dose of investigational product, the stop date will 
be assigned to the missing start date. 
Incomplete Stop Date 
Missing day and month 
• 
If the year of the incomplete stop date is the same as the year of the date of the last dose 
of investigational product, then the day and month of the date of the last dose will be assigned 
to the missing fields. 
• 
If the year of the incomplete stop date is before the year of the date of the last dose of 
investigational product, then December 31 will be assigned to the missing fields. 
• 
If the year of the incomplete stop date is after the year of the date of the last dose of 
investigational product, then January 1 will be assigned to the missing fields. 
Missing month only 
• 
The day will be treated as missing and both month and day will be replaced according 
to the above procedure. 
Missing day only 
• 
If the month and year of the incomplete stop date are the same as the month and year 
of the date of the last dose of investigational product, then the day of the last dose will be 
assigned to the missing day. 
If either the year is before the year of the date of the last dose of investigational product 
or if both years are the same but the month is before the month of the date of the last dose of 
investigational product, then the last day of the month will be assigned to the missing day. 
If either the year is after the year of the date of the last dose of investigational product 
or if both years are the same but the month is after the month of the date of the last dose of 
investigational product, then the first day of the month will be assigned to the missing day. 
Confidential 
Page 11 of 31 


Statistical Analysis Plan 
Version 1.0, dated 21-0ct-2019 
Prepared for: Xeris Pharmaceuticals, Inc. 
Studv: XSGO-AF0I 
7.2.5 
Missing Diagnosis Dates 
If the month and year are present but the day is missing, then diagnosis day will be set to "O 1 ". 
If only year is recorded, then diagnosis date and month will be set as "O 1-Jan" for that year. 
7.2.6 
Duration of Study Drug Exposure 
Duration of study drug exposure will be calculated as date oflast dosing minus the date of first 
dosing+ 1. The exposure duration will not consider breaks in therapy. 
7.2.7 
Inexact Values 
If a reported value of a clinical laboratory parameter cannot be used in a statistical summary 
table due, for example, to the fact that a character string is reported for a parameter of the 
numerical type, a coded value needs to be appropriately determined and used in the statistical 
analyses. Value of X+0.0001 will be used to impute ">X" character value and X-0.0001 will 
be used to impute "<X". That is, if X equal to 60, 60.000 I will be used to impute character 
value of">60" and 59.999 will be used to impute "<60". 
In the case where a laboratory value is recorded as "2: X" or "S X", a value of X will be taken 
for analysis purposes. 
However, the reported values will be presented in data listings. 
7.2.8 
Unscheduled Visits and Repeated assessments 
Only scheduled post-baseline safety and tolerability values will be tabulated. If more than one 
value is available at scheduled visit, then the last one will be used for analysis. 
7.2.9 
Counter Regulatory Hormones 
Hypoglycemia induction is conducted at 
-
Visit 3 Day I (baseline); 
-
Visit 7 (Week 4); 
-
Visit 9 (3 Month Follow-Up); 
-
Visit 11 (6 Month Follow-Up). 
During the hypoglycemia induction, blood samples (2) for counter regulatory hormones 
(growth, cortisol, epinephrine, norepinephrine, glucagon) are drawn 10 minutes apart at the 
following steps after meeting target PG value for minimum amount of time: 
• 
Baseline Stabilization (BS; defined as having PG between 90-110 mg/dL for at least 60 
minutes, target PG value 100 mg/dL). 
• 
Hypoglycemia induction and stabilization, 2nd step (HIS2, Subject has maintained a PG 
between 45-54 mg/di for at least 30 minutes, target PG value 50 mg/dL) 
The average of the non-missing results at each step will be used in analysis. 
Assessments captured during the hypoglycemia induction at Visit 3, Day 1 are baseline values. 
Confidential 
Page 12 of31 


Statistical Analysis Plan 
Version 1.0, dated 21-0ct-2019 
Prepared for: Xeris Pharmaceuticals, Inc. 
Study: XSGO-AF0I 
Counter regulatory hormone response to the induction is defined as the difference between 
HIS2 and BS value (e.g., response=HIS2 average value- BS average value). 
7.2.10 
CGM Derived Parameters 
CGM readings occur every 5 mins. Hence in a complete 24-hour period, 288 CGM readings 
would be captured. The following endpoints will be calculated per day ( e.g., 24-hour period 
starting from CSGI injection). 
• 
Proportional time spent with interstitial glucose< 70 mg/dL; 
• 
Proportional time spent with interstitial glucose < 60 mg/dL; 
• 
Proportional time spent with interstitial glucose < 50 mg/dL; 
• 
Proportional time within 70:'.Sinterstitial glucose<l 80 mg/dL; 
• 
Proportional time with interstitial glucose 2': 180 mg/dL. 
Proportional time spent with 1G < X mg/dL = (time spent with 1G < X mg/dL (minutes)/ 
total time spent with CGM (minutes))* 100 where x = 70, 60 or 50, given the continuous 
CGM readings. 
• 
Rate of hypoglycemic event episodes at thresholds of plasma glucose <70 mg/dL; 
• 
Rate of hypoglycemic event episodes at thresholds of plasma glucose <60 mg/dL; 
• 
Rate of hypoglycemic event episodes at thresholds of plasma glucose <50 mg/dL; 
Rate of hypoglycemic event episodes at thresholds of <X mg/dL is defined as the number 
of episodes with PG < X mg/dL, where 70, 60 or 50. Subsequent PG measures with the 
result of< X mg/dL should be considered as the same episode. 
• 
Average interstitial glucose; 
• 
Interstitial glucose standard deviation; 
• 
Area over the curve (AOC) of the reduction from baseline in the interstitial glucose 
from TO (defined as the date/time of the CSGI injection) to Tx, where x corresponds 
to time when interstitial glucose < 70, <60 and <50 mg/dL is achieved. 
AOC calculations will be done using the standard trapezoidal rule 
AOC= 
-(°"~ (abs (reduction in /Gi)+abs(reduction in /Gi+1 ) ) * (T.· 
_ T,-)) 
L.t=O 
2 
t+l 
·l 
Where: abs(reduction in IGi) = absolute value of change from baseline in interstitial 
glucose at time i, and (Ti+ l - Ti) is the Time difference in minutes between time i and 
time i+l. 
For endpoints that will be calculated per day - baseline will be based on the CGM data 
collected on the latest day prior to the date/time of the first CSGI injection. For the AOC 
endpoint baseline will be the latest interstitial glucose measure obtained prior to the 
date/time of the first CSGI injection. 
Confidential 
Page 13 of31 


Statistical Analysis Plan 
Version 1.0, dated 21-0ct-2019 
7.2.10.1 Weekly endpoints 
Prepared for: Xeris Pharmaceuticals, Inc. 
Study: XSGO-AF0l 
Additionally, all derived CGM endpoints will be derived on a weekly basis. The following 
weeks will be analyzed: Baseline (Week), Week 1, Week 2, Week 3, Week 4, Month 3 and 
Month 6. CGM-Derived parameters will be based on CGM data that fall in the following 
timeframe: 
Week 
Time window (Days) 
Baseline 
7 days prior to day 1 
Week 1 
1 
7 
Week2 
8 
14 
Week3 
15 
21 
Week4 
22 
28 
Month 3 
7 days prior to date of Month 3 visit 
Month 6 
7 days prior to date of Month 6 visit 
When deriving weekly endpoints - baseline will be based on the CGM data collected 7 days 
prior to the date/time of the first CSGI injection. For the AOC endpoint baseline will be the 
same as for the AOC calculated by day. 
7 .2.11 
Hypoglycemia Symptom Questionnaire 
This questionnaire measures the severity of 8 symptoms of hypoglycemia on a 1 (absent) to 6 
(severe) scale. The symptoms are grouped by type of symptom (Neuroglycopenic or 
Autonomic) per following table: 
Dizziness 
Blurred vision 
Difficulty in thinking 
Faintness 
Average Neuroglycopenic Symptom Score 
ANS 
Autonomics 
Sweating 
Tremor 
Palpitations 
toms 'Score 1-6 
Feelin of nervousness 
Average Autonomic Symptom Score 
AAS 
e Total S m tom Score ATS) 
An average Neuroglycopenic Symptom Score (ANS), Autonomic Symptom Score (AAS) and 
Average Total Symptom Score (ATS) will be calculated from individual symptom scores. 
Average will be calculated if at least > 50% items in each group (Neuroglycopenic and 
Autonomic) will be not missing. 
Overall Assessment of Hypoglycemia 
will be treated as a categorical variable and analyzed with descriptive statistics by timepoints; 
Confidential 
Page 14 of 31 


Statistical Analysis Plan 
Version 1.0, dated 21-0ct-2019 
Gold Scale of Hypoglycemia unawareness 
Prepared for: Xeris Pharmaceuticals, Inc. 
Study: XSGO-AF0 I 
The questionnaire measures on a 7-point scale a subject's awareness of onset of hypoglycemia 
by asking a single question "To what extent are you aware of the onset of hypoglycemia?". 
Baseline for all questionnaire measures is defined as the last value of obtained just before IV 
push dose of insulin at visit 3 (Day 1, Baseline). 
A separate summary for Average Neuroglycopenic Scores (ANS), Average Autonomic Scores 
(AAS), Average Total Scores (ATS) and Overall Assessment of Hypoglycemia assessed with 
PG <70 mg/di and PG <50 mg/di will be presented. 
7 .2.12 
Local Tolerability 
7.2.12.1 Injection Site Discomfort Assessment 
This assessment consists of a 
• 
Visual Analog Scale (VAS) (0-lO0mm) 
• 
Delivery Site Discomfort Description and Duration questionnaire that consists of the 
following questions: 
o Discomfort question with the following categories: Pain, Itching, (Tingling, 
twitching or numbness), Irritation and Other. 
o Question regarding how long after administration did the discomfort start and 
how long it lasted. 
This assessment is administered at visit 3 (Day 1, Baseline) and Visit 4 (Day 7) with the VAS 
scale being administered at several timepoints and the discomfort questionnaire being 
administered at 10 mins following delivery of study drug. 
7.2.12.2 Draize Scale 
This scale measures presence/severity of Erythema and Edema Formation on a 0-4 scale (not 
present-severe) at Visit 4 (Day 7) and visit 7 (Day 28) at multiple timepoints. 
7.3 Conventions 
7.3.1 
Technical Requirements 
The statistical analyses will be performed by Quartesian Clinical Research, using SAS Version 
9.4 (or higher). Datasets will be prepared using standards from Clinical Data Interchange 
Consortium (CDISC) Study Data Tabulation Model (SDTM) implementation for human 
clinical trials and ADaM (Analysis Dataset Model). Tables, figures and listings will be 
produced in landscape format if not specified otherwise. 
7.3.2 
Summary statistics 
Data will be tabulated by time point where appropriate. The total number of subjects in the 
study group (N) under the stated population will be displayed in the header of summary tables 
and figures. 
Confidential 
Page 15 of 31 


Statistical Analysis Plan 
Version 1.0, dated 2l-Oct-2019 
Prepared for: Xeris Pharmaceuticals, Inc. 
Study: XSGO-AF0 I 
All summaries will be presented by treatment group for baseline and each scheduled visit and 
timepoint, where applicable. If more than one assessment available per timepoint, then last 
assessment will be used for analysis. 
Summaries will be presented by treatment group and overall. Treatment group labels will be 
displayed as follows: 
Low Dose 
(20 ug/hr) 
CSGI 
High Dose 
(80 ug/hr) 
Combined 
(Low+ High) 
Placebo 
Total 
Listings will be sorted in the following order: subject, parameter, and visit unless otherwise 
stated. All data will be listed, subjects who were not randomized will be displayed after the 
randomized treatment/sequence groups. 
Continuous variables will be summarized by the number of non-missing observations, mean, 
median, standard deviation, and minimum and maximum. 
Categorical variables will be summarized with frequencies and percentages. For each variable, 
all pre-specified categories will be shown. Zero counts will be presented without percent. 
N will be used as percentage denominator in descriptive summaries, if not specified otherwise. 
Missing will be counted as difference of subjects at each visit and number of assessments. 
Note: Records collected from eCRF or eDT will not be used for 'Missing' statistics and can be 
used only for reference. 
7.3.3 
Decimal Places 
Unless otherwise stated, continuous data will be summarized with the following descriptive 
statistics: number of non-missing observations (n), arithmetic mean (Mean), standard deviation 
(SD), median, minimum (Min), maximum (Max). For presentation, Min and Max will have the 
same number of decimal places as the original data; the mean, geometric mean and median 
will be presented to 1 decimal place greater than Min, Max; SD will be to 2 decimal places 
greater than Min, Max; percentages will be presented rounded to 1 decimal place. Number of 
decimals for descriptive statistics will be limited with 4 decimals. Minimum and maximum 
will be displayed with the number of decimals reported in CRF and can be limited to 3 
decimals; converted or derived values will have from 3 to 4 significant digits in summary 
statistics and will be determined in case-by-case basis. 
If some parameter contains original and calculated values or certain timepoints ( e.g. 
hypoglycemia scores), then one decimal will be added to Min, Max for derived timepoints or 
parameters, not including other descriptive statistics. 
P-values will be displayed with 3 decimal places. P-values that are less than 0.001 will be 
presented as "<0.001". 
Confidential 
Page 16 of 31 


Statistical Analysis Plan 
Version 1.0, dated 21-0ct-2019 
7.4 Subject Disposition 
Subject disposition will be summarized as follows: 
Prepared for: Xeris Pharmaceuticals, Inc. 
Study: XSGO-AF0 I 
• 
The number of subjects who were screened, screen failures, randomized and who are 
in each analysis population will be summarized by treatment group and overall. 
• 
The number of early withdrawals and the reasons for withdrawals will be tabulated by 
treatment group and overall for ITT population 
7.5 Protocol Deviations 
Protocol deviations will be identified during blinded data review by Sponsor and Medical 
Monitor and classified as major or minor. Subjects with major protocol deviations will be 
excluded from PP population .. 
The number of subjects with major and minor protocol deviations will be summarized 
descriptively with counts and percentages for ITT population and listed. 
7.6 Demographic and Baseline Characteristics 
Demographic characteristics will include: 
• 
Age; 
• 
Gender; 
• 
Ethnicity; 
• 
Race. 
Baseline characteristics will include: 
• 
Weight; 
• 
Height; 
• 
Body Mass Index (BMI); 
• 
Body Surface Area (BSA); 
• 
Gold scale for hypoglycemia unawareness; 
• 
Glucose Correction Factor per Unit of Insulin (mg/dL); 
• 
Hemoglobin A 1 C (%) 
• 
Hemoglobin A 1 C (%) category (s;8%, >8%) 
• 
Duration of diabetes (years) 
• 
Duration of diabetes category ( <15 yrs, 15 yrs) 
Demographic and baseline characteristics will be listed and analyzed with descriptive statistics 
for Safety, ITT and PP population. 
7.7 Medical History 
Subjects will undergo a complete medical history at screening. 
Medical history of each subject will be collected at screening visit and coded using the 
MedDRA 22.0 dictionary. 
Confidential 
Page 17 of31 


Statistical Analysis Plan 
Version 1.0, dated 21-0ct-2019 
Prepared for: Xeris Pharmaceuticals, Inc. 
Study: XSGO-AF0 I 
Medical history will be listed and analyzed with descriptive statistics by SOC and PT for ITT 
population. 
7.8 Prior and Concomitant Medications 
Subjects should be on a stable dose of all concomitant medications for at least 30 days prior to 
Screening. All subjects must have their concomitant medications reviewed at each visit. 
Medications taken within 4 weeks before Day 1 will be documented in the CRF. Any changes 
to a subject's concomitant medication regimen will be documented. 
Prior medication is defined as any medication taken within 4 weeks before treatment 
administration. 
Concomitant medication is defined as any non-study medication taken on or after blinded study 
treatment was administered. 
If dates of medications are incomplete, missing, or medication is ongoing, the medication will 
be considered as concomitant if there is no evidence that medication intake stopped before 
study treatment. The medication will be considered as prior if there is an evidence that 
medication intake started before the study treatment, and there is a possibility that medication 
intake started not earlier than 6 months before screening. 
Concomitant Medications, Drugs/Therapies will be coded using WHODrug Global B3 Mar 
2019. 
Prior and Concomitant medication will be summarized and listed with ATC level 2 and 
preferred term for the Safety population. 
Patients may have more than one medication per ATC category and PT. At each level of patient 
summarization, a patient will be counted only once. 
7.9 Exposure to Study Drug 
Extent of exposure (number of days of exposure to study drug) will be presented for the Safety 
population. 
7.10 Efficacy Analyses 
7.10.1 
Primary Endpoint 
The primary endpoint is the percent change from Induction 1 (baseline visit) to Induction 2 
(visit 7, week 4) in plasma epinephrine concentration after 30 minutes of induced 
hypoglycemia with PG < 50 mg/dL. 
Hypotheses of interest: 
Ho: µx=µy vs H1: µx=;:µy 
where the treatment comparison of interest (ranked in order of interest) is as follows: 
• 
CSGI Combined vs placebo 
• 
CSGI High vs placebo 
Confidential 
Page 18 of 31 


Statistical Analysis Plan 
Version 1.01 dated 21-0ct-2019 
• 
CSGI Low vs placebo 
• 
CSGI High vs CSGI Low 
For details regarding multiplicity please see section 7.10.5. 
7.10.2 
Primary Efficacy Analysis 
Prepared for: Xeris Pharmaceuticals, Inc. 
Study: XSGO-AF0I 
The analysis of the primary endpoint will be performed using a two-group t-test for each 
treatment comparison of interest. The primary endpoint will also be analyzed, stratifying by 
duration of diabetes (<15 yrs, 2': 15 yrs) as a secondary analysis. 
A closed testing hierarchical procedure will be used to control for multiplicity. See 
section 7.10.5. 
7.10.3 
Sensitivity Analysis 
The following Sensitivity analyses of the primary outcome in the PP population will be 
conducted: 
• 
All subjects who are lost to follow-up or have missing outcome data will be 
considered to have a favorable outcome (e.g., value will be set to the largest 
(maximum) improved change in either treatment groups) in each treatment group 
• 
Subjects who are lost to follow-up or have a missing primary endpoint at Day 27 in 
the high or low dose group will be considered to have an unfavorable outcome ( e.g., 
value will be set to baseline outcome) whereas in the placebo group will be 
considered to have a favorable outcome 
• 
Subjects who have a missing outcome data will be excluded from the analysis 
7.10.4 
Secondary Endpoints 
• 
Intravenous glucose infusion rate (GIR) [time frame: 0-30 mins induced 
hypoglycemia] (cumulative glucose infusion rate required to maintain insulin-induced 
hypoglycemia) 
• 
Intravenous insulin infusion rate [time frame: 0-30 mins induced hypoglycemia] 
(cumulative insulin infusion rate required to maintain insulin-induced hypoglycemia) 
• 
Change from Induction 1 (baseline visit) to Induction 2 (visit 7, Week 4) in other 
counter regulatory hormones (norepinephrine, glucagon, cortisol and growth hormone 
plasma concentrations) after 30 mins of induced hypoglycemia 
• 
Change from Induction 1 (baseline visit) to Induction 2 (visit 7, Week 4) in 
Neuroglycopenic Symptom Scores (if hypoglycemia present) as documented using 
the hypoglycemia symptom questionnaire 
• 
Change from Induction 1 (baseline visit) to Induction 2 (visit 7, Week 4) in 
Autonomic Symptom Scores (if hypoglycemia present) as documented using the 
hypoglycemia symptom questionnaire 
• 
Change from baseline to Week 4 in CGM-derived hypoglycemia parameters of: 
o Proportional time spent with interstitial glucose <70, 60, and 50 mg/dL 
Confidential 
Page 19 of 31 


Statistical Analysis Plan 
Version 1.0, dated 21-0ct-2019 
Prepared for: Xeris Pharmaceuticals, Inc. 
Study: XSGO-AF0l 
o Rate of hypoglycemic event episodes at thresholds of plasma glucose <70, 60, 
and 50 mg/dL 
o Area over the curve (AOC) of the reduction from baseline in the interstitial 
glucose from TO to Tx, where x corresponds to time when interstitial glucose 
< 70, <60 and <50 mg/dL is achieved. 
• 
Change from baseline to Week 4 in CGM-derived parameters of: 
o 
Average interstitial glucose and standard deviation 
o 
Proportional time within 70::Sinterstitial glucose<l 80 mg/dL 
o Proportional time with intersititial~ 180 mg/dL 
• 
Change from Induction l (baseline visit) to Induction 2 (visit 7, Week 4) in the Gold 
scale as a measure of hypoglycemia awareness 
Pharmacodynamic endpoints (e.g., CGM derived parameters, counter regulatory hormones, 
GIR, insulin infusion rate) will be analyzed using a I-factor (treatment) analysis of variance 
(ANOV A) model with treatment as the main effect. 
The change from baseline for Gold scale, Neuroglycopenic Symptom Score, and Autonomic 
Symptom Score endpoints will be analyzed using non-parametric analysis of variance 
(Wilcoxon rank-sum test). 
7.10.5 
Multiplicity 
The analysis of the primary endpoint will be performed using a hierarchical hypothesis test in 
which an alpha of 5% will be preserved for each test. Testing will be employed in the 
following order: 
• CSGI combined versus Placebo (if statistically significant <0.05, then the next hypothesis 
test will be conducted) 
• CSGI high dose versus Placebo (if statistically significant <0.05, then the next hypothesis 
test will be conducted) 
• CSGI low dose versus Placebo (if statistically significant <0.05, then the next hypothesis 
test will be conducted) 
• CSGI high dose versus CSGI low dose 
All secondary endpoints and the supportive analyses will be considered as descriptive 
evidence of efficacy and will be analyzed without any procedures to account for multiple 
comparisons. 
7.11 Safety Analyses 
The safety analyses will be presented by the treatment received for the Safety Analysis 
Population. 
7.11.1 
Adverse Events 
A treatment emergent adverse event (TEAE) is defined as: 
Confidential 
Page 20 of 31 


Statistical Analysis Plan 
Version 1.0, dated 21-0ct-2019 
Prepared for: Xeris Pharmaceuticals, Inc. 
Study: XSGO-AF0I 
• 
Any AE that has an onset on or after the first dose of study drug or 
• 
Any pre-existing AE that has worsened in severity on or after the first dose of study 
drug. 
A treatment-related AE is defined as an AE as being related to the study drug if response to 
"Is there a reasonable possibility that the drug caused the event?" is Yes. If an AE has 
missing relationship it is assumed to be related to the study drug for analysis purposes. 
Maximum severity will be assumed for an AE with missing severity. 
The following tables will be presented for AEs: 
• 
Overall incidence and the number of AEs, SAEs, TEAEs leading to withdrawal. 
• 
TEAE by system organ class and preferred term, incidence and number of events 
• 
Treatment-related TEAE by system organ class and preferred term, incidence and 
number of events 
• 
Serious TEAE by system organ class and preferred term, incidence and number of 
events 
• 
TEAE by system organ class, preferred term and maximum severity, incidence 
• 
Treatment related TEAE by system organ class, preferred term and maximum 
severity, incidence 
• 
TEAEs leading to early withdrawal by system organ class and preferred term, 
incidence 
• 
Listing of Serious TEAEs (presented in the Table section of the appendices) 
• 
Listing of Deaths (presented in the Table section of the appendices) 
All AEs will be listed. 
7.11.2 
Laboratory Data 
Descriptive statistics of the observed values and change from baseline (continuous data) will 
be presented by treatment group and visit for each hematology, urinalysis and serum 
chemistry parameter. Each measurement (continuous data) will be classed as below, within, 
or above normal range, based on ranges supplied by the laboratory used. Shift tables in 
relation to the normal range from baseline to each follow-up visit will be presented. 
7.11.3 
Vital Signs 
Descriptive statistics for observed values and changes from baseline in the following vital 
signs will be presented by treatment group and visit: 
• 
Systolic blood pressure (mmHg) 
• 
Diastolic blood pressure (mmHg) 
• 
Pulse rate (bpm) 
• 
Respiration rate (breath/min) 
• 
Body temperature (degrees Celsius) 
• 
Body weight (kg). 
Confidential 
Page 21 of 31 


Statistical Analysis Plan 
Version L.0, dated 21-0ct-2019 
7.11.4 
Electrocardiogram Data 
Prepared for: Xeris Pharmaceuticals, Inc. 
Study: XSGO-AF0 I 
Overall ECG interpretation (Normal, Abnormal NCS, and Abnormal CS) data will be 
summarized by visit and treatment. Additionally, shift tables in relation to the overall 
interpretation from baseline to each follow-up visit will be presented. 
7.11.5 
Physical Examination 
Physical examination data will be listed. 
7.11.6 
Local Tolerability 
7.11.6.1 Injection Site Discomfort Assessments 
Descriptive statistics for observed Visual Analog Scale (VAS) Score (mm; measure of 
discomfort) for injection Site discomfort will be presented by timepoint (10, 30, 60 and 180 
minutes post-injection), visit and treatment group. 
Number (percent) of subjects who had any discomfort when the pump administered study 
drug presented by visit and treatment group. For those with any discomfort, Incidence of 
type of discomfort (Categories: Pain; Itching; Tingling, twitching or numbness; Irritation 
(e.g., burning, stinging) and how long after study drug administration did the discomfort start 
(less than 1 minute, 1-2 minutes, 3-5 minutes, 6-9 minutes, at least 10 minutes) and 
Descriptive statistics for how long did the discomfort last (minutes) will be presented by visit 
and treatment group. 
7.11.6.2 Draize Scale 
Incidence of erythema will be presented by summarizing the Draize Scale Score for 
Erythema Formation by time point, visit and treatment group. The incidence if edema will be 
summarized similarly based on the Draize Scale Score for Edema Formation. 
A shift table comparing Week 1, 10 minutes post-dose to Week 1, 60 minutes post-dose and 
Week 4, 10- and 60-minutes post-dose scores will be presented by treatment group. 
8 
INTERIM ANALYSIS 
No interim analyses are planned. However, the primary endpoint analysis at Day 27 will be 
executed when the last subject data for this visit has been completed and monitored. Primary 
endpoint analysis results will only be unblinded at the treatment group level (CSGI high dose, 
CSGI low dose, placebo) and individual treatment assignments will remain blinded until the 
end of the study and the final database locked. Study investigators, study staff, subjects and 
the sponsor will remain blinded to individual group assignments. Primary endpoint analysis 
is defined as all analyses that include the evaluation of epinephrine (both primary and 
secondary designated analyses) and other corresponding counter regulatory hormones 
(norepinephrine, cortisol, glucagon and growth hormone). 
9 
DATA SAFETY MONITORING BOARD ANALYSIS 
There is no data and safety monitoring board for this study. 
Confidential 
Page 22 of31 


Statistical Analysis Plan 
Version 1.0, dated 21-0ct-2019 
Prepared for: Xeris Pharmaceuticals, Inc. 
Study: XSGO-AF0 l 
10 CHANGES TO PLANNED PROTOCOL ANALYSIS 
• 
Primary analysis endpoint updated to percent change from Induction 1 (baseline visit) 
to Induction 2 (visit 7, week 4) in plasma epinephrine concentration after 30 minutes 
of induced hypoglycemia with plasma glucose <50 mg/dL. 
• 
Absolute change from Induction 1 (baseline visit) to Induction 2 (visit 7, week 4) in 
plasma epinephrine concentration after 30 minutes of induced hypoglycaemia with 
plasma glucose <50 mg/dL moved from primary to secondary endpoint. 
• 
The primary analyses will also be performed by diabetes duration category ( <15 yrs, 
2:15 yrs) and included in the secondary analyses. 
• 
The secondary endpoint of describing subject reported severe hypoglycemic events 
when glucose meter reading <36 mg/dL was updated to glucose meter reading 
<50mg/dL. This was a typo in the protocol. 
• 
The Per-Protocol Population definition has been updated to include subjects who 
participate in the study through day 27 with no major protocol deviations because 
treatment compliance data was not captured for the study. 
Confidential 
Page 23 of31 


Statistical Analysis Plan 
Version 1.0, dated 21-0ct-2019 
11 REFERENCES 
SAS Institute Inc., Cary, NC, 27513, USA 
Confidential 
Prepared for: Xeris Pharmaceuticals, Inc. 
Study: XSGO-AF0I 
Page 24 of31 


Statistical Analysis Plan 
Version 1.0, dated 21-0ct-2019 
Prepared for: Xeris Pharmaceuticals, Inc. 
Study: XSGO-AF0I 
12 LIST OF TABLES, FIGURES AND LISTINGS 
The following table includes details of the tables, figures and listings (TFLs) for the 
study. Those marked with an asterisk(*) are planned for the primary endpoint analysis 
and presentation of the accompanying safety analysis for that time period (See Section 8). 
Table 
Table Title 
Shell Number (if 
Number 
repeat) 
14.1.1.1* 
Summary of Subject Disposition - All Subjects 
14.1.1.2* 
Summary of Analysis Populations - All Randomized 
Subjects 
14.1.2* 
Summary of Protocol Deviations - Intent-to-Treat 
Population 
14.1.3.1 * 
Summary of Demographic and Baseline Characteristics 
- Safety Population 
14.1.3.2* 
Summary of Demographic and Baseline Characteristics 
14.1.3.1 
- Intent-to-Treat Population 
14.1.3.3* 
Summary of Demographic and Baseline Characteristics 
14.1.3.1 
- Per Protocol Population 
14.1.4* 
Summary of Medical History - Intent-to-Treat 
Population 
14.2.1.1 * 
Percent change from Induction I (Baseline visit) to 
Induction 2 (Visit 7, Week 4) in Plasma Epinephrine 
Concentration During Induced Hypoglycemia with PG 
<50 mg/di Intent-to-Treat Population 
14.2.1.2* 
Percent change from Induction I (Baseline visit) to 
14.2.1.1 
Induction 2 (Visit 7, Week 4) in Plasma Epinephrine 
Concentration During Induced Hypoglycemia with PG 
<50 mg/di Per Protocol Population 
14.2.1.3* 
Percent change from Induction I (Baseline visit) to 
14.2.1.1 
Induction 2 (Visit 7, Week 4) in Plasma Epinephrine 
Concentration During Induced Hypoglycemia with PG 
<50 mg/dl, Sensitivity analysis I* Per Protocol 
Population 
14.2.1.4* 
Percent change from Induction 1 (Baseline visit) to 
14.2.1.1 
Induction 2 (Visit 7, Week 4) in Plasma Epinephrine 
Concentration During Induced Hypoglycemia with PG 
<50 mg/di, Sensitivity analysis 2* 
Per Protocol 
Population 
14.2.1.5* 
Percent change from Induction 1 (Baseline visit) to 
14.2.1.1 
Induction 2 (Visit 7, Week 4) in Plasma Epinephrine 
Concentration During Induced Hypoglycemia with PG 
<50 mg/dl, Sensitivity analysis 3* 
Per Protocol 
Population 
14.2.2.1.1 * 
Absolute change from Induction l (Baseline visit) to 
14.2.1.1 
Induction 2 (Visit 7, Week 4) in Plasma Epinephrine 
Concentration During Induced Hypoglycemia with PG 
<50 mg/di Intent-to-Treat Population 
Confidential 
Page 25 of 31 


Statistical Analysis Plan 
Version 1.0, dated 21-0ct-2019 
Prepared for: Xeris Pharmaceuticals, Inc. 
Study: XSGO-AF0 1 
Table 
Table Title 
Shell Number (if 
Number 
repeat) 
14.2.2.1.2* 
Absolute change from Induction 1 (Baseline visit) to 
14.2.1.1 
Induction 2 (Visit 7, Week 4) in Plasma Epinephrine 
Concentration During Induced Hypoglycemia with PG 
<50 mg/di Per Protocol Population 
14.2.2.2.1 * 
Percent change from Induction 1 (Baseline visit) to 
14.2.1.1 
Induction 2 (Visit 7, Week 4) in Plasma Epinephrine 
Concentration During Induced Hypoglycemia with PG 
<50 mg/di by Duration of Diabetes Category 
Intent-to-Treat Population 
14.2.2.2.2 * 
Percent change from Induction 1 (Baseline visit) to 
14.2.1.1 
Induction 2 (Visit 7, Week 4) in Plasma Epinephrine 
Concentration During Induced Hypoglycemia with PG 
<50 mg/di by Duration of Diabetes Category 
Per Protocol Population 
14.2.2.3 .1 * 
Change from Induction 1 (Baseline visit) in Counter 
Regulatory Hormones During Induced Hypoglycemia 
with PG <50 mg/di - Intent-to-Treat Population 
14.2.2.3.2* 
Change from Induction 1 (Baseline visit) in Counter 
14.2.2.3.1 
Regulatory Hormones During Induced Hypoglycemia 
with PG <50 mg/di - Per Protocol Population 
14.2.2.4.1 * 
Change from Induction 1 (Baseline visit) in Counter 
Regulatory Hormones During Induced Hypoglycemia 
with PG <50 mg/di - ANOVA - Intent-to-Treat 
Population 
14.2.2.4.2* 
Change from Induction 1 (Baseline visit) in Counter 
14.2.2.4.1 
Regulatory Hormones During Induced Hypoglycemia 
with PG <50 mg/di - ANOV A - Per Protocol 
Population 
14.2.2.5.1 
Summary of Cumulative Glucose Infusion Rate (GIR) 
Required to Maintain Insulin-Induced Hypoglycemia 
Intent-to-Treat Population 
14.2.2.5.2 
Summary of Cumulative Glucose Infusion Rate (GIR) 
14.2.2.5.1 
Required to Maintain Insulin-Induced Hypoglycemia 
Per Protocol Population 
14.2.2.6.1 
Summary of Cumulative Insulin Infusion Rate 
14.2.2.5.1 
Required to Maintain Insulin-Induced Hypoglycemia 
Intent-to-Treat Population 
14.2.2.6.2 
Summary of Cumulative Insulin Infusion Rate 
14.2.2.5.1 
Required to Maintain Insulin-Induced Hypoglycemia 
Per Protocol Population 
14.2.2.7.1.1 
Change from Induction 1 (Baseline visit) in Average 
Neuroglycopenic Scores (ANS), Average Autonomic 
Scores (AAS) and Average Total Scores (ATS) with 
PG <70 m_g/dl Intent-to-Treat Population 
14.2.2.7.1.2 
Change from Induction 1 (Baseline visit) in Average 
14.2.2.7.1.1 
Neuroglycopenic Scores (ANS), Average Autonomic 
Confidential 
Page 26 of31 


Statistical Analysis Plan 
Version l.0, dated 21-0ct-2019 
Prepared for: Xeris Pharmaceuticals, Inc. 
Study: XSGO-AF0 I 
Table 
Table Title 
Shell Number (if 
Number 
repeat) 
Scores (AAS) and Average Total Scores (ATS) with 
PG <70 mg/dl Per Protocol Population 
14.2.2. 7 .2.1 * 
Change from Induction 1 (Baseline visit) in Average 
14.2.2.7.1.1 
Neuroglycopenic Scores (ANS), Average Autonomic 
Scores (AAS) and Average Total Scores (ATS) with 
PG <50 mg/dl Intent-to-Treat Population 
14.2.2.7.2.2* 
Change from Induction 1 (Baseline visit) in Average 
14.2.2. 7.1.1 
Neuroglycopenic Scores (ANS), Average Autonomic 
Scores (AAS) and Average Total Scores (ATS) with 
PG <50 mg/di Per Protocol Population 
14.2.2.8.1.1 
Summary of Overall Assessment of Hypoglycemia with 
PG <70 mg/di Intent-to-Treat Population 
14.2.2.8.1.2 
Summary of Overall Assessment of Hypoglycemia with 
14.2.2.8.1.1 
PG <70 mg/di Per Protocol Population 
14.2.2.8.2.1 
Summary of Overall Assessment of Hypoglycemia with 
14.2.2.8.1.1 
PG <50 mg/di Intent-to-Treat Population 
14.2.2.8.2.2 
Summary of Overall Assessment of Hypoglycemia with 
14.2.2.8.1.1 
PG <50 mg/di Per Protocol Population 
14.2.2.9.1.1 
Change from Baseline in CGM-Derived Hypoglycemia 
Parameters by Day - Intent-to-Treat Population 
14.2.2.9.1.2 
Change from Baseline in CGM-Derived Hypoglycemia 
14.2.2.9.1.1 
Parameters by Day - Per Protocol Population 
14.2.2.9 .2.1 
Change from Baseline in CGM-Derived Hypoglycemia 
14.2.2.9.1.1 
Parameters by Week - Intent-to-Treat Population 
14.2.2.9.2.2 
Change from Baseline in CGM-Derived Hypoglycemia 
14.2.2.9.1.1 
Parameters by Week - Per Protocol Population 
14.2.2.10.1 * 
Change from Induction 1 (Baseline visit) in Gold Scale 
Assessment of Hypoglycemia Unawareness - Intent-to-
Treat Population 
14.2.2.10.2* 
Change from Induction 1 (Baseline visit) in Gold Scale 
14.2.2.10.1 
Assessment of Hypoglycemia Unawareness - Per 
Protocol Population 
14.3.1.1* 
Overview of Adverse Events - Safety Population 
14.3.1.2* 
Summary of Treatment-Emergent Adverse Events by 
System Organ Class, Preferred Term - Safety 
Population 
14.3.1.3 
Summary of Treatment-related Treatment-Emergent 
14.3.1.2 
Adverse Events by System Organ Class, Preferred 
Term - Safety Population 
14.3.1.4* 
Summary of Serious Treatment-Emergent Adverse 
14.3.1.2 
Events by System Organ Class, Preferred Term - Safety 
Population 
14.3.1.5 
Summary of Treatment-Emergent Adverse Events 
14.3.1.2 
Leading to Study Discontinuation by System Organ 
Class Preferred Term - Safety Population 
Confidential 
Page 27 of 31 


Statistical Analysis Plan 
Version 1.0, dated 21-0ct-2019 
Prepared for: Xeris Pharmaceuticals, Inc. 
Study: XSGO-AF0l 
Table 
Table Title 
Shell Number (if 
Number 
repeat) 
14.3.1.6 
Summary of Serious Adverse Events Leading to Death 
14.3.1.2 
by System Organ Class, Preferred Term - Safety 
Population 
14.3.1.7 
Summary of Serious Adverse Events Leading to Study 
14.3.1.2 
Discontinuation by System Organ Class, Preferred 
Term - Safety Population 
14.3.1.8.1 
Summary of Treatment-Emergent Adverse Events by 
System Organ Class, Preferred Term and Severity -
Safety Population 
14.3.1.8.2 
Summary of Treatment-related Treatment-Emergent 
14.3.1.8.1 
Adverse Events by System Organ Class, Preferred 
Term and Severity - Safety Population 
14.3.1.9* 
Summary of Treatment-Emergent Adverse Events by 
System Organ Class, Preferred Term and Relationship 
to Study Drug - Safety Population 
14.3.2.1 
Summary of Deaths - Safety Population 
14.3.2.2* 
Summary of Serious Adverse Events - Safety 
Population 
14.3.2.3 
Summary of Treatment-Emergent Adverse Events 
Leading to Study Discontinuation - Safety Population 
14.3.4.1.1 
Summary of Clinical Chemistry Results - Safety 
Population 
14.3.4.2.1 
Summary of Clinical Hematology Results - Safety 
14.3.4.1.1 
Population 
14.3.4.1.2 
Summary of Clinical Chemistry Results: Shift from 
Baseline - Safety Population 
14.3.4.2.2 
Summary of Clinical Hematology Results: Shift from 
14.3.4.1.2 
Baseline Safety Population 
14.3.5.1 
Summary of Treatment Exposure 
Safety Population 
14.3.6.1 
Summary of Vital Signs - Safety Population 
14.3.7.1.1 
Summary of Overall ECG Interpretation - Safety 
Population 
14.3.7.1.2 
Summary of Overall ECG Interpretation: Shift from 
Baseline - Safety Population 
14.3.7.2.1 
Summary of Local Tolerability- Injection Site VAS 
Discomfort Score - Safety Population 
14.3.7.2.2 
Summary of Local Tolerability- Injection Site 
Discomfort at 10 Minutes Following the Injection of 
Study Drug - Safety Population 
14.3.7.2.3 
Summary of Local Tolerability- Draize Scale - Safety 
Population 
14.3.7.2.4 
Summary of Local Tolerability- Draize Scale: Shifts 
from Week 1 - Safety Population 
14.3.8.1 
Summary of Prior Medications - Safety Population 
Confidential 
Page 28 of 31 


Statistical Analysis Plan 
Version 1.0, dated 21-0ct-2019 
Prepared for: Xeris Pharmaceuticals, Inc. 
Study: XSGO-AF0l 
Table 
Table Title 
Shell Number (if 
Number 
repeat) 
14.3.8.2* 
Summary of Concomitant Medications - Safety 
14.3.8.1 
Population 
Figure 
Figure Title 
Shell Number (if 
Number 
repeat) 
14.2.2.1 * 
Observed Values and Change from Induction 1 
(Baseline visit) in Counter Regulatory Hormones Over 
Time - Intent-to-Treat Population 
14.2.1.2* 
Observed Values and Change from Induction 1 
14.2.2.1 
(Baseline visit) in Counter Regulatory Hormones Over 
Time Per Protocol Population 
14.2.2.1 
Cumulative Glucose Infusion Rate (GIR) Required to 
Maintain Insulin-Induced Hypoglycemia Over Time -
Intent-to-Treat Population 
14.2.2.2 
Cumulative Glucose Infusion Rate (GIR) Required to 
14.2.2.1 
Maintain Insulin-Induced Hypoglycemia Over Time -
Per Protocol Population 
14.2.3.1 
Cumulative Insulin Infusion Rate Required to Maintain 
14.2.2.1 
Insulin-Induced Hypoglycemia Over Time - Intent-to-
Treat Population 
14.2.3.2 
Cumulative Insulin Infusion Rate Required to Maintain 
14.2.2.1 
Insulin-Induced Hypoglycemia Over Time - Per 
Protocol Population 
14.2.4.1.1 
Average Neuroglycopenic Scores (ANS), Average 
Autonomic Scores (AAS) and Average Total Scores 
(ATS) with PG <70 mg/di Over Time - Intent-to-Treat 
Population 
14.2.4.1.2 
Average Neuroglycopenic Scores (ANS), Average 
14.2.4.1.1 
Autonomic Scores (AAS) and Average Total Scores 
(ATS) with PG <70 mg/dl Over Time - Per Protocol 
Population 
14.2.4.2.1 * 
Average Neuroglycopenic Scores (ANS), Average 
14.2.4.1.1 
Autonomic Scores (AAS) and Average Total Scores 
(ATS) with PG <50 mg/di Over Time - Intent-to-Treat 
Population 
14.2.4.2.2* 
Average Neuroglycopenic Scores (ANS), Average 
14.2.4.1.1 
Autonomic Scores (AAS) and Average Total Scores 
(ATS) with PG <50 mg/di Over Time - Per Protocol 
Population 
14.2.5.1.1 
CGM-Derived Hypoglycemia Parameters by Day -
Intent-to-Treat Population 
14.2.5.1.2 
CGM-Derived Hypoglycemia Parameters by Day - Per 
14.2.5.1.1 
Protocol Population 
Confidential 
Page 29 of31 


Statistical Analysis Plan 
Version 1.0, dated 21-0ct-2019 
Prepared for: Xeris Pharmaceuticals, Inc. 
Study: XSGO-AF0l 
Figure 
Figure Title 
Shell Number (if 
Number 
repeat) 
14.2.5.2.1 
CGM-Derived Hypoglycemia Parameters by Week -
14.2.5.1.1 
Intent-to-Treat Pooulation 
14.2.5.2.2 
CGM-Derived Hypoglycemia Parameters by Week- Per 
14.2.5.1.1 
Protocol Population 
14.2.6.1 
Gold Scale Assessment of Hypoglycemia Unawareness 
Over Time - Intent-to-Treat Population 
14.2.6.2 
Gold Scale Assessment of Hypoglycemia Unawareness 
14.2.6.1 
Over Time - Per Protocol Population 
Listing 
Listing Title 
Shell Number (if 
Number 
repeat) 
16.1.7* 
Randomization of Subjects Intent-to-Treat Population 
16.2.1.1 * 
Subiect Disposition All Subiects 
16.2.1.2* 
Subject Eligibility and Inclusion/Exclusion Criteria 
Assessment All Subjects 
16.2.2.1 * 
Protocol Deviations All Subjects 
16.2.2.2 
Major Protocol Deviations All Subjects 
16.2.3* 
Analysis Populations All Randomized Subjects 
16.2.4.1 * 
Subject Demographic and Baseline Characteristics 
Intent-to-Treat Population 
16.2.4.2* 
Medical History Intent-to-Treat Population 
16.2.4.3* 
Prior and Concomitant Medications Safety Population 
16.2.5.1 
Study Drug Administration Intent-to-Treat Population 
16.2.5.2 
Euglycemic Baseline and Hypoglycemia Induction 
Intent-to-Treat Population 
16.2.5.3* 
Plasma Blood Glucose during Euglycemic Maintenance, 
Hypoglycemia Induction and Stabilization, and 
Normalization to Euglycemia All Subjects 
16.2.5.4 
Plasma Blood Glucose Levels from Plasma Glucose 
Screener Intent-to-Treat Population 
16.2.6.1 
Subject Insulin Diary Safety Population 
16.2.6.2.1 
Interstitial Glucose Parameters During CGM Monitoring 
All Subjects 
16.2.6.3.1 
Average Glucose Infusion Rate to Maintain Glucose at 
50 mg/dL for the first 30 minutes after 50 mg/dL 
Achieved during Hypoglycemia Stabilization All 
Subjects 
16.2.6.3.2 
Cumulative Glucose Infusion to Maintain Glucose at 50 
mg/dL for the first 30 minutes after 50 mg/dL Achieved 
during Hypoglycemia Stabilization All Subjects 
16.2.6.4.1.1 
Hypoglycemia Symptom Questionnaire Responses After 
Achieving Plasma Glucose of< 70 mg/dL All Subjects 
16.2.6.4.1.2* Hypoglycemia Symptom Questionnaire Responses After 
Achieving Plasma Glucose of< 50 mg/dL All Subjects 
Confidential 
Page 30 of31 


Statistical Analysis Plan 
Version 1.0, dated 21-0ct-2019 
Prepared for: Xeris Pharmaceuticals, Inc. 
Studv: XSGO-AF0I 
Listing 
Listing Title 
Shell Number (if 
Number 
repeat) 
16.2.6.4.2.1 
Average Neuroglycopenic, Autonomic and Total 
Symptom Scores After Achieving Plasma Glucose of< 
70 mg/dL All Subjects 
16.2.6.4.2.2 * Average Neuroglycopenic, Autonomic and Total 
Symptom Scores After Achieving Plasma Glucose of< 
50 mg/dL All Subjects 
16.2.6.4.3 .1 
Overall Assessment of Hypoglycemia After Achieving 
Plasma Glucose of< 70 mg/dL All Subiects 
16.2.6.4.3.2 
Overall Assessment of Hypoglycemia After Achieving 
Plasma Glucose of< 50 mg/dL All Subjects 
16.2.6.4.4 
Gold Scale of Hypoglycemia Unawareness All Subjects 
16.2.7* 
Adverse Events All Patients 
16.2.8.1* 
Hormones and Counter Regulatory Hormone Response 
All Patients 
16.2.8.2 
Serum Concentration of Glucagon during CSGI 
Treatment All Patients 
16.2.8.3 
Serum and Plasma Concentration of Glucagon 
Antibodies All Patients 
16.2.8.4 
Clinical Laboratory Results: Hema:tolo!!v All Patients 
16.2.8.5 
Laboratory Results: Chemistry, Complete Metabolic 
Panel Safety Population 
16.2.8.6 
Laboratory Results: Drug Screen All Patients 
16.2.8.7 
Listing of Laboratory Results: Serology Intent-to-Treat 
Population 
16.2.8.8 
Urine Pregnancy Test Results All Patients 
16.2.9.1 
Injection Site Discomfort - Visual Analog Scale (VAS) 
Safety Population 
16.2.9.2 
Injection Site Discomfort - Injection Site Discomfort 
Description and Duration Questionnaire Safety 
Population 
16.2.9.3 
Iniection Site Reactions - Draize Scale Safety Population 
16.2.9.4 
Vital Signs and Weight Safety Population 
16.2.9.5 
12-Lead Electrocardiogram (ECG) Interpretation Safety 
Population 
16.2.9.6 
Physical Examinations Safety Population 
16.2.10 
Comments All Patients 
Confidential 
Page 31 of 31